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Abstract 
Much previous work on air pollution epidemiology has studied end-stage outcomes 
such as mortality or severe ill health warranting emergency admission, often based on 
clinical criteria prone to misclassification, and usually without accompanying study of 
the mediating mechanisms. Therefore this work has three specific objectives: firstly, to 
assess the effects of short-term exposure to particles and gases on acute coronary 
syndrome (ACS), by measuring the levels of cardiac troponin T (cTnT), a highly 
sensitive and specific marker of myocardial damage in patients admitted to hospital for 
chest pain of myocardial origin; secondly, to investigate the effects of short-term 
changes in ambient air pollution on the occurrence of transient ischaemic attacks (TIA); 
finally, to investigate the effects of ambient and personal exposure to air pollutants on a 
range of mediators or markers in a putative susceptible population.  
Two case-crossover studies were conducted to study the association between short-term 
changes in air pollutants and ischaemic cardiac events and TIA. Hospital data on 
admissions were analysed for actual or suspected ischaemic events and the associated 
cTnT levels were obtained. For the TIA project, data on 709 subjects were obtained 
from five TIA centres clustered around Manchester and Liverpool. In the third project a 
panel of 35 type 2 diabetes mellitus patients were prospectively followed fortnightly for 
a total of four visits. At each visit blood was collected to measure markers of 
inflammation, coagulation and endothelial function. In all three projects ambient air 
pollution data were obtained from background monitoring networks and in the third 
project personal exposure to PM2.5 was measured. 
Project 1: Of 28,622 admissions, 17.5% were ACS with myocyte necrosis (cTnT 0.03-1 
ng/ml) and 1004 (3.5%) were cases of myocardial infarction (cTnT ≥ 1 ng/ml). Both 
particulate and gaseous pollutants were associated with admission for ACS. The two 
largest effects per interquartile increase of exposure were observed with PM10 with OR 
of 1.14 (95% CI: 1.05-1.24) and with SO2, OR 1.11 (95% CI: 1.00 -1.23). Associations 
between pollution and ACS admissions were the strongest for women, those above the 
age of 65 years and in the cooler season.  
Project 2:  In the Manchester dataset, exposure to nitric oxide (NO) was associated with 
occurrence of TIA, while no effect was observed for Liverpool data. Subgroup analysis 
reveals that CO, NO and NO2 were more strongly related to the occurrence of TIA in 
participants above the age of 65 years and male patients.  
Project 3: No consistent association was observed between measured biomarkers and air 
pollutants using exposure data from ambient monitoring stations. In contrast, significant 
association between personal PM2.5 and interleukin-6 (IL-6) was observed. Similarly, 
personal PM2.5 had large but non-significant positive associations with high sensitivity 
C-reactive protein and fibrinogen.  
The results of this study reveal that short-term changes in particulate and gaseous 
pollution are related to the risk of admission for ACS as demonstrated by a specific 
marker hitherto not used for this purpose. It provides limited evidence for an association 
between changes in ambient NO concentration (which may have been a surrogate for 
another pollutant), and the occurrence of TIA, which had not previously been studied as 
an air pollution outcome, and increase in IL-6, a major pro-inflammatory marker. The 
IL-6 response to personal PM2.5 provides evidence in support of the link between 
ambient levels of particles/gases and cardiopulmonary morbidity and mortality.  
11 
 
Declaration 
I declare that no portion of the work referred to in the thesis has been submitted in 
support of an application for another degree or qualification of this or any other 
university of Manchester or any other institute of learning.  
 
Copyright 
1. The author of this thesis (including any appendices and/or schedules to this thesis) 
owns certain copyright or related rights in it (the “Copyright”) and he has given The 
University of Manchester certain rights to use such Copyright, including for 
administrative purposes.  
 
2. Copies of this thesis, either in full or in extracts and whether in hard or electronic 
copy, may be made only in accordance with the Copyright, Designs and Patents Act 
1988 (as amended) and regulations issued under it or, where appropriate, in 
accordance with licensing agreements which the University has from time to time. 
This page must form part of any such copies made.  
 
3. The ownership of certain Copyright, patents, designs, trade marks and other 
intellectual property (the “Intellectual Property”) and any reproductions of copyright 
works in the thesis, for example graphs and tables (“Reproductions”), which may be 
described in this thesis, may not be owned by the author and may be owned by third 
parties. Such Intellectual Property and Reproductions cannot and must not be made 
available for use without the prior written permission of the owner(s) of the relevant 
Intellectual Property and/or Reproductions.  
 
4. Further information on the conditions under which disclosure, publication and 
commercialisation of this thesis, the Copyright and any Intellectual Property and/or 
Reproductions described in it may take place is available in the University IP Policy 
(see http://www.campus.manchester.ac.uk/medialibrary/policies/intellectual-
property.pdf), in any relevant Thesis restriction declarations deposited in the 
University Library, The University Library’s regulations (see 
http://www.manchester.ac.uk/library/aboutus/regulations) and in The University’s 
policy on presentation of Theses  
12 
 
Acknowledgements 
I would like to thank all those people who have helped and inspired me during my 
studies. First and foremost I would like to thank Prof Raymond Agius of the Centre for 
Occupational & Environmental Health for his excellent supervision of this project and 
for his constant encouragement and guidance throughout the research process. I would 
also like to express my gratitude to my co-supervisor Dr Adrian Hirst and my advisor 
Dr Andrew Povey for their invaluable support.   
 
Many thanks to everyone who collaborated on the projects reported in this thesis. I am 
grateful to the staff of the Diabetes and Endocrinology Unit at the Salford Royal NHS 
Foundation Trust, in particular Dr John New and Dr Martin Gibson, for allowing me 
access to patients attending their clinics. Dr New and Dr Gibson were abundantly 
helpful in various ways in two of the projects.  
 
I am also grateful to Kirk Siddals and Rob Oliver of the Vascular Research Group of the 
University of Manchester for providing office space. Dr Siddals performed most of the 
laboratory analysis of the biomarkers, for which I am very grateful. Thanks also to 
Kathryn Edge, for recruiting the patients and arranging the collection of biological 
samples. I greatly appreciate the contribution of the study participants, who gave 
willingly of their time by visiting Hope Hospital several times. 
 
Thanks also to Dr Pippa Tyrrell and Dr Craig Smith of Stroke Medicine, Salford Royal 
NHS Foundation Trust and their colleagues in the NORTHSTAR project in allowing 
me to use the dataset for one of the projects.  
 
 I am also thankful to Dr Roseanne McNamee for her advice on statistical issues in 
some of the projects. I would like to thank my colleagues at the Centre for Occupational 
& Environmental Health for their support and friendship. I will not forget the many 
Arabic anecdotes and jokes of Haytham Alhamwi, which could temporarily transform 
the dreary life of a PhD student into a lively event. Anna Molter provided two maps for 
this project for which I am thankful.  
 
My most heartfelt gratitude goes to my father Bero and my mother Wolete-Michael,    
for all their love and unwavering support throughout my life. Despite not having 
received any formal education themselves, they opened a gateway to education and 
knowledge for me and my siblings.  Their huge sacrifice has changed our lives and I 
give profound thanks for that.  
 
Special thanks go to my brothers and sisters, particularly Birhanu for constant 
encouragement and untiring support. Similarly, I wish to thank all my good friends and 
extended family members back home and elsewhere who were always there when help 
was needed. 
 
My warmest gratitude is reserved for my beloved family: my wife Firehiwot and my 
daughter Meti, and my children Olana and Sena. Your encouragement, understanding, 
patience and endless love have kept me going through all the highs and lows of this 
long journey. Without your help this dream would not have come true.  
13 
 
 
List of Abbreviations 
 
ACE inhibitors angiotensin-converting enzyme inhibitors 
ACP Accumulation mode particles 
ACS Acute coronary syndrome 
ACSS American Cancer Society Study 
AHSMOG Adventist Health Study on the Health Effects of Smog 
AMI Acute myocardial infarction 
APHEA-2 Air Pollution and Health: A European Approach 
  
BC Black carbon = Black smoke 
BMI Body mass index 
  
CI Confidence Interval 
CAD Coronary artery disease 
CAPS Concentrated ambient particles 
CHD Coronary heart disease 
CHF Congestive heart failure 
CIMT Carotid intima media thickness   
CO Carbon monoxide 
COPD Chronic obstructive pulmonary disease 
COV coefficients of variation  
CPC Condensation particle counter 
CRP C-reactive protein 
cTnI Cardiac troponin I 
cTnT Cardiac troponin T 
CV Cardiovascular 
CVD Cardiovascular disease 
  
DVT Deep vein thrombosis 
  
EC Elemental carbon 
14 
 
ESR Erythrocyte sedimentation rate 
ETS Environmental tobacco smoke 
FVII Factor VII 
  
GIS Geographical information system 
  
HbA1c Glycated haemoglobin, haemoglobin A1c 
HSCS Harvard Six Cities Study 
  
HRV Heart rate variability 
hsCRP High-sensitivity CRP 
  
ICAM-1 Intracellular adhesion molecule-1 
ICAM-2 Intracellular adhesion molecule-2 
IHD Ischaemic Heart Disease 
IL Interleukin 
IQR Inter quartile range 
MCP-1 Monocyte chemo-attractant protein-1 
MI Multiple imputation 
  
NNMAPS National Morbidity, Mortality and Air Pollution Study 
NO Nitric oxide 
NO2 Nitrogen dioxide 
NOx Oxides of nitrogen 
  
O3 Ozone 
OC Organic carbon 
OR Odds ratio 
  
PM Particulate matter 
PM2.5 Mass of particles with aerodynamic diameter less than 2.5 µm 
PM10 Mass of particles with aerodynamic diameter less than 10 µm 
PMNL Polymorphonuclear leukocytes 
PNC Particle number concentration 
15 
 
  
RBC Red blood cell   
ROS Reactive oxygen species 
RR Relative risk; risk ratio 
  
SAA Serum amyloid A 
SD Standard deviation 
SES Socio economic status 
SO2 Sulphur dioxide 
  
TNF α Tumour necrosis factor alpha 
TSP Total suspended particulate 
TWA Time-weighted average  
  
UFP Ultrafine particles 
  
VCAM-1 Vascular cell adhesion molecule-1 
vWF Von Willebrand factor antigen 
WBC White blood cell count 
 
16 
 
 
 
1 Chapter One: Introduction and Background 
17 
 
1.1 Air Pollution Epidemiology 
 
1.1.1 Air Pollution and Health 
 
The health risk of poor air quality is not new and has been a concern for mankind since 
fire was first used by early humans,  suggesting an important role of combustion in air 
pollution[1]. The burning of wood and coal for domestic heating and industrial 
production has increased air pollution particularly in winter, leading to large 
concentrations of smog, a term derived from smoke and fog[1].Despite the recognition 
of the risks associated with smog, there was no uniform regulation to control pollution 
until 1956 and the rising use of industrial coal has occasionally led to episodes with 
high levels of air pollution in various cities in the past.   
The first well documented major air pollution episode occurred around the city of Liege,  
Belgium in December 1930[2], followed by an incident in Donora Valley, 
Pennsylvania, in 1948[3]. The incident in Belgium claimed the lives of 60 people, while 
in Donora, a town of 14,000 residents, an estimated 5000 to 7000 persons became ill, 
some 400 were hospitalized, and 20 died[3]. In both episodes the majority of hospital 
admissions were related to cardiac and respiratory complaints. The most severe episode 
that received widespread publicity was the notorious London smog of December 4-9, 
1952, which resulted from low wind speed, dry air and temperature inversion. The 
concentrations of SO2 and smoke reached thousands of µg/m3[4]. During this event and 
the two subsequent months, an estimated 4000 excess deaths occurred, particularly 
among frail individuals[5]. Most affected were people with pre-existing cardiovascular 
(CV) and respiratory problems. Recent research suggests that most of the smog-related 
deaths have been attributed to seasonal influenza deaths and argues that the real figure 
may be as high as 12,000[5]. The smog incident led to several investigations to 
characterize pollutants and their sources.  It also marked the beginning of modern air 
pollution research in UK and elsewhere[5]. The first Clean Air Act was enacted in the 
UK in 1956, following the London incident, to regulate domestic and industrial sources 
of pollutants and create smoke-free zones. Such effective legislation in the developed 
world has resulted in a reduction of levels of ambient pollutants from various sources. 
Nevertheless, a high level of air pollution in some developing countries is still a major 
18 
 
environmental and public health problem where pollution levels are close to those of 
London during the smog days[6].  
There has been a considerable reduction in emissions in recent years in the UK and 
many developed countries[7, 8]. Total emission into the atmosphere of particulate 
matter (PM) with a mean aerodynamic diameter of ≤ 10 µm (PM10) has fallen in the UK 
from 570 kilotons in 1970 to 200 kilotons in 2000[7]. In spite of this long-term drop in 
pollution levels, adverse health effects of ambient air pollution continue to be observed 
in different countries with varying levels and compositions of air pollutants.  
Epidemiological air pollution studies using diverse methodologies have shown 
associations between levels of suspended particles and gases and various CV and 
respiratory endpoints[8, 9].   
The adverse health effects of PM exposure ranges from mild respiratory irritation to 
serious effects such as increased hospital admission and emergency department visits, 
increased all-cause mortality and cardio-respiratory mortality, as well as different 
cancers[8-10].  As Figure 1.1 shows, the proportion of the exposed population affected 
by minor outcomes is significantly larger than those with severe outcomes such as 
mortality or cancers, which are less common.  
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Figure 1.1 Air pollution health effects pyramid 
(adapted from American Thoracic Society, 2000) 
What Constitutes an Adverse Health Effect of Air Pollution? JULY 1999. Am J Respir Crit Care Med 
2000 February 1;161(2):665-73. 
 
1.1.2 Ambient Air Pollutants   
 
Ambient air contains a heterogeneous mixture of diverse gaseous and particulate 
pollutants that vary widely in number, size, chemical composition, surface area, source 
and mode of release[11]. Generally, ambient pollutants are categorised as primary and 
secondary.  Those directly emitted into the atmosphere from an emission source are 
known as primary pollutants and they arise from combustion sources like road traffic 
and power plants. Secondary air pollutants are formed in the atmosphere as a result of 
chemical and physical reactions of primary pollutants with atmospheric gases and water 
(e.g. production of nitrates from nitric acid, sulphates formed from sulphur dioxide and 
ground level ozone).  
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Ambient air pollutants exist as gases, particulate matter or their mixture. The major 
gaseous air pollutants are nitrogen dioxide (NO2) carbon monoxide (CO) sulphur 
dioxide (SO2) and ozone (O3).  
1.1.2.1 Particulate Matter 
 
Particulate matter is any substance in liquid, solid or a mixture of solid and liquid forms 
suspended in the atmosphere. There are various approaches to classifying PM by size 
including modes (based on observed size distribution and formation mechanisms), 
dosimetry or occupational health sizes (based on entrance into various compartments of 
the respiratory system) and cut point (based on 50% cut point of sampling devices)[11]. 
Based on aerodynamic diameter, particles are classified as follows (Figure 1.2 and 1.3): 
PM10 (mean aerodynamic diameter of ≤ 10 µm), coarse particles (2.5–10 µm), fine 
particles (≤ 2.5 µm) and ultrafine particles (UFP; <0.1 µm).  Earlier epidemiological 
investigations used total suspended particle (TSP), an all-inclusive term referring to 
ambient PM of all sizes in air, as the exposure metric. However, TSP includes very 
large particles that do not enter the human respiratory system, so it is not a good 
indicator of human health exposure.  
 
The schematic modal classification of particles is shown in Figure 1.3. According to this 
classification, particles are classified in order of increasing size, into nucleation mode 
(freshly formed smallest particles of 10 nm), Aitken mode (larger particles with 
diameter  of 10-100 nm), accumulation mode (0.1 to 1 µm) fine particles (comprising 
the nucleation, Aitken and accumulation modes) and coarse particle mode (> 1 µm)[7, 
11].   
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Figure 1.2 Size distribution of ambient particulate matter, after US EPA 
 
   
1.1.2.1.1 Sources and composition 
 
Ambient particles originate from anthropogenic and natural sources. The commonest 
sources of PM are motor vehicle emissions, fragments of tyre, road dust, power 
generation and other industrial combustion, metal processing (e.g. smelting), 
agriculture, construction and demolition activities, domestic wood fires, suspended soil, 
pollens and moulds, forest fires and combustion of agricultural debris, volcanic 
emissions, and sea spray.   
Atmospheric particles have a very diverse composition depending on several factors 
including source, which also determines their size ranges. Coarse particles usually result 
from mechanical and natural processes of crushing, grinding or abrasion or from 
aggregation of smaller particles The major chemical constituents of the coarse mode 
particles are ions (nitrates and sulphates), elemental and organic carbon, organic 
compounds (such as polycyclic aromatic hydrocarbons), bio-aerosols (endotoxins, cell 
fragments, pollen and spores), and transition metals (such as iron, copper, nickel, zinc, 
and vanadium).  
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Fine and ultrafine particles are largely formed from domestic and industrial combustion 
processes, the major sources being traffic related, as well as secondary atmospheric 
transformation from gases and some organic compounds[11]. UFPs are usually formed 
by nucleation, the initial stage of the process by which a gas becomes particles, growing 
subsequently through condensation or through coagulation to form larger particles. The 
main components of fine particles are organic and elemental carbonaceous material, 
organic compounds, hydrocarbons, ions and metals whereas the main constituents of 
UFPs are hydrocarbons, metals and organic carbon. 
 
 
Figure 1.3 Idealized size distribution of particles 
 
Particles of different sizes are generated by four modes: nucleation, Aitken, 
accumulation and coarse mode. Also shown are the major formation and growth 
mechanisms of the four modes of ambient particles. V = volume, DP = particle 
diameter. Source: U.S. EPA[11] . 
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1.1.2.1.2 General characteristics 
 
The behaviour of particles in the atmosphere depends on various factors including their 
size. Coarse particles (PM2.5-10) tend to settle quickly and their lifetime is limited to 
minutes or hours, whereas fine particles (PM2.5) and UFPs tend to be suspended in the 
air for an extended period of days to weeks.  In addition, coarse particles will disperse 
over limited distances in the order of kilometres, while fine particles may spread for 
thousands of kilometres[11].  
The size of PM also determines its deposition characteristics in the respiratory system: 
fine particles and UFPs are deposited deep in the lungs, whereas coarse particles tend to 
be deposited mainly in the extra-thoracic and upper trachea-bronchial areas.   
The physical presence of PM in tissues, and their chemical constituents are important 
factors in the toxicity of PM. Generally, the toxicity of particles for human tissues and 
adverse health outcomes depend on diverse particle characteristics such as size, surface 
area, number concentration,  acidity, surface chemistry, chemical constituents such as 
content of transition metals, biogenic origin or combinations of these factors, which  
modulate toxicity[11].   
Presently, various international and national reference standards are set to limit ambient 
air pollution levels. The most frequently used are those of the World Health 
Organization (WHO), EU and USEPA.  Table 1.1 presents current Air Quality 
Guidelines (AQGs) of the WHO for PM and gaseous pollutants which provide global 
guidance on the assessment of air pollution exposure and reducing adverse health 
impacts of air pollution. These guidelines are set based on existing epidemiological and 
toxicological evidence and cover PM and gaseous pollutants. The PM guidelines 
commonly use mass per space of particles as an exposure metric. One major drawback 
of most AQGs of PM is that they target only PM10 and PM2.5, thus essentially 
overlooking the contribution of smaller UFPs which are negligible in mass of ambient 
air, but have the largest number concentration in a typical particulate sample. Besides, 
the size of a particle is determined by its source and chemical composition and certain 
modes of particles are dominated by specific chemical components which partly 
determine toxicity.  For example, combustion-derived fine particles have higher toxic 
potential than crustal- derived coarse PM. Toxicological evidence also shows diverse 
particles characteristics such as surface area, number concentration and 
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physicochemical composition play an important role in modulating toxicity of 
particles[12].  
Recent research also suggests that UFP are more toxic than fine or coarse particles due 
to their large  numbers, physicochemical composition, pro-oxidant potential, 
bioavailability, translocation into systemic circulation and pulmonary retention[12, 13]. 
UFPs have large number concentration and a large surface area per given mass, which 
increases the bio-available surface, thus facilitating catalytic action for specific 
reactions within cells and the carrying of more surface reactive substances. Likewise, 
inhaled UFPs show greater fractional deposition in deeper alveolar regions than fine and 
coarse particles and they are less likely to be phagocytised and removed by alveolar 
macrophages. In addition, UFPs appear to have high oxidant activity and free radical 
formation when compared to fine and coarse particles[12, 13]. Finally, UFP penetrate 
into the interstitium of the lungs and can translocate into the systemic circulation, 
directly causing CV toxicity[12, 14, 15]. 
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Table 1.1 WHO Air quality guideline levels 
 
Pollutant Averaging time Time-weighted average 
AQG value  
PM2.5* 24-hr (99
th 
percentile)  25 µg/m
3
  
 
Annual  10 µg/m3 
PM10* 24-hr (99
th
 percentile)  50 µg/m
3
 
 
Annual  20 µg/m3 
NO2* 1- hr 200 µg/m3 
 
Annual mean 40 µg/m3 
Ozone* 8-hr (daily maximum) 100 µg/m3 
SO2* 10 min 500 µg/m3 
 
24-hr 20 µg/m3 
CO† 15 min 100 mg/m3 
 
30 min 60 mg/m3 
 
1- hr 30 mg/m3 
 
8-hr 10 mg/m3 
 
*  Taken from WHO: Air quality guidelines – global update 2005. 
http://www.euro.who.int/document/e87950.pdf. 
†  WHO air quality guidelines for Europe, 2nd edition, 2000, WHO Regional Publications, 
European Series, No. 91 
PM2.5, mass concentration of particles < 2.5 µm in aerodynamic diameter; PM10,  mass 
concentration of particles < 10 µm in aerodynamic diameter; NO2,  nitrogen dioxide; SO2, 
sulphur dioxide; CO, carbon monoxide;  
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1.1.2.2 Gaseous Pollutants   
Gaseous air pollutants constitute an important component of indoor and outdoor air and 
are linked to various human health outcomes, including increased mortality and 
morbidity. Ambient air contains both primary and secondary gases. Primary gaseous 
pollutants of health importance include SO2, oxides of nitrogen and CO while the main 
secondary gaseous pollutant is ozone. In contrast to particles, which are studied quite 
extensively, knowledge of the adverse effects of gaseous air pollutants is limited. All of 
these gases are known to cause a number human health outcomes, including morbidity 
(hospital admissions, emergency department visits, exacerbation of asthma and chronic 
obstructive pulmonary disease [COPD], reduced lung function etc.) and mortality from 
CV and respiratory causes[10, 16].    
An important secondary gas of health relevance is ozone, a highly reactive  
photochemical oxidant formed through a series of complex chemical reactions by the 
action of ultraviolet light on NO2 and volatile organic compounds, which may be 
summarized as follows [16].   
Photolysis of NO2 by UV photons forms nitric oxide (NO) and atomic oxygen (Figure 
1.4): 
NO2 + hv (λ ≤ 430 nm)1 → O + NO                                                                               (1) 
Atomic oxygen combines with molecular oxygen to form ozone: 
O + O2 → O3                                            (2) 
Ozone is decomposed by reacting with nitric oxide, forming nitrogen dioxide and 
molecular oxygen: 
O3 + NO → NO2 + O2                (3) 
Ozone is a major constituent of photochemical smog. The level of ozone is 
characterized by significant temporal and spatial variability as well as strong seasonal 
and diurnal variability with peaks in summer and in the afternoon. In areas with high 
                                                 
1
 In the equation h is Planck’s constant and υ is the frequency of light 
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emissions like urban centres, the concentration of ozone is low, as newly formed ozone 
quickly reacts with NO to form NO2. This contrasts with suburbs and rural areas, where 
recorded concentrations are higher. Ozone formation and concentration is high on hot 
sunny days, thus ozone pollution generally occurs in hot summers in the UK and 
continental Europe.   
There is extensive evidence from epidemiological and controlled animal and human 
exposure studies linking ozone to a number of both acute and chronic health  outcomes  
including mortality and hospital admission[17]. Ozone-dependent toxicity is related to 
its oxidant nature and results from direct oxidation of cells, free radical formation, 
induction of pulmonary and systemic inflammation and neural reflexes[16]. Ozone 
damages respiratory epithelial cells, initiating an inflammatory response with release of 
various pro-inflammatory cytokines such as IL-6, IL-8 and TNF. A review of 
epidemiological and toxicological evidence on the health effects of exposure to ozone 
by the WHO lists a number of human health outcomes such as increased hospital 
admissions for various respiratory diseases including asthma, COPD and pneumonia, 
and reduction of pulmonary function. In addition, various CV outcomes are reported 
including increased mortality and emergency admission for congestive heart failure 
(CHF), acute myocardial infarction (AMI) and stroke[16, 17]. Ozone exposure  is also 
related to various intermediate outcomes like arterial vasoconstriction, reduction in 
heart rate variability (HRV) and paroxysmal atrial fibrillations[16]. Both short- and 
long-term exposure to ozone are related to increased all-cause, CV and respiratory 
mortality, particularly in summer months in some regions[16]. Long-term ozone 
exposure is also associated with lung cancer mortality[16, 18]. 
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Figure 1.4 Nitrogen oxides-ozone photolytic cycle 
Reference:  Air Quality Guidelines, Global Update 2005, World Health Organization, 
the Regional Office for Europe 
O, oxygen atom; O2, molecular oxygen; 
 
Nitrogen oxide species (NOX) include two principal oxides: NO and NO2.  Both are 
toxic gases but NO2 is highly reactive. The primary anthropogenic sources of NOx are 
combustion processes like heating, power generation and motor vehicles. In urban 
centres the main source of NOx is vehicle emissions, thus NOx is considered a strong 
indicator of traffic emissions. The main indoor sources are gas-fired appliances, oil 
stoves and cigarette smoke. The bulk of NOx (about 95 %) is released as NO, which is 
oxidized by ozone to form NO2 (Figure 1.4). Oxides of nitrogen are sources of several 
harmful air pollutants, including nitrate components of fine PM, ozone and nitric acid.  
In urban areas, oxides of nitrogen as well as CO and UFP exhibit substantial spatial 
variability with high levels near emission sources such as major roads. In addition, NOx 
is highly correlated with other ambient pollutants, including fine PM, due to common 
combustion sources and atmospheric conversion reactions. Spatial variability and strong 
correlation between pollutants has two implications for epidemiological studies. Firstly, 
it is very difficult to disentangle the effects of a specific pollutant when there is high 
correlation. Secondly, if exposure data is averaged from a few central monitors to 
estimate community wide adverse health outcomes, there is a high likelihood of error in 
exposure measurement. 
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The WHO has reviewed the epidemiological evidence that links short-term effects of 
NO2 to adverse health outcomes[16],  revealing that short-term exposure to NO2 was 
related
 
to
  
increased total, respiratory and CV mortality as well as increased admission 
for CV and respiratory problems including COPD and asthma[16].  Animal models as 
well as controlled human exposure studies have shown that NO2 can increase both 
reactivity and  inflammatory response in the airways[16]. In controlled human exposure 
studies in healthy subjects as well as among those with asthma and COPD, exposure to 
low levels of NO2 was associated with minimal to mild effects on pulmonary 
inflammation, bronchial reactivity and lung functions[16].  
Carbon monoxide (CO) is a primary pollutant formed during the incomplete combustion 
of carbon-containing fuels. The main source of ambient CO is motor vehicle emission 
and other sources are industrial combustion, residential wood burning and waste 
treatment and disposal. The concentration of CO is high near major roads and in 
enclosed places like motor vehicles, underground garages, multi-storey car parks and 
road tunnels. The main sources of indoor CO are tobacco smoke and gas appliances.  
In high concentrations and in severe poisoning, CO forms high levels of 
carboxyhaemoglobin (COHb) in red blood cells, which prevents oxygen binding to 
haemoglobin, thereby reducing the oxygen-carrying capacity of the blood and leading to 
tissue hypoxia. In non-smokers and non-exposed individuals, the concentration of 
COHb, which results from endogenous production from haem catabolism, is < 0.5%, 
whereas it can reach 15% in smokers and levels above 50% are usually fatal. CO may 
also cause toxicity through its effects on myoglobin, impairing myocardial performance, 
and interfere with cellular respiration due to its effect on mitochondrial cytochrome 
oxidase.  
Some recent epidemiological studies from various countries have shown associations 
between short-term changes in ambient CO and various CV admissions, including for 
AMI[19-21]. The effect of exposure to ambient CO, which is generally lower than other 
exposure routes, cannot be explained by the above mechanism and there may be other 
unidentified mechanisms through which CO exerts its effects. CO concentrations are 
possibly surrogates for other traffic-related pollutants.  
Sulphur dioxide (SO2) is a colourless gas which is produced mainly by anthropogenic 
sources including combustion of sulphur-containing fossil fuels such as coal oil and 
natural gas for domestic heating, power generation and motor vehicles. Concentrations 
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of SO2 have decreased dramatically in developed countries due to declining use of coal, 
use of low sulphur oil and tighter emission controls[16]. Elevated levels of SO2 have 
been associated with significant mortality in various countries in the last century, as 
exemplified by the London smog. Presently, ambient SO2 levels are very low. A 
number of earlier epidemiological studies have examined the link between SO2 
concentration and daily variation in various human health outcomes including hospital 
admissions, deaths, respiratory symptoms and lung function[16]. Some of these studies 
from various countries have found significant association between short-term exposure 
to SO2 and hospital admissions for asthma, COPD and CV diseases which were 
independent of PM and other gaseous pollutants[16].  A recent human challenge study 
that examined the effect of SO2 and carbon particles on HRV and inflammatory markers 
has found significant association between SO2 and reduced HRV[22]. Other controlled 
chamber studies of SO2 on healthy subjects and subjects with asthma have shown 
associations with bronchoconstriction, reduced lung function and increased airway 
resistance[16]. 
1.2 Exposure Assessment and Monitoring Methods 
 
Exposure assessment is a crucial element of epidemiological investigation, providing 
data on actual or potential exposure to particulate or gaseous air pollutants. A 
framework of environmental exposure assessment currently in use in epidemiological 
studies is shown in Figure 1.5. In air pollution epidemiology, exposure assessment may 
be undertaken by direct and indirect approaches[11, 23]. Direct approaches determine 
the contact of a person with the chemical concentration in the exposure media over an 
identified period of time and this involves biological monitoring including the 
measurement of biomarkers and personal monitoring, in which personal samplers are 
used to collect exposure data. Indirect methods involve the use of routinely available 
information on concentrations of chemicals in different microenvironments and on the 
time and activity of individuals in each microenvironment, the collection of data by 
environmental monitoring, questionnaires or diaries, and modelling[11, 23].  
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Most epidemiological studies rely on data obtained from fixed-site central background 
monitors as surrogate measures of exposure to estimate health effects, on the 
assumption that the pollutant concentration represents area-wide exposure for all 
individuals and thus serves as a valid surrogate for personal exposure. Other studies 
have used models when direct measurements are unavailable or insufficient, or to make 
predictions about a pollutant. A combination of ambient background monitors and 
modelling is also used.  
 
A review by Jerrett et al. suggests various modelling approaches to estimate intra-urban 
air pollution exposure. These are proximity based assessments, statistical interpolation 
models, land use regression models, dispersion models, integrated meteorological 
emission models, hybrid models which use existing methods and combine a variety of 
sources, including time activity data, personal exposure measurements and models[24]. 
The authors suggest that hybrid models provide more accurate exposure assessment, as 
they combine one or more modelling approaches and take account of exposure variation 
at the individual level[24].    
 
Personal exposure monitoring involves measuring individuals’ exposure to 
environmental contaminants in their breathing zone as they move through different 
microenvironments. Quantified personal monitoring provides an objective and direct 
way of assessing exposure and represents total exposure of an individual to diverse 
pollutants from different sources and microenvironments such as outdoors, indoors (at 
work or at home) and while commuting[11, 23]. However, personal monitoring cannot 
be used on a large scale as it is expensive and time consuming. Furthermore, as the risk 
associated with air pollution is generally smaller than other well established CV risk 
factors, a large sample size is required to detect this small effect and this cannot be 
achieved by personal monitoring. As a result, personal monitoring is employed to 
supplement and validate other exposure assessment methods and models, in the study of 
small sensitive populations and in occupational settings[23].  
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Figure 1.5 Approaches to human exposure assessment 
After Zou e t al.  Air pollution exposure assessment methods utilized in epidemiological studies. J 
Environ Monit 2009;11 (3):475-90. 
 
 
Few studies have investigated the relationship between personal exposure and ambient 
concentrations of pollutants.  These associations exhibit temporal and spatial variation 
and are influenced by several factors such as area of residence, type of pollutant, 
housing characteristics, presence of indoor sources (e.g. environmental tobacco smoke), 
activities such as cooking, vacuum cleaning, the penetration capacity of outdoor 
pollutants and the time activity patterns of individuals[11]. In short-term studies, 
individual correlations between ambient concentrations and personal PM depend on the 
activity of each individual. For spatially heterogeneous pollutants, particularly those 
from traffic or indoor sources, use of central site ambient air pollution data may affect 
health effect estimates. For pollutants with few indoor sources such as sulphates, or 
spatially homogenous pollutants like fine PM, there is strong longitudinal correlation 
(when data are obtained from many repeated measurements per person) between 
ambient and personal exposure measurements at population level, particularly when a 
large underlying population is studied[11, 25].   
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1.2.1 Implications of Using Ambient Air pollutants 
 
Individuals are exposed to particulates and gases from indoor and outdoor 
microenvironments and a valid exposure assessment should ideally include data from all 
microenvironments. It is well recognized that the majority of people spend most of their 
time indoors and thus a large proportion of exposure to air pollution also occurs indoors.  
Conversely, most epidemiological studies assessing the health effects of air pollution 
have used data from ambient air as a surrogate for exposure to air pollution. Thus, use 
of data from central monitors does not consider other microenvironmental determinants 
of exposure such as home, outdoors, workplace and travel. In addition, individuals 
move from one microenvironment to another, each with its own sources and 
concentrations of pollutants. Furthermore, the location of ambient monitors could be far 
away from the residence of individuals. Consequently, the use of exposure data from 
ambient monitors fails to capture accurately actual personal exposure and this could 
lead to misclassification of individual exposure and bias in effect[26].   
Zeger and colleagues identify three sources of exposure measurement errors in short-
term air pollution studies: 1) the use of aggregate ecological data; 2) the difference 
between the average personal exposure and the true ambient level; and 3) the difference 
between the true and measured ambient levels. The authors argue that the first and third 
lead to Berkson-type errors, therefore are likely to have relatively small effects on risk 
estimates, while the second type is the classical measurement error (random 
measurement error which is independent of the true level) and likely to cause substantial 
bias of the estimated health effect towards the null value[26].       
1.3 Air pollution Study Designs  
 
The health effect of air pollution on human health has been studied in the fields of 
epidemiology and toxicology. Epidemiological methods are generally of two kinds, 
measuring short-term or acute effects and long-term or chronic ones. Short-term effects 
vary with time of exposure and occur in one or a few days of exposure, whereas long-
term ones are consequences of subclinical, cumulative exposure lasting several weeks, 
years or decades. The main short-term effect studies are time series, case-crossover and 
panel studies whereas chronic effect studies are cohort, case control and cross-sectional 
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ones. The following subsections briefly discuss the main epidemiological methods used 
in air pollution studies. 
1.3.1 Short term Health Effects 
1.3.1.1 Time series 
 
Time series analysis is used to study short-term temporal exposure changes of pollution 
levels in association with time varying adverse health outcomes including death, 
hospitalization or emergency department visits, all of which are aggregated over the 
same time period [27]. Typically, a time series design uses counts of health outcomes 
and relates them to time varying pollution levels adjusted for time variant confounding 
factors such as meteorological variables and seasonal trends which are known 
confounders2 for the association of air pollution and health effects[27]. A large number 
of studies from around the world have used time series design to investigate various 
health outcomes.   
One major advantage of this design is that factors which do not vary over short periods, 
like socio-economic status, smoking, educational status or occupation, do not confound 
the relationship between health outcomes and the pollutant being studied. Others are 
that time series studies are inexpensive and applicable to large publicly available 
databases, so can be used to target large populations[28].  
The main shortcoming of this design is the inability to adjust adequately for weather, 
season and long-term trends [27, 28]. Although most time series studies have been 
adjusted for temperature and relative humidity, many have not considered seasonal 
variations in disease such as influenza and other viral infections, which could confound 
the association between air pollutants and the outcome of interest. Like most air 
pollution studies, times series studies use centrally located background monitors to 
assess individual exposure and this is likely to lead to exposure misclassifications. 
                                                 
2
 The extraneous factors that are responsible for difference in disease frequency between the exposed and 
unexposed are called confounders.  Rothman, KJ, Greenland  S; Lash TL Modern Epidemiology. 3rd 
Edition, Lippincott Williams & Wilkins, 2008. 
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Furthermore, the design does not allow for direct evaluation of effect modification3 or 
statistical interaction, as individual data are lacking[28].  
The majority of time series studies have ecological designs, in which data on both 
exposure and health outcomes are collected at group level, as individual level data are 
usually unavailable. This could lead to a spurious association (ecological bias) due to 
the use of aggregate exposure data to make individual-level inferences[29]. Ecological 
designs are generally considered the weakest in the hierarchy of epidemiological 
evidence.   
1.3.1.2 Case-crossover studies 
 
Another way to examine the relationship between ambient air pollution and potential 
health outcome is to use a case-crossover study design. This is a modified version of the 
matched case control study design, which was developed  by Maclure in 1991 to study 
the effect of short-term exposure on rare acute outcomes[30]. In this design, the cases 
serve as their own controls, automatically eliminating the possibility of confounding by 
personal variability, which is observed in classical case control studies. In a case-
crossover design, exposures near the time of the event (case period) are compared to a 
set or referent period of non-event times (control), which could be before or after the 
event. Thus, measured and unmeasured time-invariant characteristics of the subject are 
matched. Unlike time series studies, which uses statistical models to control for 
confounders, case-crossover design inherently accounts for unmeasured time invariant 
confounding. In addition, the design controls for day of week, seasonality and long-term 
time trends, rather than relying on statistical modelling to do so. A variety of referent 
selection schemes have been used in case-crossover design, such as unidirectional, 
symmetric bidirectional, full-stratum bidirectional and time stratified sampling[28, 31]. 
An example of the time stratified sampling strategy used in two limbs of the study 
reported in this thesis is shown in Table 1.2. Janes et al. suggest using the time stratified 
approach as a standard method in selecting referent periods, as it ensures unbiased 
estimation[32].    
                                                 
3
 Effect modification is a variation in a measure of statistical association between an outcome and 
exposure which depend on the presence of one or more other conditions. Rothman KJ, Greenland S, Lash 
TL Modern Epidemiology. 3rd Edition, Lippincott Williams & Wilkins, 2008 
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Table 1.2 Time stratified sampling strategy 
 
Monday Tuesday Wednesday Thursday Friday Saturday Sunday 
1* 2 3 4† 5 6 7 
8† 9 10 11† 12 13 14 
15† 16 17 18* 19 20 21 
22† 23 24 25† 26 27 28 
29† 30 31     
* Cases; † controls; 
The table shows that for a case admitted on the 18th day of a hypothetical month, the 
referent days are the 4th, 11th and 25th of the same month and year. Similarly, for a case 
admitted on the 1st of this month, dates 8, 15, 22 and 29 constitute referent days. 
 
The main strength of this design is the ability to study the modification effect of various 
personal characteristics like age, gender and co-morbidity. Furthermore, the design 
inherently controls for key confounding factors. However, it also has some limitations. 
First, it is sensitive to the selection of control periods and lag choices. Secondly, the 
design cannot be used to investigate long-term cumulative exposure associations. 
Additionally, it is less efficient and imprecise than time series studies, due to loss of 
statistical power, as information from a control period is not included in the analysis. A 
number of air pollution studies of various outcomes including AMI[33] and stroke[17] 
have used case-crossover designs. 
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1.3.1.3 Panel studies 
 
Panel studies enrol a group of respondents and follow them at regular intervals in time 
for a short predetermined period to investigate changes in repeated outcome 
measures[28]. Like time series studies, they focus on acute effects of air pollution, 
particularly in a susceptible subpopulation. In contrast to environmental time series 
studies, which collect data on exposure, outcome and covariates at group level, panel 
studies collect outcome data at an individual level. In panel studies, exposure data may 
be gathered at group level, using central monitors, or by personal monitoring of an 
individual. The duration of measurements and the follow-up of panel studies is usually 
short, in contrast to cohort studies, which follow their subjects for many years[28].  
In panel studies, adjustment for possible confounders is similar to that employed in time 
series studies and usually includes meteorological variables, seasonal and long-term 
trends. This type of design accounts for within- and between-person variations and 
incorporates total personal exposure. It is frequently used to study sensitive 
subpopulations[28]. The main limitation of a panel design is that it is time consuming, 
requires intensive effort, relies on small samples and is costly. It is also sensitive to the 
selection of the lag period[28]. Panel studies have been used to estimate the effects of 
air pollution on various human health outcomes[34, 35].  
1.3.2 Long-term Health Effects 
1.3.2.1 Cohort studies 
 
A cohort study is used to investigate the effects of long-term exposure to air pollution 
with several health endpoints. Air pollution cohort studies are usually mortality studies 
and compare long-term exposure to PM after adjusting for important personal 
characteristics such as age, race, gender, BMI, educational level, occupation, socio-
economic status and smoking[27, 28].  
There are few cohort studies in air pollution epidemiology and prototype examples are 
three US studies, the Harvard Six Cities Study (HSCS)[36], the American Cancer 
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Society Study (ACSS)[37] and the Adventist Health Study of Smog (AHSMOG)[18], 
which have shown an increase in all-cause, cardiopulmonary and cancer mortality. A 
European study in the Netherlands has also shown an increase in cardiopulmonary 
mortality in people living close to major roads[38].   
The main limitations of cohort studies are high cost, long follow-up, which could lead 
to losses, and the use of exposure data from fixed monitoring sites (usually in existing 
monitoring networks), which may lead to exposure misclassification[28]. In addition, 
there are problems due to unmeasured and uncontrolled confounders.   
1.3.2.2 Cross-sectional studies 
 
Cross-sectional studies examine associations between outcome (usually disease 
prevalence) and exposure to air pollutants at a single point in time while adjusting for 
known confounders. The design employs spatial variability in exposure to estimate 
occurrence of outcome status. Various studies have used cross-sectional designs to 
investigate the prevalence of respiratory outcomes in relation to ambient air pollutants, 
traffic or other surrogate measures of exposure. Cross-sectional designs are quick to 
execute and relatively inexpensive. They usually undertaken to determine disease 
prevalence and can be used to investigate several outcomes. The design is usually 
employed to generate hypotheses and serves as a starting point to search for associations 
which could be further studied by advanced methods like cohort and experimental 
studies.  Its main limitations are failure to establish temporal associations between 
exposure and outcome, and difficulty in separating cause from effect.   
1.3.2.3 Case control studies 
In a case control study, cases with a health outcome of interest are matched on various 
individual characteristics with cases without the outcome (controls), then the occurrence 
of the intended outcome is compared between cases and controls in relation to their 
exposure to air pollution. An example of this design is provided by a recent study by 
Baccarelli and colleagues[39], who examined the association of exposure to PM10 with 
deep vein thrombosis (DVT) risk in 870 patients and 1210 controls from the Lombardy 
region in Italy and found a 70% increase of DVT (95% CI, 30 to 123) for each 10 µg/m3 
increase in PM10[39].  
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1.4 Overview of key air pollution epidemiological findings  
 
A systematic search of various databases including Medline (through PubMed and 
OVID interfaces), Embase, Web of Science and Scopus was undertaken to retrieve 
studies published in English with search terms dependent on the particular subtopic of 
the thesis. Furthermore, reference lists of all relevant scholarly articles, reviews and 
book chapters were scanned to identify any further studies. In addition, the official 
websites of the following organisations were searched for relevant reports and reviews: 
Health Effects Institute (USA); World Health Organization; Environmental Protection 
Agency (USA); and the Department of Health (UK).  
The extreme air pollution episodes of the last century in Belgium, the US and the UK 
have provided compelling evidence of the adverse outcomes of air pollution, including 
hospitalization and mortality. The interest generated by the London smog episode led to 
efforts to prevent such extreme episodes of air pollution, which are consequently now 
rare in the western world. This is in contrast to the situation in many developing 
countries, which experience extremely high levels of ambient air pollution, close to 
those recorded during the London smog[6].  
The WHO has identified air pollution as a major priority area; it considers it to pose a 
major environmental risk to health and has estimated that it causes approximately two 
million premature deaths worldwide per year[40]. The WHO also states that more than 
50% of the burden on human health is borne by people from developing countries. In a 
European assessment of the health impact of outdoor air pollution, specifically 
undertaken for Austria, Switzerland and France, Kunzli and colleagues estimated that 
outdoor PM10 was responsible for 6% of total mortality, half of which was attributed to 
road traffic[41]. 
National and international legislation aimed at raising air quality standards in many 
countries in the western world has led to a steady decline in ambient air pollutants[16]. 
Despite this downward trend in the concentration of pollutants, however, hundreds of 
studies continue to show associations between human health and pollutants, as reported 
in many recent reviews[8-10, 42]. Epidemiological studies using diverse methods and 
toxicological studies have consistently documented an association of air pollution with a 
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range of adverse health outcomes. Most of these associations are related to respiratory 
and cardiovascular outcomes, while adverse effects on pregnancy outcomes and in 
children have also been reported.  
Large cohort studies in the USA have demonstrated a relationship between long- term 
exposure to ambient air pollutants and both total and CV mortality[18, 36, 37, 43]. The 
HSCS followed 8111 individuals from six US cities from 1975 to 1991 and found an 
adjusted all-cause mortality of 1.26 (95% CI: 1.08 to 1.47) for the most polluted city 
compared to the least polluted[36]. It also found an increase in cancer and CV mortality. 
Adjustment for some individual-level confounders did not alter these associations.  
 Another US cohort study, the ACSS, followed 500,000 adults in 151 metropolitan areas 
from 1982 to 1989[37] and found an adjusted RR of 1.17 (95% CI: 1.09 to 1.26) for all-
cause mortality for the most polluted areas compared with the least polluted in 
association with fine particles. The authors also report that a 10 µg/m3 increase in PM2.5 
is associated with coronary artery disease (CAD) mortality, cardiac dysrhythmia, heart 
failure and cardiac arrest. Reanalysis of the original ACSS cohort reported increases of 
4%, 6% and 8% respectively in risk of all-cause, cardiopulmonary and lung cancer 
mortality for each 10 µg/m3 elevation in PM2.5 pollution[44]. 
Similarly, the AHSMOG study followed 6,338 non-smoking adults and found 
significant increases in all-cause mortality in males and in non-malignant respiratory 
mortality in both sexes, in association with increased PM10. In contrast to the two cohort 
studies discussed above, the AHSMOG study found no increase in cardiovascular 
mortality[18].  
A study in the Netherlands investigated 5000 adults of 55 to 69 years from 1986 to 
1994[38]. The authors report a relative risk (RR) for cardiopulmonary mortality of 1.95 
(95% CI: 1·09–3·52) for living close (< 100 m) to major roads. Moreover, a non-
significant increase in cardiopulmonary mortality in association with background black 
smoke exposure was reported. The RR for cardiopulmonary mortality related to each 
increase of 10 µg/m3 black smoke was 1.34 (95%CI: 0·68–2·64). The study clearly 
shows that use of background pollution measures from central sites underestimates risks 
related to ambient air pollution. 
Another US cohort study analyzed the health records of 65,893 postmenopausal women 
who participated in the Women’s Health Initiative (WHI) study to assess mortality risk 
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associated with PM2.5 exposure. After adjusting for potential risk factors, the authors 
found that each 10µg/m3 increase in the concentration of PM2.5 was associated with 
24% relative increase in the risk of CV disease (CVD) events (hazard ratio 95% CI:9-
41) and a 76% relative increase in the risk of death from CVD (95% CI:25-147) 
respectively. The cardiovascular risks reported in the study are significantly higher than 
earlier US cohort studies, which implies that women might be more susceptible to the 
effects of pollutants than men. Furthermore, the study has identified an association 
between PM2.5 exposure and cerebrovascular events. Each 10 µg/m3 increase in PM2.5 
was
 
associated with a 35% increase in cerebrovascular events and 83% in risk of death 
from cerebrovascular causes[43]. 
In addition to large cohort studies, hundreds of other time series studies have researched 
the harmful effect of ambient air pollution on human health. Air pollution is 
significantly related to mortality[45, 46] and hospital admission on a range of 
cardiopulmonary events[9, 10]. Studies have found these effects on health outcomes in 
various parts of the world.   
The two largest time series studies are the US National Mortality, Morbidity and Air 
Pollution Study (NMMAPS) and Air Pollution and Health: a European Approach 
(APHEA II)[45, 46]. The NMMAPS, based on the analysis of data from 20 large 
metropolitan areas, reported an increase in daily all-cause mortality of 0.5% (95 CI: 
0.1%-0.9%) for each 10 µg/m3 increase in PM10[45]. APHEA II similarly analyzed data 
for more than 43 million people from 29 different European countries and reported an 
increase in all cause mortality of 0.6% (95 CI: 0.4%- 0.8%)[46] and in cardiovascular 
mortality of 0.69% (95% CI 0.31%-1.08%)[47] for each 10 µg/m3 increase in PM10.  
There is compelling evidence that the health effects of air pollution are not uniform in 
populations and that individuals respond to the effect of air pollution differently. As 
reported in various studies[42, 48-50] and recent reviews[9, 10, 16], some population 
sub-groups such as the elderly, infants, patients with underlying disease (CVD, 
respiratory disease and type 2 diabetes) and those with low socio-economic or 
educational status are more susceptible to the effects of air pollution. Two recent 
epidemiological findings also suggest that women and men may be differentially 
susceptible to the effects of PM[51, 52].  
The impact of PM on human health represents a serious public health problem, as even 
small changes in levels of PM would seem to affect various health outcomes. Studies 
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have shown that concentration-response relationships are linear and that there is no 
discernible lower threshold concentration below which health effects no longer occur. 
Indeed, current research suggests that the observed health associations are still 
detectable even when exposures are essentially at and below the accepted air quality 
standards of many countries[8, 9]. 
 
Epidemiological intervention and natural experimental studies have provided indirect 
evidence, by showing that a reduction in air pollution is followed by health benefits. In 
Utah Valley, USA, a 13-month labour dispute that resulted in the closure of a local steel 
mill was associated with significant decrease in average PM10 concentrations by 
15 µg/m3 and in total mortality by 3.2%, as well as a reduction in respiratory 
admissions[9].  
An Irish study has provided evidence of the benefits of long-term air quality 
improvement on health[53]. Clancy and colleagues conducted a semi-intervention study 
to investigate the effect of the 1990 ban on coal sales[53]. They report a 35.6 µg/m3 
(70%) reduction in black smoke during the six years after the ban compared with the six 
years before it. During the ban, adjusted non-trauma death rates decreased by 5·7% 
(95% CI: 4–7), respiratory deaths by 15·5% (12–19) and CV deaths by 10·3% (8–13). 
Similar declines in morbidity and mortality rates following reduction of ambient 
pollutants have been reported in the USA and the former German Democratic 
Republic[8].  
A more recent evaluation of the effect of air quality improvement on health was 
reported from London, where a charging scheme was introduced in 2003 to alleviate 
traffic congestion[54].Tonne and colleagues found a reduction in absolute and relative 
concentrations of NO2 and PM10 in charging wards compared with non-charging 
wards[54].  Furthermore, predicted benefits in the charging zone wards were 183 years 
of life gained per 100 000 population, compared with 18 years in the remaining 
wards[54].  
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1.5 CV Effects of Ambient Air Pollutants 
 
Cardiovascular disease remains the leading cause of death and disability worldwide[55].  
An estimated 17.1 million people died from CVD in 2004, representing 29% of all 
global deaths. Of these, an estimated 7.2 million deaths were due to CAD[55]. Well 
established risk factors for CAD are dyslipidaemia, hypertension, cigarette smoking, 
diabetes, abdominal obesity and lack of physical activity[56].  
In recent years there has been considerable interest in the role of air pollution levels and 
an association with CAD is increasingly recognized[10, 57], as even a brief (1 hour) 
encounter with traffic could lead to an increased risk of AMI[33], while chronic 
exposure  may increase the risk of death due CAD[43]. The CV effects of ambient 
particulates and gases have been extensively documented and thoroughly reviewed 
during the past few years[10, 57-59]. The totality of the evidence suggests that both 
short-term and chronic exposure to ambient air pollutants and traffic are associated with 
CV hospitalization and mortality[9, 10, 56, 59]. These associations have been observed 
for various gaseous co-pollutants and different metrics of particulates (PM10 and PM2.5).  
CVD encompasses various diseases that have multifactorial aetiology. Many of the 
established risk factors are commonly shared by most CVDs, which have differing 
presentation and underlying pathophysiology. The CV health endpoints considered by 
air pollution studies include established diseases like ischaemic heart disease (IHD) and 
CHF and physiological measures of cardiovascular function such as heart rate and HRV, 
blood pressure, DVT, various ECG changes and atherosclerosis[10].    
1.5.1 Short-term effect studies  
 
Several epidemiological time series have reported associations between daily changes in 
ambient air pollution levels and hospital admissions and mortality for various indices of 
CVD. Many of these studies have been reported from single cities and a few have 
combined data from various cities and countries. Two large-scale studies in the USA 
and Europe have assessed the relationship between daily changes in ambient air 
pollutants and CV hospital admissions rates[45, 46].  Most associations were observed 
with exposure data of the same day or a lag of a few days.  
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A study by Samet et al. examined the effect of  daily mortality in the 20 largest US 
cities in connection with five criteria pollutants4 (PM10, CO, SO2, NO2 and ozone)[45]. 
It found that each 10 µg/m3 increase in PM10 was associated with a 0.68% (95% CI, 
0.20 to 1.16 %) rise in CV and respiratory mortality. The study also found a weak 
association between ozone and mortality in summer, when ozone levels were highest, 
but not in winter. Levels of CO, SO2 and NO2 were not associated with mortality[45].   
As part of APHEA-II,  Katsouyani and colleagues investigated the effects of PM10 and 
gaseous pollutants on mortality outcomes in 29 European cities with an estimated 
combined population of 43 million[46]. The estimated rise in daily CV mortality for 
each 10 µg/m3 increase in PM10 was 0.69% (95% CI: 0.31-1.08). Additional analysis of 
the APHEA-II mortality data by Zanobetti et al. found a doubled CV mortality risk   
associated with air pollution when they considered long-term effects of up to 40 days.  
The authors report a 1.97% increase in CV mortality (95% CI 1.38% to 2.55) per 
10 µg/m3 elevation in PM10[47]. 
In addition to large multi-city time series, a number of smaller studies of short-term 
effects have been conducted in various countries and reviewed by several 
investigators[9, 59]. These have reported associations between short-term changes in 
ambient air pollutants and various CV outcomes including mortality[60] and hospital 
admissions[61, 62]. Several studies have reported associations between acute coronary 
syndrome (ACS) and ambient pollutants and exposure to traffic[20, 33]. Based on 
pooled estimates of metanalyses and published multi-city time series studies, Pope and 
Dockery estimate that each 10 µg/m3 increase in PM2.5 concentration is associated with 
a 1% increase in CV mortality[9]. A recent major review of air pollution and CVD 
conducted for the UK Department of Health has produced a meta-estimate of published 
time series studies, according to which, for each 10 µg/m3 increase in PM2.5 there was a 
1.4% (95 % CI: 0.7, 2.2) increase in CV mortality[59].
   
Most such studies have used ambient central environmental monitoring data to estimate 
individual exposure, which will lead to exposure misclassification. In addition, the 
focus of most studies was on PM and the independent effect of gases was not 
satisfactorily explored. Air pollution is caused by a complex mixture of pollutants, most 
of those studied having common sources and being strongly and positively correlated, 
                                                 
4
 Criteria air pollutants include the six most common air pollutants in the U.S.: CO, lead, NO2, ozone, 
PM, and SO2. 
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except ozone. Thus it is difficult to attribute an observed association between air 
pollution and health outcome to a single pollutant without consideration of others, as 
has been done in many time series studies. A Canadian time series study that 
investigated mortality outcomes in 8 cities has shown that gaseous pollutants are 
strongly related to hospital mortality from various CV and respiratory causes. The 
authors report that size fractionated particulate mass explained only 28% of the total 
health effect of the mixture, the remainder being accounted for by gases. They conclude 
that any air pollution mitigation strategy should not target a single pollutant but should 
consider the mix of all pollutants[63].   
1.5.2 Studies of long-term effects  
 
Long-term exposure to ambient particulates and gases has been linked to CV outcomes, 
as reported by a number of cohort studies[36, 38, 43, 44]. The first to present 
convincing evidence of long-term risk from exposure to PM2.5 was the seminal HSCS, 
which reported an adjusted CV mortality rate of 1.26 in the most polluted city when 
compared to the least polluted[36]. Likewise, the much larger ACSS showed that each 
10 µg/m3 increase in annual PM2.5 mean concentration was associated with a 6% 
increase in cardiopulmonary mortality[44].  
The WHI evaluated the mortality outcome in 65 893 healthy post-menopausal women 
in 36 US cities between 1994 and 1998. During the follow-up, 1816 deaths occurred. 
The study found that each 10 µg/m3 increase in PM2.5 was associated with a hazard ratio 
(HR) of 1.24 (95% CI: 1.09-1.41) for CV events and 1.76 (95% CI: 1.25-2.47) for CV 
mortality.   
An analysis of a sub-cohort of the AHSMOG study of 3259 subjects with 22 years of   
follow-up has reported an RR of 1.42 for CHD mortality with each 10 µg/m3  increase in 
PM2.5, PM2.5-10 and PM10 in women, but not in men[51].  
Another US cohort study examined the relationship of chronic fine and coarse 
particulate exposure with all-cause mortality and fatal and nonfatal incident CHD in 
women from the Nurses’ Health Study between 1992 and 2002. The authors report that 
each 10 µg/m3 increase in annual PM2.5 was associated with fatal CHD (HR = 2.02; 95% 
CI, 1.07-3.78) after adjusting for known risk factors[64]. 
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A cross-sectional study of the relationship between PM2.5 exposure and atherosclerosis 
in 798 individuals reported that for each 10 µg/m3 increase in PM2.5 there was an 
increase of 3.9-4.3% in carotid intima-media thickness (CIMT), which is a marker of 
generalized atherosclerosis and a strong predictor of cardiovascular morbidity[52]. 
The HSCS and ACSS results were instrumental in the setting of air quality standards for 
PM2.5 in the USA and this generated scepticism among different interest groups 
including the scientific community, leading to a particulate study reanalysis project 
which involved meticulous auditing and reanalysis of the original data by independent 
investigators. The reanalysis procedure validated the quality of the original data and 
replicated most of the results of both cohorts[65]. The reanalysis further disclosed that 
the estimated effects of fine particles on mortality were strongly modified by 
educational status. The association between an increase in fine particulates and 
mortality was stronger in individuals without a high school education than in those who 
had completed high school and in those with more than a high school education[65].  
The two large studies by Dockery[36] and Pope[44] that assessed the relationship 
between PM and mortality outcomes relied on a comparison of exposure between cities 
and thus did not account for geographic variations within cities. As reported by Miller 
and colleagues,[43] substantial intra-urban variability in exposure as well as exposure 
gradient proximity to main roads[38] would challenge the interpretation of the observed 
results.  Furthermore, the role of other social factors (e.g. socio-economic status, 
housing characteristics, location of residence), lifestyle factors (e.g. diet, nutritional 
status, smoking habits) and unmeasured risk factors could confound the observed 
association. 
1.6 Air Pollution and Stroke  
 
Stroke, also called brain attack or cerebrovascular disease, is defined as the clinical 
syndrome of rapid onset of cerebral deficit lasting more than 24 hours or leading to 
death, with no apparent cause other than a vascular one. TIA or mini-stroke is a short-
lived focal neurological deficit lasting from few seconds to 24 hours, usually followed 
by complete recovery. TIA results from temporary occlusion of brain arteries.  
Stroke is generally classified into 2 subtypes, ischaemic (87 % of all case of stroke) and 
hemorrhagic (13%), the latter further classified into intracerebral haemorrhage (10%) 
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and subarachnoid haemorrhage (3%)[56]. The main causes of ischaemic stroke are 
thrombus (clot) formation and occlusion of cerebral arteries due to atherosclerosis and 
cardio-embolism[66]. Haemorrhagic strokes are caused by bleeding in and around the 
brain.  
The principal risk factors for stroke are hypertension, cigarette smoking, diabetes 
mellitus, dyslipidaemia, obesity, atrial fibrillation, past TIA and carotid artery 
stenosis[56]. Advanced age, black ethnicity, male gender, alcohol consumption, post-
menopausal hormone therapy and a physically inactive lifestyle are also known 
demographic risk factors for stroke[56]. 
Recent research has identified a large number of non-traditional vascular risk factors of 
stroke such as markers of inflammation like C-reactive protein (CRP), intracellular 
adhesion molecule 1 (ICAM-1), white blood cell count and various cytokines, various 
infectious agents, elevated homocysteine levels, rennin angiotensin system, coagulation/ 
platelet related factors (tissue factor, fibrinogen, platelet reactivity, hypercoagulability 
and plasminogen activator inhibitor type1), elevated serum levels of lipoprotein-
associated phospholipase-A2 and troponins[67]. Furthermore, various novel 
environmental risk factors for stroke are reported, including lower educational and 
socio-economic status, depression, obstructive sleep apnoea syndrome, environmental 
pollution and diet[68]. Despite intensive search for causes, about 15-30% of all 
ischaemic strokes have no known identifiable vascular cause[68].  
A large number of epidemiological studies have identified various health outcomes 
following short-term exposure to ambient air pollutants, as reviewed elsewhere[9, 10]. 
Many of these studies have focused on respiratory and CV morbidity and mortality, 
whereas very few have addressed stroke and TIA as outcomes. Whilst the CV risks 
related to air pollution are now widely recognized, research into the relationship 
between air pollution and stroke is limited.   
Traditional personal risk factors like hypertension and smoking are associated with 
large RR on CV outcomes, but the consequences are generally restricted to individuals 
with that risk, such as those who have hypertension or those who smoke, rather than to 
communities. In comparison, as shown in many studies and reviews, exposure to air 
pollution has a small RR for most individuals in relation to the risk associated with 
traditional risk factors[9, 45]. A large time series study in 20 US cities found an increase 
in CV and respiratory mortality of 0.68%[45] (95% posterior  interval, 0.07-0.93) for 
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each 10 µg/m3 increase in PM10, while a cohort study by Pope and colleagues estimates 
that each 10 µg/m3 increase in PM2.5 was associated with an RR of 1.06 (95% CI 1.02-
1.10) for cardiopulmonary mortality[44]. In contrast, the corresponding RR of smoking 
20 cigarettes a day for 35 years starting before age 18 years was 2.89 for 
cardiopulmonary mortality[44]. Thus, the risk of traditional risk factors is substantially 
larger than that of exposure to air pollutants. However, the ubiquitous and involuntary 
exposure of all individuals to ambient air pollutants means that the estimates of air 
pollution apply to the entire community and that their public health significance is 
enormous. As stoke is a highly prevalent disease, the small RR for individuals means a 
higher absolute risk. 
In the last decade, a few short-term effect studies have reported associations between 
ambient particulates and gases and stroke/TIA. Most of these have investigated the 
impact of ambient air pollution on hospital admissions[17, 69-72], emergency 
department visits[73] and stroke mortality[74]. Long-term cohort studies have also 
reported associations between ambient pollutants and stroke mortality[43].  
The earliest evidence  linking ambient air pollutants to stroke mortality was provided by  
a study that investigated the major London smog of December 1952[4]. It reported 
increased CV, respiratory and stroke death during the episode. Despite falling levels of 
ambient air pollutants in industrialized countries, associations between various health 
outcomes, including stroke, are reported. The observed associations are with measured 
pollutants of different indices of particles (UFP, PM2.5 and PM10) and various gases. 
Similarly, proximity to main roads as a proxy of exposure to ambient  pollutants was 
used in one study[75]. Most of the studies were conducted in towns in Taiwan[69, 72], 
South Korea[74] and China[76] where the concentrations of pollutants were very high, 
while few were in towns where the ambient concentrations were  relatively low[77-80]. 
A multicity study in the USA found an association between measured ambient 
pollutants and ischaemic stroke[71]. The majority of these studies have examined 
associations between air pollution and ischaemic stroke, and a few have examined the 
link with haemorrhagic stroke, while some have not made the distinction. 
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1.7 Air Pollution, Diabetes Mellitus and Inflammation  
 
Diabetes mellitus is an ever-increasing global epidemic that affects an estimated 220 
million people worldwide and 1,765,000 in the UK[81]. Its prevalence is expected to 
rise to 366 million worldwide by the year 2025, with the largest increases in Africa, 
Asia and South America[81, 82]. According to the WHO, 80% of diabetes deaths occur 
in low- and middle-income countries and half occur in people under the age of 70 
years[81].  The WHO projects that diabetes deaths will double between 2005 and 
2030[81]. Diabetes has a number of complications and is associated with huge 
economic, social and health burdens.  
Diabetes mellitus is a chronic metabolic condition that is marked by a heightened 
inflammatory state[83], endothelial dysfunction[84], oxidative stress[85], disturbance of 
coagulation and propensity to thrombosis[86]. The adverse health effects of PM 
pollution are known to follow these same pathways. Furthermore, diabetes is associated 
with significant adverse CV events[87] and a constellation of CV risk factors such as 
obesity and atherosclerosis, which have a common feature: inflammation.  
There are two types of diabetes. Type 1, which is more prevalent in childhood, is 
characterized by autoimmune destruction of pancreatic islet cells and insulin deficiency. 
Type 2 diabetes, which is increasingly recognized as a disease of the innate immune 
system, is more prevalent in older people and caused by a combination of insulin 
resistance and impaired insulin secretion[88, 89]. It accounts for more than 90% of all 
diagnosed cases. Research studies have identified various modifiable and non-
modifiable risk factors for diabetes. The former include conditions related to behaviour 
and lifestyle, like obesity, physical inactivity, diet and stress[88].  
Evidence is currently accumulating to link disturbance of the innate immune system to 
the pathogenesis of type 2 diabetes, insulin resistance and metabolic syndrome, mainly 
due to cytokine-mediated activation of the immune system[90]. According to this 
theory, constant and ongoing activation of innate immunity by environmental stressors, 
both physical and psychological, and by infectious agents leads to disproportionate 
response to stimuli, so that a system which was meant to defend the body and help it to 
recover from injury now causes a disease[83, 90]. 
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Diabetes is related to increased oxidative stress, inflammatory response and endothelial 
dysfunction, with an abnormal elevation of acute phase proteins like fibrinogen and 
CRP. Several studies show that in initially non-diabetic subjects various markers of 
inflammation like white blood cell (WBC) count, CRP and IL-6 are independent 
predictors of future development of type 2 diabetes[83, 90]. Furthermore, treatment by 
high dose anti-inflammatory drugs like aspirin reduces fasting levels of blood glucose, 
triglyceride and CRP, and improves control of established diabetes, suggesting the role 
of immunity in the disease[83, 90]. Pickup argues that the association of inflammation 
with both type 2 diabetes and atherosclerosis suggests activation of the innate immune 
system as antecedent of both diseases and that this association also explains why 
patients with diabetes have an increased propensity to accelerated atherogenesis[83].  
Diabetes is an independent, strong risk factor for CVD and cross-sectional as well as 
community -based epidemiological studies have shown a strong relationship between 
CVD and prevalence of diabetes[87]. Furthermore, a consistent temporal relationship 
between diabetes and incident CVD and mortality has been shown in prospective 
studies[87]. Diabetes mellitus has a number of macro-vascular complications including 
CAD, peripheral arterial disease and stroke, primarily due to endothelial and smooth 
muscle dysfunction and impaired platelet functions[91].   
The vascular endothelium is a thin layer of single cells that lines the inner surface of 
blood vessels, forming an interface between blood components and tissues. It regulates 
blood flow and nutrient delivery, is involved in the synthesis of diverse biologically 
active molecules and helps to protect blood vessels from toxic substances[92]. Among 
the endogenous substances produced by the endothelium are vasoactive substances, 
including nitric oxide, prostacyclin and endothelins. These substances are involved in 
regulation of vascular tone and regional blood flow, suppression of vascular smooth 
muscle cell proliferation, modulation of leukocyte-endothelial interactions and 
modulation of thrombosis. The endothelium  also modulates the proliferation and injury 
response of the vascular smooth muscle layer, thus protecting against atherogenesis[92].  
Diabetes and other major CV risk factors like hypertension, obesity, insulin resistance 
and hyperlipidaemia have a common feature of endothelial dysfunction, an important 
early feature of atherosclerosis[92]. Endothelial dysfunction may also be caused by 
metabolic toxins like free fatty acids, by inflammatory cytokines including IL-6 and 
TNF-α or by production of reactive oxygen species (ROS) that scavenge vascular 
NO[92]. Recent epidemiological and animal models have shown that exposure to 
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ambient particulates and diesel exhaust particles is associated with generation of 
oxidative stress[93] and ROS[94]. Furthermore, diabetic patients exposed to PM were 
found to have impairment of vascular reactivity and endothelial dysfunction[50]. 
Consequently, reduced availability of endothelium-derived NO due to reduced 
production or increased degradation from various causes may be one factor that links 
diabetes, other CV risk factors and air pollution to atherogenesis.   
 
1.8 Air pollution and markers of inflammation 
 
Inflammation is the body’s response to noxious stimuli including infection, acute injury 
and PM. Among the many constituents involved are cells such as phagocytes 
(neutrophils and monocytes in blood; macrophages), plasma proteins, vascular cell 
walls and connective tissue. These contribute to acute phase responses, which occur 
shortly after injury and are characterized by increased production of protein by liver 
hepatocytes as well as changes in endocrine, immunological and autonomic functions.  
The inflammatory response is accompanied by the activation and mobilization of 
inflammatory cells, with endothelial activation, production of acute phase proteins and 
the production of circulating inflammatory mediators[95]. Acute phase proteins 
comprise several groups whose plasma concentration increases (positive acute-phase 
proteins) or decreases (negative acute-phase proteins) during inflammatory disorders; 
these changes in concentration occur primarily due to increased production in the 
liver[96]. The release of acute phase proteins is regulated by cytokines, particularly 
interleukin 6 (IL-6), interleukin 1β (IL-1β ), and tumour necrosis factor alpha 
(TNFα)[96]. The final result of the inflammatory response is the local release of 
inflammatory mediators and increased vascular permeability.   
Various observational epidemiological studies and toxicological studies have 
investigated the role of particulates and gases on various markers of inflammation.       
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1.8.1 Observational studies and inflammatory response 
 
Seaton and colleagues[97] suggest that deposition of UFPs in the lungs may induce 
alveolar inflammation and lead to the release of inflammatory mediators. They 
speculate that UFPs may trigger hypercoagulability of blood, which would predispose 
susceptible individuals to cardiac events. Several studies have tested this hypothesis and 
despite some inconsistencies appear generally to confirm it[34, 35, 98-103]. The 
majority of investigations of the effect of PM on inflammatory markers have been short-
term exposure studies, but recently a few mid- to long-term ones have examined the 
effect of chronic exposure to PM on inflammatory markers[104, 105]. 
Peters et al. retrospectively analyzed blood collected during an air pollution episode in 
Germany[98]. They report an increase in plasma viscosity in association with PM10 and 
SO2 in higher values of plasma viscosity (95th percentile) on polluted days. A follow-up 
study found a positive association between CRP and TSP, and SO2[106].   
A cross-sectional analysis by Schwartz suggests a positive association between PM10 
and increase in fibrinogen, platelets and WBC count[99], while a study in London found 
an association between daily concentration of black smoke and NO2 and 
fibrinogen[101]. A cross-sectional survey by Liao et al. also found a significant 
association between PM10 and von Willebrand factor antigen (vWF) among diabetics.  
A positive association between adhesion molecules (ICAM-1 and VCAM-1) and 
exposure to black carbon has also been reported[107], as has an increase in fibrinogen 
and erythrocyte sedimentation rate  in association with particle number[108].  
Bone marrow stimulation is another feature of exposure to air pollution. Tan and 
colleagues[109] made serial measurement of WBC count in national service men during 
the 1997 Southeast Asian smoke-haze episode. They reported a significant increase in 
WBC during the haze period, which returned to normal after the haze had cleared.     
Seaton and colleagues conducted a panel study on 112 elderly subjects and found 
decreased haemoglobin concentration, packed cell volume, red cell and platelet count in 
association with personal and ambient PM10. In addition, an increase in CRP and a 
decrease in fibrinogen were observed. No association between PM10 and IL-6, Factor 
VII and WBC was found[35].   
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A study of the effect of occupational exposure to welding fumes on inflammatory 
markers reported a significant increase in CRP 16 hours after welding exposure[110]. A 
panel study in CAD patients found positive associations between PM pollution and CRP 
and ICAM-1. The odds of observing a CRP value above 90th percentile is reported as 
3.2 (95% CI: 1.7 to 6) in relationship with accumulation mode particles and 2.3 (95% 
CI 1.3 to 3.8) for UFP[34].  
A small panel study on nine healthy patrol troopers found an association between in-
vehicle PM2.5, decreased lymphocytes, increased RBC indices, CRP and vWF[103].  
Another panel study of 88 elderly subjects found a positive association between PM2.5 
and CRP[102].  
Several recent panel studies have found associations between PM exposure and 
CRP[111, 112], IL-6[111-113], impaired blood vessel reactivity[50] and increased 
markers of oxidative stress[93]. In contrast to the above studies, others have failed to 
show an association or have found only a weak association between PM exposure and 
CRP, fibrinogen and D-dimer[114-116]. A recent panel study of 132 non-smoking 
patients with stable chronic heart failure found no association between measured 
pollutants and markers of inflammation or HRV. All study participants were receiving 
one or more cardioprotective therapies, such as angiotensin-converting enzyme (ACE) 
inhibitors, beta blockers, diuretics, aspirin and statins, and the authors attribute the lack 
of association to the effect of such treatment[115].  
Recently, a few investigators have examined the role of long-term exposure to ambient 
PM in various populations[104, 105, 108, 117, 118], finding that PM exposure was 
related to increased WBC[104], CRP and fibrinogen[105], and fibrinogen and 
ESR[108]. Other investigators have found no evidence of an association between PM 
exposure and CRP and fibrinogen[118], while some report only a weakly suggestive 
association with CRP[117]. 
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1.8.2 Experimental and toxicological studies 
 
Epidemiological studies, owing to their observational nature, have difficulty in 
establishing causality, as they are unable to influence the exposure parameter or the 
population under study. Thus, establishing causality in environmental and air pollution 
studies is difficult and epidemiological inferences have to be confirmed by experimental 
and toxicological studies. In contrast to epidemiological studies, experimental studies 
can control the exposure parameter. However, they are not able to reproduce either the 
real-time ambient particulate mixtures or temporal variation that occurs in natural 
ambient exposures. In addition, factors such as the concentration and duration of 
exposure, the type of human subjects studied (usually healthy and young) and 
dissimilarities between humans and other animal species will affect the interpretation 
and generalization of experimental studies. The following section briefly summarizes 
selected recent experimental and animal studies in air pollution research which have 
studied the hypothesized mechanistic link between PM pollution and CV outcomes.  
1.8.2.1 Human exposure studies  
 
The systemic inflammatory responses observed in association with ambient particles in 
observational epidemiological studies have been supported by various animal and 
human exposure studies[119, 120]. Ghio et al. exposed 38 healthy subjects to 
concentrated ambient particles (CAPs) and found a mild increase in neutrophils in both 
bronchial and alveolar fractions in those with CAP exposure compared with those 
exposed to filtered air. They also report that blood obtained 18 hours after CAP 
exposure contained more blood fibrinogen than that obtained before exposure[121]. A 
similar study by Holgate and colleagues found a modest increase in blood fibrinogen 18 
hours after exposure to CAPs[122].   
Another study found an increased level of neutrophils and B-lymphocytes in broncho-
alveolar lavage and increased level of  neutrophils, T and B lymphocytes, mast cells and 
endothelial adhesion molecules (ICAM-1 and VCAM-1) in bronchial biopsy among 
those exposed to diesel exhaust[123]. Other experimental studies also found an increase 
in serum fibrinogen[124] and ICAM-1[125] after CAP exposure.  
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An experimental study by Routledge and associates investigated the effect of pollutants 
on human subjects (20 healthy volunteers and 20 patients with multivessel CAD) in a 
placebo-controlled double blind setting[22]. In a crossover design, subjects were 
exposed to carbon particles, SO2 and a combination of carbon particles and SO2 at 
baseline, and on 7 and 14 days, whereas controls were exposed to bottled medical air. In 
contrast to most other studies, the researchers found no effect of measured pollutants on 
inflammatory and coagulative markers at 0, 4 and 24 hours after exposure. They argue 
that the effect of particles on inflammatory markers depend on the composition and 
presence of reactive species such as transition metals, which were absent in their case.  
 
1.8.2.2 Experimental animal studies  
 
During the last decade, various experimental animal studies have supported the 
mechanistic links between PM exposure and different health outcomes by providing 
plausible and relatively consistent results[126]. These animal studies have been used in 
the identification of the different active and toxic constituents of PM, which was not 
feasible in epidemiological and human experimental studies. 
Suwa et al[127] provided the first experimental evidence of the harmful effect of PM on 
rabbit tissue. Their experiment on Watanabe heritable hyperlipidaemic rabbits showed 
an increase in circulating polymorphonuclear (PMN) immature cells and an increase in 
the size of the bone marrow mitotic pool of PMNs in the experimental group. In 
addition, they demonstrated a dose-dependent progression of atherosclerotic lesions 
toward a more advanced phenotype with deposition of extracellular lipid pools in 
coronary and aortic lesions, as well as in the total amount of lipids in aortic lesions in 
the experimental group. Similarly, Sun and associates[128] carried out an experimental 
study in mice by exposing them to concentrated PM2.5 or filtered air. They found an 
increase in plaque formation, altered vasomotor tone and increased vascular 
inflammation in those exposed to fine particles.  
Similarly, dogs exposed to CAPs developed ECG signs of myocardial ischaemia[129]. 
In another study, hamsters instilled with ultrafine and diesel exhaust particles developed 
an increased systemic thrombosis, pulmonary inflammation and rapid activation of 
blood platelets[9, 59]. Studies with CAPs in rats have also shown an increased 
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inflammatory effect and oxidative stress in the lungs. Short-term exposure to PM in 
canines has resulted in an increase in neutrophils, lymphocytes and macrophages in 
bronchial lavage and blood[130]. Another recent animal study investigated the 
proatherogenic effect of filtered air, PM2.5 and UFPs in apolipoprotein E null mice. The 
authors report that mice exposed to UFPs exhibited larger early atherosclerotic lesions 
and increased expression of antioxidant genes in the liver compared to mice exposed to 
PM2.5 or filtered air. They argue that UFPs have greater propensity to generate systemic 
oxidative stress[131].  
The study of animal models further strengthens the existing hypothesis that progression 
of atherosclerosis and increased vulnerability to plaque rupture may underlie the 
relationship between PM pollution and increased cardiovascular events. 
1.9 Inflammatory Markers and CVD 
 
Coronary artery disease accounts for more than 20% of all deaths in developed 
countries. The underlying cause of CAD is atherosclerosis, which is a slow and complex 
process characterized by deposition of lipids in the subendothelial layer and formation 
of atheromatous plaques in the arterial intima, causing progressive narrowing and 
eventual occlusive thrombosis. The basic lesion of atherosclerosis is plaque formation, 
the major component of which includes intimal smooth muscle cells, cells and cell 
debris, calcium, cholesterol esters and crystals, and a fibrous cup which is made of 
connective tissue. 
Recent research suggests that atherosclerosis is an inflammatory process and that 
inflammation plays an important role in the pathophysiological process of 
atherosclerosis[132-136]. According to this theory, inflammation is involved in the 
inception and development to its endpoint of thrombotic complication. A number of 
cells (macrophages and monocytes, T lymphocytes, endothelial cells and platelets), 
chemical mediators (adhesion molecules, chemokines, pro-inflammatory cytokines and 
growth factors) vascular smooth muscle and fibrous tissue are involved in the whole 
process from initiation to thrombotic complications[132, 136].   
Several prospective and cross-sectional studies and metanalyses have suggested a 
positive  relationship between cell- and cytokine-mediated markers of inflammation 
such as IL-6, CRP, serum fibrinogen, leukocyte count and future development of 
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cardiovascular disease[137-142]. These studies suggest that the markers are independent 
predictors of CVD in both healthy individuals and patients with an underlying CVD. In 
addition, an association between serum viscosity, whose main component is fibrinogen,  
and CHD is also reported[143]. A joint statement of the Centres for Disease Control and 
Prevention and the American Heart Association recommends the use of high sensitivity 
CRP (hs-CRP) assay as the analyte of choice for CVD risk prediction from a clinical 
chemistry standpoint[144].  
CRP and many of the markers that are positively associated with CAD are also 
positively associated with short-term exposure to different metrics of PM. Prescott and 
colleagues have reported that people with high plasma level of fibrinogen may be more 
sensitive to the effects of particulate pollution on the cardiovascular system[145].  
The local and systemic effects of pollutants that result from the activation of 
inflammatory cells, the production of hydroxyl radicals and the resultant oxidative 
stress, and endothelial dysfunction may be responsible for the subsequent development 
of atherosclerosis or its progression due to instability of atheromatous plaques (Figure 
1.6). The observed changes in blood coagulation parameters subsequent to particle 
exposure may also affect the stability of the atheromatous plaque, which may ultimately 
lead to acute myocardial ischaemia.  
Both toxicological animal and observational epidemiological studies have recently 
investigated the role of PM exposure in atherosclerosis. An animal study by Suwa 
provided the first evidence to link PM exposure to the subsequent development of 
atherosclerosis. The authors showed that repeated instillation of urban PM10 in 
Watanabe heritable hyperlipidaemic rabbits was associated with increases in circulating 
PMNL and in bone marrow mitotic pool of PMNL. It also enhanced the progression and 
destabilization of atherosclerosis plaques[127]. Another animal model by Sun and 
colleagues has shown that long-term exposure to PM10 leads to increased atherosclerotic 
plaque volume in apolipoprotein E null mice[128].   
Human epidemiological research has also shown the atherogenic potential of exposure 
to PM. A Los Angeles  study has shown an increase in CIMT with long-term exposure 
to fine particles[52].  A more recent prospective epidemiological study demonstrated 
that residential proximity to major urban roads is associated with increased coronary 
artery calcium scores[146].  All in all, these studies suggest that chronic exposure to PM 
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and the ensuing systemic inflammation could contribute to the development or 
progression of atheromatous lesions. 
Other research has shown that CRP could be used as a stronger and more reliable 
predictor of future cardiovascular events than some conventional risk markers, such as 
serum cholesterol level[147-149]. CRP is also related to classical risk factors of CAD 
such as obesity, smoking, serum fibrinogen, HDL-cholesterol, heart rate, blood 
pressure, serum triglycerides, fasting blood glucose and apolipoprotein B[139].   
The mechanism by which CRP leads to CVD is not fully known, but is thought to be 
through impairment of vasoreactivity, activation of leukocytes and the complement 
system, and through stimulation of the expression of adhesion molecules[10, 150]. 
Furthermore, CRP may lead directly to initiation and progression of atherosclerosis via 
different mechanisms such as enhanced formation of foam cells and recruitment of 
inflammatory cells[10, 151]. CRP is believed to induce significant expression of 
adhesion molecules by human endothelial cells which produce ICAM-1, VCAM-1, 
selectin and monocyte chemotactic and activating factor, and this finding points to the 
proinflammatory and proatherogenic nature of CRP[152].   
1.10 Mechanisms of PM-induced CV damage 
 
The review above shows that air pollutants have an effect on general health and CV 
health which could lead to hospital admission or death. Although the underlying 
mechanisms that link particulate pollution to CV are still under study, currently three 
main hypotheses have been proposed (Figure 1.6). These are:   
1. Inflammation, coagulation and endothelial damage: The first hypothesis 
suggests that inhaled PM would cause local inflammation and oxidative stress in 
the lungs. This would subsequently lead to systemic inflammation with release 
of inflammatory mediators and endothelial activation with the end result of 
atherogenesis[97].  
2. Autonomic and neural effects: This hypothesis suggests that PM in the lungs can 
induce neural activation via irritant receptors and lead to autonomic imbalance 
with either increased sympathetic activation or parasympathetic withdrawal.  
3. Translocation of particles into systemic circulation: Soluble compounds or 
nanosized particles may enter the pulmonary vasculature and then be carried to 
the systemic circulation or brain.  
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Figure 1.6 Potential mechanism of CV damage from PM exposure 
Modified from Brook et al.[10], Pope and Dockery[9] and  Mills et al.[153]. 
AMI, Acute myocardial infarction; CRP, C-reactive protein; HRV, heart rate variability; IL-6, 
interleukin 6; IL-8, interleukin 8; TIA, transient ischaemic attack; TNF-α, tumour necrosis 
factor alpha; WBC, white blood cells. 
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1.10.1 Inflammation, coagulation and endothelial damage 
 
The first hypothesis suggests that deposition of particulates in the lungs induces local 
inflammation and generation of reactive oxygen species with resultant oxidative stress 
in the lungs, leading in turn to systemic inflammation[97, 154, 155]. Pulmonary 
inflammatory responses have been observed in animal models and human volunteers 
following PM exposure[124, 156] [121] and oxidative stress following exposure to 
particulate transition metals is well documented [93, 157]. Human alveolar 
macrophages and bronchial epithelial cells exposed to PM release various 
proinflammatory cytokines in a dose-dependent manner[95]. 
Alveolar macrophages and lung epithelial cells are the first line of defence of the 
pulmonary tree against invading microorganisms or other noxious substances such as 
inhaled atmospheric particles or tobacco smoke. The uptake of PM by alveolar 
macrophages and lung epithelial cells releases several coagulatory and proinflammatory 
cytokines such as IL-1, IL-6, interleukin 8 (IL-8), TNFα and neutrophils (Figure 1.6).    
The release of cytokines and chemokines stimulates a systemic inflammatory response 
and activation of the haematopoietic system particularly the bone marrow[158], leading 
in turn to leukocytosis and the production of many acute phase proteins including CRP 
and fibrinogen[96]. The synthesis of CRP by the liver is regulated by many 
inflammatory cytokines such as IL-6 and IL-1β, which are directly related to increased 
cardiovascular events[10, 119, 154, 159]. 
Epidemiological studies have shown that PM exposure can stimulate an acute phase 
response with release of CRP[34, 35, 106, 110] and  fibrinogen[99, 101, 113, 145].  
Similarly, PM exposure has been associated with the release of IL-6[95, 111, 113] and 
increased plasma viscosity[98].  Likewise, controlled human experimental studies have 
shown increased inflammatory responses of the airways[123], increased numbers of 
circulating PMNL and immature cells in the blood[123] and increased markers of 
inflammation in the blood[121, 123] following exposure to air pollutants. 
The release of inflammatory cytokines could also lead to endothelial erosion, instability 
of atheromatous plaque and thrombosis[154]. Studies have shown that atmospheric 
pollution can lead to endothelial dysfunction with up-regulation of adhesion 
molecules[107, 119] and vWF[107]. It has also been shown that endothelial dysfunction 
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is the earliest detectable pathological process in atherosclerosis[132, 160], manifested 
by the expression of selectins and adhesion molecules (ICAM and VCAM), which 
attract and capture inflammatory cells[160]. The increased levels of coagulation 
parameters, increased viscosity and enhanced platelet aggregation, in association with 
endothelial dysfunction, may predispose susceptible individuals to plaque 
destabilization, procoagulatory states and formation of a thrombus. 
 
1.10.2 Autonomic dysfunction and neural effects 
 
The second hypothesis suggests that particles deregulate autonomic control of the heart 
due to stimulation of neuronal receptors in the lung parenchyma (Figure 1.6)[10, 154]. 
Numerous epidemiological studies have shown that a short-term change in ambient air 
pollution is associated with changes in heart rate, HRV and arrhythmia, suggesting a 
possible direct effect of PM on autonomic control of the heart. A Taiwanese panel study 
of 40 young healthy students has reported an elevation of heart rate and blood pressure 
following exposure to indoor PM2.5 and PM10[161]. Several observational 
epidemiological studies have shown reduced  HRV in association with increased 
particulate mass[102, 162, 163] and reduced HRV has been shown to be a significant 
predictor of morbidity and mortality among the elderly[164]. In addition, short-term 
changes in ambient air pollutants have been associated with disturbance of cardiac 
repolarisation[165] and ventricular tachyarrhythmia[166, 167]. 
 
Autonomic changes have also been observed in experimental animal studies[168] and in 
controlled human exposure studies[169]. Dogs chronically exposed to fine PM were 
found to have elevation of arterial blood pressure, which indicates an increased 
sympathetic nervous system activity[168]. Similarly, healthy elderly subjects exposed to 
CAPs experienced a significant decrease in HRV[169].   
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1.10.3 Translocation of Particles into Systemic Circulation 
 
Soluble compounds and/or nanometre-sized PM may rapidly enter the pulmonary 
vasculature and subsequently be transported throughout the systemic circulation[170].  
Human and animal experimental studies have shown the presence of particles in many 
extra-pulmonary sites such as liver, heart, spleen and the central nervous system, 
including the brain. Animal and human toxicological studies have shown translocation 
of ultrafine particles into the systemic circulation through blood or through olfactory 
nerve[14, 15, 171, 172].  Other studies have not found particles in blood circulation 
following  inhalation of technetium-99m-labeled carbon aerosols in humans[173, 174]. 
Translocation of particles is still a controversial issue. Particles which gain access to the 
systemic circulation may cause CV toxicity directly without antecedent pulmonary and 
systemic inflammation[175].  
 
1.11 Summary and Conclusion 
 
This chapter has attempted to present an overview of the effect of air pollutants on 
human health outcomes, with particular emphasis on CVD. Epidemiological studies 
have demonstrated convincingly an association between exposure to PM and CVD, 
while toxicological studies have offered explanations of the mechanisms that underlie 
the various CV outcomes. These include systemic inflammation, autonomic disturbance 
and the role of particles that gain entry to the bloodstream, all of which were discussed 
but which remain incompletely understood and need further investigation.  
Despite some inconsistencies and contradictions, exposure to ambient air pollutants has 
been shown to have both long- and short-term effect on CV health which could lead to 
increased mortality, hospital admissions and emergency department visits. Short-term 
exposure to ambient air pollution may result in pulmonary and systemic inflammation 
with subsequent release of inflammatory mediators and impact on CV health. Particles 
may also trigger neural reflex in the lungs, with subsequent disturbance of the 
autonomic control of the heart. This would in turn lead to arrhythmia, change in heart 
63 
rate and HRV and an increase in blood pressure. Finally, smaller UFPs may penetrate 
the lungs, gain access to the systemic circulation and reach various organs including the 
heart, where they may cause CV toxicity. Moreover, human and animal studies show 
that long-term exposure to air pollutants may lead to the formation or progression of 
atherosclerosis and peripheral thrombosis, which may predispose individuals to acute 
cardiac events such as AMI and stroke. Various pre-existing diseases, in particular 
CVD, COPD and diabetes mellitus, would predispose individuals to the adverse effects 
of air pollution. Prolonged exposure to PM is also likely to cause increased total and CV 
mortality.  
However, not all studies, whether epidemiological or experimental, have found 
associations between PM exposure and various health outcomes. There are various 
explanations for these observed discrepancies in the observational studies, such as 
differences in study design and methodology, choice of outcome measures, exposure 
assessment methods, the characteristics of the air pollutants and of the study population, 
confounders, and the size of the study population. In addition, the characteristics, 
content, mixture and sources of PM and the presence of co-pollutants may be 
responsible for the observed differences.   
Table 1.3 provides a summary of selected epidemiological studies of the association 
between exposure to different pollutants and inflammatory, coagulation and endothelial 
markers. 
1.12 Aims  
1.12.1 General aims:  
 
There is epidemiological and toxicological evidence that links exposure to ambient PM 
and gaseous pollutants to oxidative stress, increased proinflammatory biomarkers and 
vascular dysfunction. Systemic inflammation secondary to air pollution could 
subsequently trigger acute ischaemic events in heart (AMI) or brain (Stroke and TIA).   
In addition, there is epidemiological and experimental support for the long term 
vascular effect of exposure to PM as evidenced by progression of atherosclerosis. It has 
been suggested that certain groups or individuals are particularly susceptible to the 
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effects of air pollutants, including the elderly and those with pre-existing CVD, COPD 
and diabetes mellitus, more so than healthy individuals.   
 
The aim of this study is to investigate the relationships between PM and gaseous air 
pollutants by studying early biochemical markers for the heart and early clinical 
markers for the brain. A further aim of the study is to investigate the effect of air 
pollutants on markers of systemic inflammation, as an intermediate health outcome in a 
vulnerable type 2 diabetes mellitus population. For the first two studies existing data 
was utilized, while for the last study new data collection was undertaken.  
 
This study has important public health implications.  Stoke, AMI and diabetes are major 
causes of death and/or disability in UK and worldwide, and there is epidemiological 
evidence that shows the role of air pollution in triggering or worsening these outcomes.  
Furthermore, as virtually everyone can be affected by air pollution, the risk to public 
health is enormous. 
1.12.2 Specific objectives 
 
i. To investigate whether daily changes in ambient PM10 and gaseous pollutants are 
related to ACS by studying cardiac troponin T, a highly sensitive and specific 
marker of myocardial damage.  
ii. To investigate the association between daily changes in ambient PM10 and gaseous 
pollutants and the occurrence of TIA. 
iii. To investigate whether exposure to personal PM2.5 and ambient air pollutants (PM10   
and gases) are related to elevation of markers of inflammation and coagulation and 
endothelial dysfunction in a susceptible type 2 diabetic mellitus population. 
1.12.3 Structure of the thesis 
 
The remainder of this thesis is divided into four parts. Chapter 2 deals with the short-
term effects of ambient PM10 and gaseous pollutants on ACS in a hospital setting. In 
chapter 3 the relationship between short-term exposure to ambient air pollutants and 
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TIA is considered. Chapter 4 examines the relationships of inflammatory biomarkers 
with personal PM2.5, ambient particulates and gases. Finally, Chapter 5 discusses the 
overall study results and main findings in comparison with past studies and concludes 
with suggestions for future work. 
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Table 1.3 Epidemiological studies and short-term effects of particulate air pollution on markers of inflammation 
 
 
Author  and 
reference 
number 
Study participants and 
sample size 
Outcome measures Exposure & 
assessment 
method 
Effect size and key findings Remarks 
Peters et al., 
199798, 
2001106 
Cohort study in 
Augsburg, Germany, in 
631 men 45–64 years of 
age with no history of 
AMI at their baseline 
assessment 
CRP, blood viscosity Ambient TSP, SO2 
and CO  
An ↑ CRP level above the 80th 
percentile, OR = 1.31 (95% CI, 
1.09–1.56) in relation with 
TSP (Peters et al 2001);  
The odds ratio for plasma 
viscosity above 95th percentile 
of distribution was 3.6 (95% 
CI 1.6-8.1) (Peters et al, 1997) 
 
Seaton et 
al., 199935 
Panel study of 112 aged 
60+, 12 repeated 
measurement over 18 
months 
 
Haemoglobin, packed 
red cells, RBC count, 
platelets, WBC count, 
CRP, fibrinogen, 
Factor VII, IL-6 
Ambient and 
personal exposure 
to PM10. 3-day 
personal exposure 
estimated from one 
24-h fixed site 
monitor  
An ↑ in personal PM10 and 
ambient PM10 exposure 
resulted in decreased 
haemoglobin concentration, 
PCV, RBC count, platelets and 
Factor VII levels; CRP 
increased only with ambient 
PM10; fibrinogen decreased 
with ambient PM10  
Personal 
exposure 
measurement  
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Schwartz 
200199 
Cross sectional survey of  
the 3rd National Health and 
Nutrition 
Examination Survey (USA) 
Fibrinogen 
Platelets 
WBC 
PM10 
NO2, O3, SO2 
 
Relative odds of being above 
90th percentile were 1.77 (95% 
CI 1.26 to 2.49), 1.27 (95% CI 
0.97 to 1.67 and 1.64 (95% CI 
1.17 to 2.30) for fibrinogen, 
platelet count and WBC 
respectively for an IQR ↑ of 
PM10. 
 
Pekkannen 
et al., 
2001101 
Cross sectional survey 
of 7,205 office workers 
Fibrinogen PM10, CO, NO2, 
SO2 
An increase of NO2 from 10th 
to 90th percentile associated 
with 1.5% higher fibrinogen 
(95% CI, 0.4%–2.5%); 
respective increase for CO 
resulted in 1.5% higher 
fibrinogen (95% CI, 0.5%–
2.5%);  
No association 
with PM10, SO2 
or O3. Effect 
modification of 
season observed 
in relation to 
PM10 
Sorensen et 
al. 200393 
Panel study of 50 
students in central 
Copenhagen. Four 
repeated measures 
RBC and platelet 
counts, haemoglobin 
and fibrinogen.  
Protein and lipid 
oxidation plasma. 
Personal 
monitoring of 
PM2.5, carbon black 
and ambient PM2.5 
 
Small increase in markers of 
oxidative stress and increase 
RBCs in peripheral blood 
 
 
Pope et al., 
2004102 
Panel study in 88 elderly 
subjects, 3 repeated 
observations  
CRP, WBC and 
differential count, 
RBC, platelets, blood 
viscosity 
Ambient PM2.5 
 
An ↑ of 100 µg  PM2.5 was 
associated with 0.81 mg/dl 
increase in CRP 
No association 
with WBC, RBC, 
blood viscosity 
and platelets 
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Riediker et 
al., 2004103 
Panel study in 9 young, 
healthy male highway 
patrol policemen 
CRP, plasminogen, 
vWF, lymphocyte 
count, lymphocytes, 
neutrophils, 
haematocrit, RBC 
indices 
Portable air quality 
monitor in cars, 
roadside monitor 
and ambient 
monitor of PM2.5 
In-vehicle ↑ of 10 µg/m3 PM2.5 
associated with decreased 
lymphocytes (-11%), increased 
RBC indices (1% mean 
corpuscular volume), 
neutrophils (6%), CRP (32%) 
and vWF (12%) 
No association 
with roadside 
and ambient 
particles. Only 9 
hour follow-up. 
Short duration 
and few subjects   
Liao, et al., 
2005100 
Cross sectional study of 
10,208 middle aged 
subjects  
Fibrinogen, Factor 
VIII-C, vWF, 
albumin, WBC count 
PM10, NO2, CO, 
SO2, O3 
 
One SD increment of PM10 
associated with 3.93% higher 
vWF among diabetics and 
0.006 g/dl serum albumin 
among persons with CVD. One 
SD increment of CO associated 
with 0.018 g/dl decrease in 
serum albumin. 
 
Rueckerl et 
al.,  200634 
Panel study of 57 male 
patients with coronary 
heart disease 
CRP, SAA,  ICAM-1, 
E-selectin 
prothrombin 
fragments 1+2,  
Fibrinogen , 
D-dimer, vWF , FVII  
UFP, PM2.5, PM10, 
OC, EC, CO, NO2.  
All pollutants were 
measured at one 
fixed site monitor  
One IQR increase in PM10, 
UFP, NO2 and CO   associated 
with increased CRP above 90th 
percentile with a delay of 2 
days. Strong effect (OR 3.2; 
CI, 1.7, 6.0 with accumulation 
mode). 
No effect of EC 
and OC  
Zeka A et l., 
2006108 
Cohort study of 710 
Normative Aging study 
Fibrinogen, CRP, 
ESR and WBC count 
Particle number, 
black carbon, 
Significant increase in 
fibrinogen 48 hour and one 
Effect 
modification by 
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cohort PM2.5, sulphate week after exposure to PNC. 
Similar increases at 4 week lag 
in association with BC. ESR 
increased in relationship with 
PNC, PM2.5 and BC.  
Gluathione-S-
transferase 
status obesity 
and age 
Diez  Roux 
et al., 
2006117 
A cross sectional survey 
of 5,634 subjects 
CRP PM2.5, IL-6 10 µg/m3 increase in PM2.5 was 
associated with 3% (95% CI -
2-10) and 4% (95% CI -3, 11) 
increase in CRP for 30-day and 
60-day mean exposures. 
Associations 
between PM & 
CRP were weak 
& null with IL-6  
Dubowsky S 
et al., 
2006111 
Panel study of 44 elderly 
people on 4 bus trips 
CRP, IL-6 and WBC Ambient PM2.5, BC, 
CO, NO2,SO2, O3 
IQR increase in PM2.5 
associated with 5.5% (95% CI: 
0.10 to 11%) increase in WBC 
averaged over a week. PM2.5 
and CRP also exhibited 
positive associations among all 
individuals for averages longer 
than 1 day 
Largest effects 
observed in 
patients with 
diabetes, obesity 
and 
hypertension 
O’Neill et 
al. 2007107 
Cross sectional analysis 
of 92 diabetic subjects  
ICAM-1, VCAM-1, 
vWF 
Ambient PM2.5, BC, 
sulphates 
A positive association between 
exposure to BC and ICAM and 
VCAM is observed. 
Strong effects 
among smokers 
& those who do 
not take statins 
Sullivan J et 
al., 2007114 
Panel study of 47 elderly 
individuals.  
CRP, fibrinogen, D-
Dimer, Endothelin 1, 
IL-6 TNF-α, MCP-1 
Outdoor, indoor 
and central site 
PM2.5 
No statistically significant 
association between measured 
pollutants and CRP, fibrinogen 
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and D-dimer.  
Ruckerl al, 
2007.113 
Multi-centre panel 
study on 1,003 AMI 
survivors 
IL-6, fibrinogen, hs-
CRP 
 
Black smoke, 
black carbon, 
PM10, PM2.5, PNC,  
gaseous pollutants 
(CO, SO2, O3, NO, 
and NO2) 
Increase in PNC was 
associated with increased IL-
6.   
Five day average PM10 was 
associated with ↑ fibrinogen 
concentrations.  
No associations 
with CRP.   
Steinvil et al, 
2007116 
 
Cross-sectional study 
involving 3659 
individuals 
WBC and 
differential count, 
Fibrinogen, hs-CRP 
 
PM10, CO, SO2, O3 
and NO2 
Negative correlation between 
NO2, SO2, and CO and 
fibrinogen in males. Positive 
correlation was found for 
PM10 at lag 7. 
 
No correlation 
was found for 
CRP and WBC, 
or for the female 
population. 
Delfino et al. 
2008112 
Panel study of 29 elderly 
subjects with coronary 
artery disease 
IL-6, TNF-α soluble 
receptor II (sTNF-
RII), soluble platelet 
(sP-selectin), CRP, 
antioxidant enzymes 
PM0.25, PM0.25–2.5, 
PM2.5–10 , EC, BC, 
OC, PNC, CO, 
NOx, NO2.   
EC, BC, OC, CO, NOx, NO2, 
were positively associated with 
biomarkers. PNC & PM0.25 
were more strongly associated 
with biomarkers than PM0.25–2.5.  
Associations for 
all exposures 
were stronger 
during cooler 
periods 
Barclay 
et.al., 
2009115 
Panel study of 132 non-
smoking patients  with 
stable chronic heart 
failure  
RBC, Haemoglobin,   
WBC, platelet count, 
fibrinogen, F- VIIc,   
vWF,   E-selectin, 
IL-6,  CRP,  
Albumin,   D-dimer. 
PM10, PNC & 
nitrogen oxides; 
personal PM2.5 
and PNC & 3-day 
cumulative 
personal NO2. 
No associations were 
demonstrated between 
arrhythmias, HRV or 
haematological/biochemical 
measures and any variations 
in pollutant exposures. 
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Abbreviations  
 
AMI Acute myocardial infarction O3 Ozone 
BC Black carbon = Black smoke OC Organic carbon 
CAD Coronary artery disease OR Odds ratio   
CI Confidence Interval PCV Packed cell volume  
CO Carbon monoxide PM0.25 particles with aerodynamic diameter < 0.25 
CRP C-reactive protein PM2.5 particles with diameter < 2.5 
CVD Cardiovascular disease PM10 particles with diameter less than 10 µm 
EC Elemental carbon PM2.5–10  particles with diameter between 2.5 -10 µm 
ESR Erythrocyte sedimentation rate PNC Particle number concentration 
FVII  Factor VII RBC Red blood cell  
HRV Heart rate variability SAA Serum amyloid A 
hs-CRP High-sensitivity CRP SD Standard deviation 
ICAM-1 Intracellular adhesion molecule-1 SO2 Sulphur dioxide 
IL-6 Interleukin-6 TNF-α Tumour necrosis factor alpha 
IQR Inter quartile range TSP Total suspended particulate 
MCP-1 monocyte chemoattractant protein-1 UFP Ultrafine particles 
NO Nitric oxide VCAM-1 Vascular cell adhesion molecule-1 
NO2 Nitrogen dioxide vWF Von Willebrand factor antigen 
NOx Oxides of nitrogen WBC White blood cells 
72 
 
 
2 Chapter two: A Case Crossover Analysis of Acute Coronary 
Syndrome and Short Term Exposure to Ambient Air Pollution  
 
73 
 
2.1 Introduction 
 
A number of epidemiological studies from worldwide, using diverse methods have 
shown a consistent association between short term fluctuations in concentrations of 
commonly measured ambient air pollutants and a variety  of cardiovascular outcomes[9, 
10, 176]. A summary epidemiological report concluded that daily variations in 
concentration of particle and gaseous pollutants are related to increased cardiovascular 
mortality and morbidity[59]. Chronic exposure to ambient particulate matter is also 
related to cardiovascular mortality[44].  The existing evidence shows that short term 
exposure to ambient air pollutants and traffic could trigger acute ischaemic heart 
events[33, 170, 177] as well as other cardiovascular outcomes such as heart failure, 
hypertension, arrhythmia and changes in heart rate variability[175].   
Most short-term effect air pollution studies of AMI investigate the count of daily CV 
events from routinely available data and relate it to daily changes of pollutant 
concentration, while adjusting for potential confounders. However, use of hospital 
admission or discharge data may be prone to inaccuracies and misclassification. 
Frequent changes in definitions  and diagnostic practices in myocardial infarction, the 
inaccuracy of some diagnostic techniques and incorrect coding could lead to 
misclassification of outcome[178]. Differences among countries which use different 
hospital information systems may lead to differences in diagnosis and misclassification 
of AMI.  
The diagnosis of myocardial infarction has depended on clinical, electrocardiographic, 
biochemical and pathologic findings that have varying degrees of sensitivity and 
specificity[178]. According to the new global definition, AMI can be diagnosed by the 
detection of a rise and/or fall of cardiac biomarkers, preferably troponin, with at least 
one value above the 99th percentile of the upper reference limit, accompanied by 
ischaemic symptoms and or other evidence[179].  
Over recent years there have been a number of advances in the area of cardiac 
biomarkers, in particular, the identification of cardiac troponins, cTnT(cardiac troponin 
T) and cTnI (cardiac troponin I), which are markers of cardiac necrosis; elevated levels 
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of cTnT and cTnI are detectable in the blood for approximately 12 hours following heart 
damage. Elevated cTnT is widely recognized as the method of choice in the diagnosis of 
AMI due to its nearly absolute myocardial tissue specificity and high sensitivity[180]. 
The present study was designed to evaluate the effect of transient changes in ambient air 
pollutants on ACS as assessed by the level of cTnT. This use of cTnT measurements as 
health outcome is intended to reduce the likelihood of outcome misclassification and to 
permit better comparison with future studies. 
2.1.1 Acute Coronary Syndrome 
 
The umbrella term ACS is used to describe a constellation of symptoms including 
unstable angina, subendocardial myocardial infarction (non transmural) and transmural 
myocardial infarction[56]. The underlying pathophysiology is the progression, 
instability, rupture or erosion of the fibrous cap of coronary artery plaques[56]. These 
factors lead to platelet aggregation and adhesion, thrombus formation, inflammation, 
distal embolization and reduced blood flow, leading in turn to myocardial ischaemia and 
necrosis.  
ACS is a widely prevalent disease. The recent Heart Disease and Stroke Statistics 2008 
Update of the American Heart Association estimates that 1,413,000 hospital discharges 
in the United States were due to ACS in 2005[56]. According to the global burden of 
disease, IHD is the leading cause of death and disability both for low- and middle-
income countries and for high-income countries,  accounting for 5.7 and 1.36 million 
deaths respectively[181]. 
Patients with ACS typically present with symptoms of new onset acute central chest 
pain, sweatiness, dyspnoea and palpitations. Some also present with atypical symptoms 
and without chest pain (silent ischaemia), particularly in the elderly and in diabetics. 
ACS is diagnosed by a combination of clinical presentation, electrocardiography and 
biochemical markers, which have varying levels of sensitivity and specificity. A number 
of biomarkers are used to diagnose ACS, including creatinine-kinase-MB, cardiac 
troponins I and T, myoglobin, serum glutamic oxaloacetic transaminase, brain 
natriuretic peptide, lactate dehydrogenase and others[182]. Patients presenting with 
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ACS are usually classified into three categories based on the ST segment elevation: ST-
elevation AMI, non-ST-elevation MI and unstable angina.  
  
Recently, the joint task force of the European Society of Cardiology, the American 
College of Cardiology, the American Heart Association and the World Heart Federation 
formulated an updated redefinition of myocardial infarction (MI) in which biomarkers 
play a central role[179]. The new definition recommends that the diagnosis of AMI 
requires the presence of a rise or fall of a biomarker, preferably troponin, with at least 
one value above the 99th percentile of upper reference limit of a healthy reference 
population coupled with at least one of the following: symptoms of ischaemia, ECG 
changes of ischaemia and development of pathological Q waves in ECG[179]. The task 
force recognized troponin as a preferred biomarker due to its high clinical sensitivity 
and near absolute cardiac muscle specificity[179].  
2.1.2 Cardiac Troponins 
 
Troponins are complex proteins situated in the myofibrillar thin (actin) filament of 
striated muscle (skeletal and cardiac) and consisting of three distinct structural proteins: 
troponin T, troponin I and troponin C. The cardiac isoforms troponin T and I are 
expressed only in cardiac muscle, thus they are specific to the heart muscle, whereas 
isoform C is not specific to the heart.  
The cardiac troponins are not detectable in normal individuals and their detection 
always indicates myocardial damage, but does not indicate the underlying 
mechanism[182]. Following myocardial injury, cTnT is released into the systemic 
circulation and can be detected within 4-6 hours after the onset of an acute event, even 
after a small amount of myocardial necrosis. It reaches maximal serum concentration 
after 12 to 24 hours and levels remain elevated for about 3-10 days, longer than other 
markers, thus providing an extended diagnostic window for ACS (Figure 2.1).  If the 
initial assay of troponin is negative, it should be repeated after 9-12 hours. In addition to 
their use in clinical assessment of ACS, troponin assays are increasingly used to 
determine prognosis and risk stratification[183].  
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Figure 2.1 Timing of release of various biomarkers following acute ischaemic 
myocardial infarction. 
Peak A: early release of myoglobin or CK-MB isoforms after AMI 
Peak B: cardiac troponin after AMI. 
Peak C: CK-MB after AMI. 
Peak D: cardiac troponin after unstable angina. Data are plotted on a relative scale, 
where 1.0 is set at the AMI cut-off concentration. 
AMI = acute myocardial infarction; CK = creatine kinase. 
Source:  The Joint European Society of Cardiology/American College of Cardiology 
Committee[178].   
2.2 Materials and Methods 
2.2.1 Subjects 
 
The study subjects were patients admitted to Salford Royal Hospital in Greater 
Manchester, UK. According to the 2001 census, the population of Salford was 216,103 
(106,191 males and 109,912 females). Data on possible or confirmed ACS cases 
admitted between July 2000 and December 2006 to Hope Hospital were used for this 
study. All patients residing in the Greater Manchester area and acutely admitted to the 
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hospital for chest pain suspected to be of cardiac origin and for whom cTnT 
measurements were done were eligible for the study.  
Information on age, gender, area of residence, date of admission, date and time of 
collection of blood for measuring cTnT and diabetes status were retrieved from the 
Electronic Patient Records and the District Diabetes Information System of Hope 
Hospital. 
All first suspected ACS admissions and readmissions at least 30 days after previous 
admissions were considered for the current analysis. Typically, subjects admitted to 
hospital with a suspected or actual cardiac event had a cTnT reading taken on admission 
and a subsequent reading approximately 12 hours later (the time generally taken for 
cTnT to reach a maximum). It was also possible for patients to have further readings 
taken during their hospital stay. In view of this, the cTnT reading used in this study was 
the maximum reading taken during any one event (continuous stay in hospital).  
2.2.2 Outcome Parameter 
 
The main outcome parameter for this study is the occurrence of ACS defined by the 
levels of cTnT. For analysis, the elevated cTnT levels were divided into two groups: 
between 0.03 and 1 ng/ml and above 1 ng/ml. This classification is consistent with the 
nomenclature of the British Cardiac Society working group practice guideline, which 
stipulates “possible unstable angina” for those with a clinical syndrome and no 
detectable cTnT in blood, “acute coronary syndrome (ACS) with myocyte necrosis” for 
those cases with elevated cTnT levels below 1 ng/ml and “ACS with acute myocardial 
infarction,” henceforth referred to as AMI, for ACS cases with typical clinical syndrome 
and cTnT levels above 1 ng/ml[184]. The study includes all patients with detectable 
levels of troponin (≥ 0.03 ng/ml). The analysis was restricted to the two ACS categories 
with detectable levels of troponin in their blood.  
2.2.3 Exposure Assessment  
 
Environmental air quality data were obtained from the UK National Air Quality Archive 
available at http://www.airquality.co.uk/index.php, which provided hourly 
measurements of data from background monitoring stations in Greater Manchester. The 
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monitors, which provide data on PM10, NO, NO2, CO, ozone and SO2, are fully 
automated and provide hourly readings of data from various automatic analysers: UV 
absorption for O3, chemiluminescence for NOx, infrared absorption for CO and Tapered 
Element Oscillating Microbalance (TEOM) for PM10[7].  
A 24-hour average was calculated from the hourly measurements of each pollutant 
except ozone, for which an eight-hour daytime average was calculated to represent an 
exposure parameter for each individual. Meteorological data on temperature, relative 
humidity and barometric pressure were obtained from the UK Meteorological 
Office[185].  
For each pollutant, 24-hour average exposure metrics of the daily concentration of 
pollutants were calculated for the current day (lag 0) and the three immediately 
preceding days (lag 3 to lag 1, where lag 3 is three days before day 0). Similarly, the 
meteorological variables temperature, barometric pressure and relative humidity were 
averaged over each 24-h period for up to three preceding days. 
Missing data for some days were imputed by a multiple imputation (MI) procedure. 
Missing observations are commonly encountered in environmental epidemiology 
research due to various causes such as inadequate sampling, errors in measurements or 
instrument failure.  Several techniques are used to handle missing data including mean 
substitution, complete case analysis, and univariate and multivariate imputations. Mean 
substitution can distort the structure of the data and could lead to errors in the variance-
covariance structure, thus distorting the statistical model. On the other hand, complete 
case analysis deletes observations with missing values on any of the covariates, thus 
leading to loss of information, reduced precision/power and biased results if the 
incomplete cases systematically differ from the complete cases. 
Imputation or substitution for a missing data point however allows prediction of 
plausible values for those missing data. MI accurately allows for the uncertainty 
associated with the missing data, providing unbiased estimates for the parameters of 
interest and their variances and has the potential to increase efficiency in the data 
analysis[186, 187]. MI consists of 3 main steps: generation of several complete copies 
of datasets (usually 5 to 10) by filling in the missing values, carrying out analyses of 
each imputed datasets, and finally pooling of the results from the multiply imputed data 
sets to yield one final inference on the parameters of interest.  MI was implemented 
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using the iterated chain equations (ice) procedure of Stata[188]. Five multiple data sets 
were created for the analysis within this project. MI has some potential limitations such 
as requirement for specialized software and statistical knowledge. The generation and 
analysis of the data also requires more computational space and time, particularly with 
large data sets, than single imputation methods.   
2.2.4 Statistical Analysis 
 
The analysis was conducted using a case crossover design[30] with a time stratified 
referent selection approach. The case crossover design is a variant of the matched case 
control study and consists of only cases, which serve as their own controls in the 
analysis. Exposure data on the day of the health event were studied in relation to the 
index and compared with selected referent days. Case-crossover design inherently 
controls for fixed individual characteristics like gender and race, and allows the 
evaluation of effect modification by individual characteristics. In addition, the design 
controls for seasonal confounding and time varying factors[31].  
For each index event, three to four control periods were selected. For instance, if an 
individual was admitted on 9th October as an index case, days 2nd, 16th, 23rd and 30th 
October constituted a control set of four weekdays (see Chapter 1,Table 1.2). In time 
stratified case-crossover design, the control periods for a given subject are restricted to 
the same weekday, month and year, which controls for season, long-term trends and day 
of the week[31].   
All models were adjusted for mean daily temperature, relative humidity and barometric 
pressure. All meteorological parameters were entered into the model as linear terms. A 
conditional logistic regression model was used to fit different ACS categories as 
determined by the levels of cTnT and environmental pollutants. Effect estimates were 
calculated as odds ratios and 95% confidence intervals, which were scaled to the 
interquartile range (IQR) of each pollutant. All statistical analyses were carried out 
using Stata version 10.0 (Stata Corp., College Station, Texas). 
Records were linked by privacy-protected pseudonyms, so the researchers did not know 
the identity of individual patients. In addition, all of the data required for analysis were 
anonymised before analysis. Ethical approval was obtained from the Central Office for 
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Research Ethics Committees and the Salford and Trafford Local Ethics Committee. 
 
2.3 Results 
 
Baseline descriptive data on the study participants is shown in Table 2.1. A total of 
28,622 cTnT measurements were made, of which 18,897 were unique first-ever 
admissions. The majority of admissions (76%) involved elderly individuals above the 
age of 65. About 12% of individuals had diabetes mellitus. Most cTnT measurements 
(78.7%) were below the detection limit (< 0.03 ng/ml) and were cases of unstable 
angina, while 17.8% were ACS with myocyte necrosis (cTnT 0.03 to 1 ng/ml) and a 
small number (3.5%) were cases of AMI (cTnT ≥ 1 ng/ml) following the British 
Cardiac Society definition of ACS[184]. The majority of subjects with ACS with 
myocyte damage and AMI were 65 years or older, whereas those with unstable angina 
were dominated by the age group below 65 years.  
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Table 2.1 Baseline characteristics of patients admitted with chest pain 
(N=28,622) 
 
 All  Unstable 
angina* 
(n=22,526) 
ACS with 
myocyte 
damage† 
(n=5093) 
AMI‡ 
(n=1003) 
Age( years), 
(mean±SD) 
65 62.8(17.3) 73.1(13.8) 70.6(13.9) 
Age groups in  years %     
  18 - 64 23.6 49.5 22.6 28.9 
≥65 76.4 54.5 77.4 71.1 
Diabetes mellitus % 12.6  11.6 16.7 16.9 
Male gender % 52 52 55 61 
 
 
*
   cTnT values < 0.03 ng /ml;  †cTnT 0.03-1 ng/ml; ‡ cTnT > 1 ng/ml 
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Table 2.2 shows summary statistics for daily measurement of background air pollutants 
and meteorological parameters during the study period, 2000-2006. The exposure 
variables show considerable variation and are positively skewed. The observed mean 
concentrations were all below the UK air quality objective standards for each specific 
pollutant. However, the maximum values of ambient PM10, NO2 and ozone were above 
the UK air quality objective standard, whose annual mean is 40 µg/m3 for PM10 and NO2 
and
 
whose
 
daily maximum of 8 hour mean is 100 µg /m3. 
  
Figure 2.2
 
to Figure 2.8 show 
the time series of ambient mean concentrations of air pollutants and temperature during 
the study period. From these figures, clear evidence of seasonal variation of pollutants 
and temperature is observed.  
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Figure 2.2 Concentrations of NO2 over the study period  
(24-hr mean) 
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Figure 2.3 Time course of PM10 over the study period 
(24-hr mean) 
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Figure 2.4 Time course of CO over the study period 
(24-hr mean) 
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Figure 2.5 Time course of NO over the study period 
(24-hr mean) 
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Figure 2.6 Concentrations of ozone over the study period 
(8-hr mean) 
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Figure 2.7 Concentrations of SO2 over the study period 
(24-hr mean) 
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Figure 2.8 Time course of temperature over the study period 
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Table 2.2  Characteristics and distribution of ambient air pollutants and 
meteorological variables during the study period  
(July 2000-Dec 2006) 
 
Pollutant &  
meteorological variable 
Mean S.D. * Min. Max. IQR* 
CO† - mg/m3 0.4 0.2 0.1 3.9 0.2 
PM10† - µg/m3 24.4 10.7 3.0 117.0 11.5 
NO† - µg/m3 21.1 27.2 1.7 505.7 14.7 
NO2† - µg/m3 39.7 14.7 11.0 130.3 19.1 
SO2 †- µg/m3 7.7 4.1 0.0 50.5 4.5 
Ozone† - µg/m3 35.6 18.0 1.0 111.5 24.0 
Temperature - °C 11.2 5.6 -4.7 27.7 8.3 
Relative humidity - % 78.2 9.2 44.9 96.6 13.5 
Mean sea level pressure - mb‡ 1013.8 10.9 970.5 1042.6 14.3 
        
 *    SD, standard deviation; Min, minimum; Max, maximum; IQR, interquartile 
 range (25-75 percentile) 
       † CO, carbon monoxide; PM10, mass concentration of particles < 10 µm in  
  aerodynamic diameter; NO, nitric oxide; NO2, nitrogen dioxide; SO2, sulphur 
  dioxide;   
        ‡   mb, millibars 
 
Table 2.3 shows the correlations between average daily pollutants and meteorological 
variables. It is apparent from this table that CO is strongly correlated with NO and NO2 
(r = 0.87 and 0.73 respectively). NO and NO2 show similar high correlation (r=75).  
Concentrations of PM10 showed moderate correlations with NO2 (r=0.56) and CO 
(r = 0.48). Ozone was negatively correlated with all other pollutants, the largest 
negative association of ozone being with NO2 (r = -0.61). Daily mean air temperatures 
were inversely correlated with daily concentrations of all pollutants except ozone 
(r = 0.33). The largest negative correlation of temperature was with CO (r = -0.41). 
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Table 2.3 Correlation coefficients between daily concentration of pollutants and 
meteorological variables 
 
 
CO PM10 NO NO2 SO2 Ozone Temp* RH† 
CO 1 
       
PM10 0.48 1       
NO 0.87 0.46 1 
     
NO2 0.73 0.56 0.75 1     
SO2 0.37 0.45 0.29 0.39 1    
Ozone -0.51 -0.17 -0.57 -0.61 -0.17 1 
  
Temp* -0.41 0.00 -0.42 -0.46 -0.13 0.33 1 
 
RH† 0.27 -0.19 0.29 0.19 -0.14 -0.55 -0.32 1 
 
*  Temperature 
†  Relative humidity 
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Table 2.4 and Figure 2.9 show the estimated OR and 95 % CI for the relationship 
between ambient air pollutants and measured cTnT levels for outcomes with discernible 
serum troponin. As Table 2.4 reveals, there was no statistically significant positive 
association for the same day (lag 0) and a lag of 1 day with all pollutants. At lag 2, CO, 
NO, NO2 and SO2 were positively associated with increased cTnT. For lag 3, a 
significant positive association was found between cTnT and concentrations of PM10 
and SO2. An IQR increase in both PM10 and SO2 was associated with an OR of 1.07 
(95% CI: 1.03-1.10) with PM10 and 1.07 (95% CI: 1.03-1.11) with SO2. Conversely, a 
negative association with ozone was observed for lag 0 and lag 2. In a single pollutant 
model the largest significant effect was with NO2 at lag 2. An IQR increase of NO2 was 
associated with a 9 % increase (95% CI: 4-15) in ACS.  
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Table 2.4 Associations between ambient air pollutants and ACS with troponin 
elevation*  
Adjusted† odds ratio and 95% CI for an IQR change in air pollutant 
(N=6096)  
 
Lag‡ Pollutant§ OR|| 95% CI|| P|| 
0 CO 0.99 (0.96  , 1.03) 0.76 
 
NO 0.99 (0.97 , 1.01) 0.47 
 
NO2 1.04 (0.99 , 1.09) 0.13 
 
Ozone 0.94 (0.89 , 0.99) 0.03¶ 
 
PM10 1.01 (0.97 , 1.04) 0.77 
  
SO2 1.02 (0.97 , 1.06) 0.49 
1 CO 0.98 (0.95 , 1.01) 0.25 
 
NO 0.99 (0.97 , 1.01) 0.26 
 
NO2 1.03 (0.99 , 1.07) 0.2 
 
Ozone 0.96 (0.92 , 1) 0.06 
 
PM10 0.9 (0.88 , 0.94) 0.00¶ 
  
SO2 0.98 (0.94 , 1.02) 0.35 
2 CO 1.06 (1.03 , 1.09) 0.00¶ 
 
NO 1.04 (1.02 , 1.06) 0.00¶ 
 
NO2 1.08 (1.04 , 1.13) 0.00¶ 
  
Ozone 0.94 (0.91 , 0.98) 0.01¶ 
 
PM10 1.03 (0.99 , 1.06) 0.12 
 
SO2 1.09 (1.04 , 1.15) 0.00¶ 
3 CO 0.98 (0.95 , 1.01) 0.19 
 
NO 0.99 (0.98 , 1.01) 0.47 
 
NO2 0.98 (0.94 , 1.03) 0.43 
 
Ozone 1.01 (0.97 , 1.06) 0.6 
 
PM10 1.07 (1.03 , 1.1) 0.00¶ 
  
SO2 1.07 (1.03 , 1.11) 0.00¶ 
 
*
 Acute coronary syndrome with troponin value >0.03 ng/ml 
†   All models are adjusted for mean daily temperature, relative humidity 
and barometric pressure 
‡ Lag 0,  1, 2 and 3, average pollutant concentration 0-23, 24-47, 48-71 
and 72-95 hours before an acute cardiac event respectively 
 § CO, carbon monoxide; PM10, mass of particles with aerodynamic 
 diameter less than 10 µm; NO, nitric oxide;NO2, nitrogen dioxide;SO2, 
 sulphur dioxide 
 || OR, odds ratio; CI, confidence interval; P, p value 
 ¶ P <0.05 
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Figure 2.9 Associations of troponin > 0.03 ng/ml with ambient air pollutants  
(Lags 0,1,2 and 3) 
The triangles, squares and circles indicate odds ratio, vertical lines 95 % CI calculated for an 
IQR of the respective pollutant under consideration. 
L0, L1, L2 and L3, average pollutant concentration 0-23, 24-47, 48-71 and 72-95 hours before 
an acute cardiac event respectively 
 
 
In a further analysis, the ACS cases were stratified into two groups to examine whether 
the effect differed with the levels of troponin: cTnT 0.03-1 ng/ml (ACS with myocyte 
necrosis) and cTnT > 1 ng/ml (ACS with myocardial infarction). Table 2.5 and 2.6 and 
Figure 2.10 and 2.11 present the effect of stratified analysis for ACS with myocyte 
damage and AMI respectively.  
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Table 2.5 Associations between ambient air pollutants and ACS with myocyte 
necrosis* 
Adjusted† odds ratio and 95% CI for an IQR change in air pollutant  
(N=5093) 
 Lag  Pollutant OR 95% CI P  
0 CO 1.00  0.96  , 1.04  0.99 
 
NO 1.00  0.98  , 1.02  0.81 
 
NO2 1.04  0.99  , 1.10  0.12 
 
Ozone 0.93  0.87  , 0.99  0.02‡ 
 
PM10 1.01  0.97  , 1.05  0.7 
  
SO2 1.02  0.97  , 1.08  0.39 
1 CO 0.97  0.94  , 1.01  0.12 
 
NO 0.99  0.97  , 1.00  0.13 
 
NO2 1.02  0.97  , 1.07  0.45 
 
Ozone 0.97  0.92  , 1.01  0.14 
 
PM10 0.90  0.87  , 0.94  0.00‡ 
  
SO2 0.99  0.95  , 1.04  0.68 
2 CO 1.06  1.02  , 1.09  0.00‡ 
 
NO 1.04  1.02  , 1.06  0.00‡ 
 
NO2 1.08  1.04  , 1.13  0.00‡ 
 
Ozone 0.95  0.91  , 0.99  0.02‡ 
 
PM10 1.02  0.99  , 1.06  0.22 
  
SO2 1.10  1.05  , 1.16  0.00‡ 
3 CO 0.98  0.95  , 1.01  0.2 
 
NO 0.99  0.97  , 1.01  0.49 
 
NO2 0.98  0.93  , 1.02  0.35 
 
Ozone 1.01  0.97  , 1.06  0.53 
 
PM10 1.05  1.02  , 1.09  0.01‡ 
  
SO2 1.06  1.02  , 1.11  0.01‡ 
 
*    Acute coronary syndrome with troponin value > 0.03 ng/ml 
†  All models are adjusted for mean daily temperature, relative humidity 
and barometric pressure 
‡ P <0.05 
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As in the combined analysis, there was a statistically significant positive association for 
a lag of day 2 with both categories of cTnT for all pollutants. At lag 2, CO and NO were 
positively associated with both categories of cTnT. In addition, a positive association 
was detected between NO2 and SO2 for the lower category of ACS at lag 2. Conversely, 
ozone was negatively associated with the lower category of cTnT at lag 2.  
At lag 3, PM10 and SO2 were positively associated with both categories of cTnT. In a 
single pollutant model the strongest effect was observed for the association between 
PM10 and AMI for lag 3. The effect of an IQR increase of PM10 was a 14 % (95% CI: 5-
24) increase in AMI.  
 
 
Figure 2.10 Associations between ACS with myocyte damage and ambient air 
pollutants  
The triangles, squares and circles indicate odds ratio, vertical lines 95 % CI for an IQR 
increase of the respective pollutant 
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Table 2.6. Associations between ambient air pollutants and ACS with AMI* 
Adjusted†  odds ratio and 95% CI for an IQR change in air pollutant (N=1003)  
 
Lag Pollutant OR 95 % CI P- Value 
0 CO 0.97 0.9 , 1.06 0.53 
 
NO 0.97 0.92 , 1.02 0.27 
 
NO2 1.01 0.89 , 1.15 0.84 
 
Ozone 1.00 0.87 , 1.15 0.99 
 
PM10 1.00 0.91 , 1.09 0.94 
  
SO2 0.97 0.85 , 1.11 0.69 
1 CO 1.03 0.95 , 1.10 0.5 
 
NO 1.01 0.97 , 1.06 0.51 
 
NO2 1.08 0.97 , 1.2 0.15 
 
Ozone 0.94 0.84 , 1.04 0.23 
 
PM10 0.93 0.86 , 1.01 0.1 
  
SO2 0.94 0.84 , 1.04 0.25 
2 CO 1.09 1.02 , 1.16 0.02‡ 
 
NO 1.04 1 , 1.08 0.04‡ 
 
NO2 1.07 0.96 , 1.18 0.21 
 
Ozone 0.93 0.84 , 1.03 0.18 
 
PM10 1.04 0.96 , 1.13 0.37 
  
SO2 1.05 0.95 , 1.17 0.32 
3 CO 0.98 0.91 , 1.06 0.67 
 
NO 0.99 0.95 , 1.04 0.79 
 
NO2 1.01 0.91 , 1.12 0.83 
 
Ozone 1.00 0.9 , 1.11 0.93 
 
PM10 1.14 1.05 , 1.24 0.00‡ 
  
SO2 1.11 1 , 1.23 0.04‡ 
 
*   Acute coronary syndrome with troponin value >1 ng/ml 
†  All models are adjusted for mean daily temperature, relative humidity 
  and barometric pressure 
‡   Statistically significant (P<0.05) 
94 
 
. 
 
 
Figure 2.11 Associations between AMI (troponin >1 ng/ml) and ambient air 
pollutants. 
2.3.1 Analysis of Effect Modification  
             
To explore the potential differential effect of ambient particulates and gases on ACS, a 
stratified analysis was conducted on various personal and environmental covariates such 
as age (above and below 65 years) gender and season (October–March vs. April–
September) for the two categories of troponin separately. Results with consistent 
difference between groups are presented below. Overall, few differences by gender and 
season were detected for the same day and lag 1.   
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2.3.1.1 Analysis by Gender 
Table 2.7 and Table 2.10 present the results of stratified analysis by gender for the 
association between various pollutants and ACS with myocyte damage and AMI 
respectively. Gender seems to modify effect of the both categories of ACS, with 
stronger influence in those with AMI (Figure 2.12 and Figure 2.13). 
 
 
Figure 2.12 Associations between ACS with myocyte damage  and ambient air 
pollutants  
(Lags 2 and 3, stratified by gender) 
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Generally, the observed effects were larger in female subjects in ACS cases with 
myocyte damage. For example, an IQR increase in SO2 was associated with OR of 1.11 
(95% CI: 1.04–1.18) at lag 2. There was a comparable effect of SO2 for lag 3 in 
females, whereas there was no effect of SO2 for either lag in men. 
 
Figure 2.13 Associations between ACS with AMI (troponin > 1ng/ml) and ambient 
air pollutants  
(Lags 2 and 3, stratified by gender) 
 
 
Similarly, strong evidence of effect modification by gender was observed for the 
associations of PM10 and SO2 with ACS admission and AMI. For women, the estimated 
OR values for the IQR increase in PM10 and SO2 on AMI at lag 3 were 1.22 (95% CI: 
1.08–1.38) and 1.25 (95% CI: 1.06-1.46) respectively. The effects on males were in the 
same direction but much smaller and none achieved statistical significance. On the other 
hand, a strong positive effect of CO on AMI was observed in males with a lag of two 
days (P < 0.03).  
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Table 2.7 Associations between ACS with myocyte damage (troponin 0.03-1ng/ml) 
and ambient air pollutants stratified by gender 
Adjusted* odds ratio and 95% CI for an IQR change in air pollutant 
 Female Male 
Lag Pollutant OR 95%  CI P OR 95% CI P 
0 CO 0.98   0.92 , 1.04 0.46 1.02   0.97 , 1.07 0.50 
0 PM10 0.97   0.91 , 1.03 0.30 1.04   0.99 , 1.09 0.14 
0 NO 0.99   0.96 , 1.03 0.76 1.00   0.97 , 1.03 0.98 
0 NO2 1.01   0.94 , 1.09 0.75 1.07   0.99 , 1.15 0.07 
0 SO2 0.98   0.9 , 1.06 0.59 1.06   0.99 , 1.14 0.09 
0 Ozone 0.99   0.9 , 1.09 0.83 0.88   0.81 , 0.96 0.00‡ 
1 CO 0.97   0.92 , 1.02 0.20 0.98   0.93 , 1.03 0.37 
1 PM10 0.89   0.84 , 0.95 0.00‡ 0.91   0.87 , 0.96 0.00‡ 
1 NO 0.98   0.95 , 1.01 0.29 0.99   0.96 , 1.01 0.30 
1 NO2 1.01   0.94 , 1.08 0.88 1.03   0.96 , 1.1 0.39 
1 SO2 0.94   0.88 , 1.02 0.13 1.03   0.97 , 1.09 0.38 
1 Ozone 0.96   0.89 , 1.03 0.21 0.97   0.91 , 1.04 0.40 
2 CO 1.07   1.02 , 1.12 0.00‡ 1.05   1 , 1.09 0.03‡ 
2 PM10 1.01   0.96 , 1.07 0.67 1.03   0.98 , 1.08 0.21 
2 NO 1.04   1.02 , 1.07 0.00‡ 1.03   1.01 , 1.06 0.00‡ 
2 NO2 1.07   1 , 1.14 0.05 1.10   1.04 , 1.17 0.00‡ 
2 SO2 1.11   1.04 , 1.18 0.00‡ 1.09   1.02 , 1.18 0.02‡ 
2 Ozone 0.95   0.89 , 1.01 0.11 0.95   0.89 , 1.01 0.08 
3  CO 0.94   0.89 , 0.99 0.03‡ 1.00   0.96 , 1.05 0.85 
3  PM10 1.04   0.99 , 1.1 0.15 1.06   1.01 , 1.11 0.02‡ 
3  NO 0.98   0.95 , 1.01 0.17 1.00   0.98 , 1.03 0.83 
3  NO2 0.96   0.89 , 1.02 0.20 1.00   0.94 , 1.06 0.88 
3  SO2 1.07   1.01 , 1.15 0.03‡ 1.05   0.99 , 1.12 0.08 
3  Ozone 1.01   0.94 , 1.08 0.76 1.02   0.96 , 1.09 0.55 
 
*  All models are adjusted for temperature, relative humidity and barometric pressure 
‡  Statistically significant (P<0.05) 
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Figure 2.14 Associations between ACS with myocyte damage and ambient air 
pollutants 
(Lags 2 and 3, stratified by age) 
 
 
Figure 2.15 Associations between ACS with AMI and ambient air pollutants  
(lags 2 and 3, stratified by age)
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2.3.1.2 Analysis by Age 
 
Associations between the two ACS categories and ambient air pollutants stratified by 
age are shown in Table 2.8 and Table 2.11. There was evidence of effect modification 
by age for both categories of ACS (Figure 2.14 and Figure 2.15). In the group of ACS 
with myocyte damage, participants above the age of 65 have a more consistent positive 
association with various pollutants and at different exposure lags. For example, NO2 on 
the same day, CO, NO, NO2 and SO2 at lag 2 and PM10 at lag 3 were associated with 
ACS with myocyte damage. In this subgroup, the estimated OR associated with an IQR 
increase of PM10 was 1.06 (95% CI: 1.0- 1.10) for ACS with myocyte necrosis. There 
were also significant associations of CO, NO and NO2 with myocyte damage in those 65 
years or older for lag 2. 
 
Figure 2.16 Associations between ACS with myocyte damage and ambient air 
pollutants for lags 2 and 3, stratified by season 
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Table 2.8 Associations between ACS with myocyte damage† and ambient air 
pollutants stratified by age 
Adjusted odds ratio and 95% CI for an IQR change in air pollutant 
 
  Age ≥ 65 Age < 65 
Lag Pollutant OR 95 % CI P OR 95 % CI P 
0 CO 1.03 0.98 , 1.07 0.23 0.92 0.85 , 1 0.05‡ 
0 PM10 1.03 0.99 , 1.08 0.13 0.92 0.85 , 1 0.05‡ 
0 NO 1.01 0.99 , 1.04 0.38 0.95 0.91 , 1 0.05‡ 
0 NO2 1.08 1.01 , 1.14 0.02‡ 0.94 0.84 , 1.05 0.27 
0 SO2 1.04 0.99 , 1.11 0.14 0.95 0.85 , 1.07 0.38 
0 Ozone 0.94 0.88 , 1.01 0.11 0.88 0.77 , 1.01 0.07 
 
       
1 CO 0.97 0.94 , 1.01 0.19 0.97 0.91 , 1.04 0.39 
1 PM10 0.90 0.86 , 0.95 0.00‡ 0.91 0.84 , 0.99 0.03‡ 
1 NO 0.99 0.96 , 1.01 0.24 0.98 0.94 , 1.02 0.33 
1 NO2 1.01 0.96 , 1.07 0.66 1.04 0.94 , 1.15 0.43 
1 SO2 1.00 0.94 , 1.05 0.86 0.98 0.88 , 1.08 0.63 
1 Ozone 0.96 0.91 , 1.01 0.13 0.98 0.89 , 1.09 0.76 
 
       
2 CO 1.06 1.02 , 1.09 0.00‡ 1.06 1 , 1.13 0.06 
2 PM10 1.02 0.98 , 1.06 0.38 1.04 0.96 , 1.12 0.34 
2 NO 1.04 1.02 , 1.06 0.00‡ 1.03 0.99 , 1.06 0.10 
2 NO2 1.08 1.03 , 1.13 0.00‡ 1.10 1.01 , 1.21 0.04‡ 
2 SO2 1.08 1.02 , 1.14 0.01‡ 1.17 1.07 , 1.29 0.00‡ 
2 Ozone 0.95 0.9 , 1 0.05‡ 0.94 0.85 , 1.03 0.19 
 
       
3  CO 0.96 0.93 , 1 0.05‡ 1.03 0.96 , 1.1 0.46 
3  PM10 1.06 1.01 , 1.1 0.01‡ 1.04 0.96 , 1.13 0.32 
3  NO 0.99 0.97 , 1.01 0.28 1.01 0.97 , 1.05 0.64 
3  NO2 0.96 0.91 , 1.02 0.18 1.03 0.93 , 1.13 0.58 
3  SO2 1.04 0.98 , 1.1 0.17 1.14 1.03 , 1.27 0.01‡ 
3  Ozone 1.02 0.97 , 1.08 0.40 0.99 0.9 , 1.09 0.82 
 
  
 †   Acute coronary syndrome with troponin value 0.03 -1 ng/ml 
 ‡  Statistically significant (P<0.05) 
All models are adjusted for temperature, relative humidity and barometric  
 pressure 
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PM10 was associated with AMI in the older subjects as well. For lag 3 an IQR increase 
of PM10 was associated with a 15% increase in AMI (95% CI: 4–27%) in older subjects. 
In individuals below 65, a comparable effect of PM10 on ACS was observed, but it did 
not reach statistical significance. On the other hand, those below the age of 65 showed a 
stronger association between ACS with myocyte damage and SO2 at lags 2 and 3. In 
this age group an IQR increase in SO2 was associated with OR of 1.17 (95% CI: 1.07-
1.29) at lag 2 and 1.14 (95% CI: 1.03-1.27) at lag 3.  
The subgroup analysis by age for troponin above 1 ng/ml similarly showed some 
differential effect by age. At lag 3 the effect of PM10 on AMI was significant in those 
subjects above the age of 65 years. 
 
Figure 2.17 Associations between ACS with AMI (troponin > 1ng/ml) and ambient 
air pollutants for lags 2 and 3, stratified by season 
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Table 2.9 Associations between ACS with myocyte damage† and ambient air 
pollutants stratified by season 
Adjusted odds ratio and 95% CI for an IQR change in air pollutant 
  
   Warm    Cold  
Lag Pollutant OR 95 % CI P OR 95 % CI P 
0 CO 1.08 0.97 , 1.2 0.16 0.98 0.94 , 1.03 0.42 
0 PM10 0.98 0.91 , 1.05 0.49 1.02 0.97 , 1.07 0.39 
0 NO 1.17 1.04 , 1.31 0.01 0.99 0.96 , 1.01 0.27 
0 NO2 1.06 0.95 , 1.17 0.29 1.04 0.97 , 1.11 0.29 
0 SO2 1.01 0.92 , 1.11 0.84 1.03 0.96 , 1.1 0.40 
0 Ozone 0.92 0.84 , 1.01 0.09 0.93 0.85 , 1.02 0.13 
 
       
1 CO 1.10 1.04 , 1.17 0.00‡ 0.92 0.88 , 0.96 0.00‡ 
1 PM10 0.90 0.85 , 0.95 0.00‡ 0.91 0.86 , 0.96 0.00‡ 
1 NO 1.09 1.05 , 1.13 0.00‡ 0.95 0.93 , 0.97 0.00‡ 
1 NO2 1.16 1.08 , 1.24 0.00‡ 0.93 0.87 , 0.99 0.02‡ 
1 SO2 0.93 0.86 , 1 0.04‡ 1.05 0.99 , 1.11 0.14 
1 Ozone 0.74 0.69 , 0.79 0.00‡ 1.25 1.17 , 1.34 0.00‡ 
 
       
2 CO 0.91 0.86 , 0.96 0.00‡ 1.14 1.1 , 1.19 0.00‡ 
2 PM10 0.97 0.92 , 1.02 0.24 1.08 1.03 , 1.14 0.00‡ 
2 NO 0.97 0.94 , 1 0.08 1.07 1.05 , 1.09 0.00‡ 
2 NO2 0.90 0.84 , 0.96 0.00‡ 1.26 1.19 , 1.34 0.00‡ 
2 SO2 1.05 0.98 , 1.12 0.15 1.15 1.08 , 1.22 0.00‡ 
2 Ozone 1.03 0.97 , 1.09 0.38 0.86 0.81 , 0.92 0.00‡ 
 
       
3 CO 0.75 0.71 , 0.8 0.00‡ 1.15 1.1 , 1.2 0.00‡ 
3 PM10 1.00 0.95 , 1.05 0.88 1.12 1.06 , 1.18 0.00‡ 
3 NO 0.83 0.79 , 0.86 0.00‡ 1.08 1.06 , 1.11 0.00‡ 
3 NO2 0.72 0.67 , 0.77 0.00‡ 1.28 1.2 , 1.36 0.00‡ 
3 SO2 1.01 0.95 , 1.08 0.70 1.11 1.05 , 1.18 0.00‡ 
3 Ozone 1.35 1.27 , 1.44 0.00‡ 0.73 0.69 , 0.79 0.00‡ 
 
†   Acute coronary syndrome with troponin value 0.03 -1 ng/ml 
‡   Statistically significant (P<0.05) 
All models are adjusted for temperature, relative humidity and barometric pressure 
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2.3.1.3 Analysis by Season 
 
Table 2.9 and Table 2.12 show regression results for associations between ambient air 
pollutants, respectively, ACS with myocyte damage and AMI stratified by season. 
Season too is an important modifier for both categories of ACS (Figure 2.16 and Figure 
2.17). There was a strong positive association between most ambient pollutants and 
both ACS categories in colder seasons. The strongest effect was observed in association 
with NO2 in both categories. For lag 3, an IQR increase of NO2 was associated with 
estimated OR of 1.28 (95% CI: 1.20-1.36) for ACS with myocyte damage and 1.29 
(95% CI: 1.12- 1.48) for AMI. A comparable large effect of NO2 was observed at lag 2 
for both categories in colder seasons. By contrast, ozone was strongly and positively 
associated with ACS with myocyte damage at lag 3 in warm months. An IQR increase 
of ozone was associated with a 35% increase in ACS with myocyte damage (95% CI: 
27-44%) and 36% (95% CI: 17-58%) for AMI. Apart from ozone, the only pollutant to 
have a positive effect on ACS was PM10. An IQR increase of PM10 was associated with 
a 17% increase in AMI (95% CI: 4-31%). 
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Table 2.10 Associations between AMI* and ambient air pollutants stratified by 
gender 
Adjusted odds ratio and 95% CI for an IQR change in air pollutant 
 
   Female   Male  
Lag Pollutant† OR‡ 95% CI‡ P‡ OR‡ 95% CI‡ P‡ 
0 CO 0.96 0.84 , 1.10 0.56 0.98 0.88 , 1.09 0.72 
0 PM10 1.01 0.87 , 1.18 0.85 0.98 0.88 , 1.10 0.78 
0 NO 0.97 0.89 , 1.05 0.44 0.97 0.91 , 1.04 0.39 
0 NO2 0.91 0.75 , 1.11 0.36 1.07 0.92 , 1.25 0.35 
0 SO2 0.90 0.73 , 1.11 0.33 1.02 0.86 , 1.20 0.83 
0 Ozone 1.10 0.86 , 1.39 0.45 0.94 0.79 , 1.13 0.53 
         
1 CO 1.01 0.9 , 1.13 0.92 1.04 0.95 , 1.14 0.44 
1 PM10 0.93 0.81 , 1.07 0.29 0.93 0.84 , 1.04 0.22 
1 NO 1.02 0.96 , 1.09 0.54 1.01 0.96 , 1.06 0.75 
1 NO2 1.12 0.95 , 1.32 0.18 1.05 0.92 , 1.21 0.46 
1 SO2 0.92 0.76 , 1.11 0.38 0.95 0.83 , 1.09 0.48 
1 Ozone 0.97 0.82 , 1.15 0.71 0.92 0.80 , 1.05 0.23 
        
2 CO 1.06 0.95 , 1.18 0.27 1.10 1.01 , 1.2  0.03¶ 
2 PM10 1.02 0.90 , 1.17 0.75 1.05 0.94 , 1.17 0.39 
2 NO 1.03 0.97 , 1.1 0.28 1.04 0.99 , 1.09 0.10 
2 NO2 1.06 0.90 , 1.24 0.47 1.07 0.94 , 1.22 0.33 
2 SO2 0.99 0.85 , 1.17 0.94 1.1 0.96 , 1.25 0.16 
2 Ozone 0.97 0.82 , 1.14 0.69 0.91 0.79 , 1.04 0.16 
        
3 CO 0.96 0.85 , 1.08 0.49 1.00 0.91 , 1.10 0.96 
3 PM10 1.22 1.08 , 1.38   0.00¶ 1.09 0.98 , 1.22 0.13 
3 NO 0.98 0.92 , 1.05 0.60 1.00 0.95 , 1.06 0.98 
3 NO2 1.04 0.89 , 1.23 0.60 0.99 0.86 , 1.13 0.84 
3 SO2 1.25 1.06 , 1.46   0.01¶ 1.02 0.90 , 1.16 0.73 
3 Ozone 1.00 0.85 , 1.17 0.96 1.00 0.87 , 1.15 0.97 
 
* Acute coronary syndrome with troponin value >1 ng/ml 
† CO, carbon monoxide; PM10, mass of particles with aerodynamic diameter less 
than 10 µm; NO, nitric oxide;NO2, nitrogen dioxide;SO2, sulphur dioxide 
‡ OR, odds ratio; CI, confidence interval; P, p value 
¶ P <0.05 
All models are adjusted for temperature, relative humidity and barometric pressure 
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Table 2.11 Associations between AMI* and ambient air pollutants stratified by age 
Adjusted odds ratio and 95% CI for an IQR change in air pollutant 
 
  Age >65 Age < 65 
Lag Pollutant† OR‡ 95% CI‡ P‡ OR‡ 95% CI‡ P‡ 
0 CO 0.98 0.89 , 1.08 0.65 0.96 0.82 , 1.13 0.64 
0 PM10 0.97 0.87 , 1.08 0.60 1.06 0.90 , 1.25 0.49 
0 NO 0.97 0.92 , 1.03 0.31 0.98 0.89 , 1.07 0.61 
0 NO2 1.00 0.87 , 1.15 0.98 1.05 0.84 , 1.31 0.65 
0 SO2 0.97 0.83 , 1.14 0.71 0.98 0.80 , 1.20 0.86 
0 Ozone 1.01 0.86 , 1.20 0.87 0.96 0.74 , 1.25 0.77 
        
1 CO 1.02 0.93 , 1.11 0.68 1.05 0.91 , 1.20 0.52 
1 PM10 0.89 0.80 , 0.99 0.03 1.03 0.89 , 1.21 0.66 
1 NO 1.02 0.97 , 1.06 0.51 1.01 0.93 , 1.09 0.84 
1 NO2 1.10 0.97 , 1.24 0.14 1.04 0.86 , 1.26 0.69 
1 SO2 0.93 0.82 , 1.06 0.28 0.95 0.78 , 1.17 0.65 
1 Ozone 0.91 0.81 , 1.04 0.17 1.00 0.82 , 1.22 1.00 
        
2 CO 1.07 1.00 , 1.16 0.06 1.11 0.97 , 1.28 0.13 
2 PM10 1.03 0.93 , 1.13 0.60 1.06 0.91 , 1.24 0.47 
2 NO 1.03 0.99 , 1.08 0.14 1.05 0.98 , 1.13 0.18 
2 NO2 1.07 0.95 , 1.20 0.28 1.06 0.87 , 1.29 0.57 
2 SO2 1.02 0.91 , 1.16 0.70 1.14 0.94 , 1.38 0.18 
2 Ozone 0.94 0.83 , 1.06 0.30 0.92 0.76 , 1.12 0.40 
        
3 CO 0.99 0.91 , 1.08 0.79 0.97 0.85 , 1.11 0.69 
3 PM10 1.15 1.04 , 1.27 0.01¶ 1.13 0.97 , 1.32 0.11 
3 NO 1.00 0.95 , 1.05 0.93 0.97 0.90 , 1.05 0.49 
3 NO2 1.02 0.90 , 1.16 0.78 0.99 0.82 , 1.2 0.91 
3 SO2 1.10 0.98 , 1.24 0.10 1.12 0.90 , 1.38 0.31 
3 Ozone 0.99 0.87 , 1.12 0.84 1.01 0.83 , 1.23 0.90 
 
*
 Acute coronary syndrome with troponin value >1 ng/ml  
† CO, carbon monoxide; PM10, particles with aerodynamic diameter less than 10 
µm;NO, nitric oxide;NO2, nitrogen dioxide;SO2, sulphur dioxide ‡ OR, odds ratio; CI, confidence interval; P, p value 
¶  P < 0.05 
All models are adjusted for temperature, relative humidity and barometric pressure 
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Table 2.12 Associations between AMI* and ambient air pollutants stratified by 
season 
Adjusted odds ratio and 95% CI for an IQR change in air pollutant 
 
  Warm Cold 
Lag Pollutant† OR‡ 95% CI‡ P‡ OR‡ 95% CI‡ P‡ 
0 CO 1.11 0.85 , 1.45 0.42 0.92 0.83 , 1.02 0.11 
0 PM10 1.09 0.93 , 1.27 0.28 0.92 0.81 , 1.05 0.22 
0 NO 1.07 0.79 , 1.44 0.66 0.95 0.89 , 1.00 0.06 
0 NO2 1.12 0.90 , 1.39 0.32 0.92 0.77 , 1.09 0.33 
0 SO2 1.04 0.83 , 1.30 0.73 0.92 0.78 , 1.08 0.29 
0 Ozone 0.90 0.73 , 1.11 0.32 1.11 0.91 , 1.34 0.30 
        
1 CO 1.00 0.86 , 1.17 0.99 1.04 0.96 , 1.12 0.38 
1 PM10 0.90 0.79 , 1.02 0.11 0.97 0.86 , 1.09 0.61 
1 NO 1.04 0.94 , 1.14 0.46 1.01 0.97 , 1.06 0.61 
1 NO2 1.01 0.86 , 1.20 0.87 1.13 0.99 , 1.30 0.08 
1 SO2 0.82 0.68 , 0.98 0.03 1.04 0.90 , 1.20 0.60 
1 Ozone 0.79 0.67 , 0.92 0.00¶ 1.09 0.94 , 1.26 0.28 
        
2 CO 0.93 0.80 , 1.07 0.28 1.16 1.07 , 1.26 0.00¶ 
2 PM10 0.95 0.84 , 1.08 0.47 1.12 1.00 , 1.25 0.04¶ 
2 NO 0.96 0.88 , 1.05 0.37 1.07 1.02 , 1.12 0.00¶ 
2 NO2 0.89 0.75 , 1.06 0.18 1.22 1.07 , 1.39 0.00¶ 
2 SO2 0.97 0.83 , 1.13 0.66 1.14 0.99 , 1.32 0.07 
2 Ozone 0.94 0.81 , 1.09 0.44 0.91 0.78 , 1.05 0.21 
       
 
3 CO 0.71 0.60 , 0.83 0.00¶ 1.15 1.05 , 1.26 0.00¶ 
3 PM10 1.17 1.04 , 1.31 0.01¶ 1.12 0.99 , 1.27 0.06 
3 NO 0.82 0.74 , 0.91 0.00¶ 1.07 1.02 , 1.13 0.01¶ 
3 NO2 0.75 0.64 , 0.88 0.00¶ 1.29 1.12 , 1.48 0.00¶ 
3 SO2 1.08 0.92 , 1.26 0.33 1.14 0.99 , 1.32 0.06 
3 Ozone 1.36 1.17 , 1.58 0.00¶ 0.72 0.61 , 0.84 0.00¶ 
 
*
 AMI,  acute myocardial infarction 
† CO, carbon monoxide; PM10,  particles with a aerodynamic diameter less than 
10 µm; NO, nitric oxide;NO2, nitrogen dioxide;SO2, sulphur dioxide 
‡ OR, odds ratio; CI, confidence interval; P, p value 
¶ P < 0.05 
All models are adjusted for temperature, relative humidity and barometric pressure 
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2.4 Discussion 
 
The study investigated the relationship between ambient air pollutants and daily hospital 
admission for cardiac ischaemic pain, the level of cTnT being measured to confirm the 
diagnosis of ACS. It found that short-term changes in concentrations of PM10 and 
gaseous pollutants were associated with increased admissions for ACS. This is the first 
large case-crossover study in which cTnT levels have been investigated as an index of 
myocardial damage in association with exposure to ambient air pollution. cTnT is a 
highly sensitive and specific biomarker of myocardial injury and is a preferred marker 
for the diagnosis of ACS[189]. The study found a significant association between short-
term exposure to ambient pollutants and increased risk of hospital admission for ACS 
with myocyte necrosis and AMI. 
Most of the associations were observed on day 2 (a lag of 48 to 71 hours) and day 3 (a 
lag of 72 to 95 hours) and the strongest estimated effects were observed in association 
with PM10, followed by SO2 and NO2. The results of the study provide further evidence 
in a growing body of epidemiological and experimental literature that links short-term 
exposure to PM and gaseous pollutants with ischaemic cardiac events.  
Epidemiological studies have confirmed the association between short-term changes in 
PM and gaseous pollutants and cardiovascular morbidity, including ACS[9, 59]. Despite 
some inconsistencies and conflicting results, there is now sufficient evidence that links 
short-term changes in ambient particles and gases to AMI. The results of this study are 
partly in accordance with earlier studies[62, 177, 190, 191]. There are several possible 
explanations for the differences between this study and others, which may be due to 
differences in population, data sources, age composition and air pollution mix among 
countries. The divergence could also be due to differences in methodology, use of 
varied outcome measures and case ascertainment methods. The main strength of this 
study is in its use of a biochemical marker in the diagnosis of ACS which is exceedingly 
sensitive to myocardial damage. Use of electronic records to capture all events, a stable 
ethnically homogeneous population and referral of all suspected cases to the index 
hospital are additional strengths of the study. In addition, the availability of National 
Health Service treatment enabled all patients to be referred irrespective of insurance 
status, thus minimizing bias due to varying ability to pay for health care.   
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Some earlier studies have shown an increased risk of ACS in relation to changes in 
concentrations of particles and gases[19, 20], particles alone[190] or various gases[21], 
whereas others have detected no discernible effect[192, 193]. A large multi-city study 
that enrolled elderly people over the age of 65 years has reported a 0.65% increase in 
hospitalization for AMI for a 10 µg/m3 increase in PM10. A study by Peters et al 
reported a much stronger effect of PM2.5 on the risk AMI, using 2-hour and 24-hour 
average exposure windows before the onset of AMI. The authors found that a 25 µg/m3 
increase in PM2.5 two hours before the onset of AMI was associated with an estimated 
48% increase in AMI.  The corresponding result for a 24-hour average increase in 20 
µg/m3 of PM2.5 was an increased risk of 62%. Poloniecki and colleagues evaluated the 
effect of black smoke, SO2, NO2 and CO risk on acute myocardial infarction in London 
and found a significant association with AMI admission which was stronger in cold 
seasons[62]. They also found a positive association between black smoke and angina. 
Another study showed that a 10 µg/m3 increase in PM2.5 was associated with a 4.5% 
increase in admission for acute coronary events[194]. Strong effects were found in those 
with angiographically demonstrated CAD, while those with stable presentation and 
those with clean coronaries were not susceptible[194]. A multi-centre study of 
admission for first AMI has shown suggestive associations between short-term exposure 
to CO and particle number concentrations[21]. Similarly, a study in Rome has reported 
a significant association between CO, NO2 and total suspended particle exposure and 
hospital admission for AMI, with stronger effects among older age groups and in warm 
seasons[191].  
cTnT is an established biomarker of myocardial injury and various studies have shown 
troponin elevation to be associated with an adverse clinical outcome even at low levels  
of elevation[195]. The usefulness of cTnT is not limited to establishing the diagnosis of 
ACS; it is also widely used in risk stratification[196]. The study has found associations 
between various ambient pollutants and both categories of troponin elevation.  
The study found effect modification by age and gender; the effect of PM10 was stronger 
among female and elderly subjects above the age of 65 years. As there were more ACS 
events among male subjects, the statistical power is insufficient to explain the effect 
modification observed among females. This finding supports previous research which 
showed that women were more susceptible to the short- and long-term effects of PM 
and gaseous pollutants[33, 43, 51, 52]. Peters et al. have reported a stronger effect of 
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traffic pollution on AMI among women than men following short-term exposure[33]. 
Similarly, a study that investigated the long-term effect of PM on IHD has revealed an 
increased risk of fatal coronary heart disease in women but not in men[51].  
A conflicting result of ozone on ACS was observed in the study. Paradoxical negative 
effects of ozone were observed in association with ACS with myocyte damage.  A 
recent review of the short-term effects of  air pollution on AMI has reported a similar 
negative effect of ozone[197].  The authors reviewed 12 studies which investigated the 
effects of ozone exposure on AMI. The majority of the studies reported no association 
between ozone and AMI, while a single study reported a positive association.  Three 
studies found a negative effect of ozone.  In all the studies that reported a negative role 
of ozone, ozone was negatively correlated with other measured pollutants[197].  
Similarly, in this study ozone was negatively correlated with all other pollutants. 
Ozone is a highly reactive secondary pollutant that is not emitted from primary sources 
but is generated by a complex chemical reaction. Its level in ambient air is influenced by 
various factors including the concentrations of NO, NO2, hydrocarbons, volatile organic 
compounds, UV irradiation and various meteorological parameters. The observed effect 
of ozone could be the effect of other gaseous pollutants with which ozone is negatively 
correlated.  
Atherosclerosis is increasingly recognized as an inflammatory process and is a major 
cause of adverse cardiovascular outcomes [132, 136]. Animal experiments have shown 
enhancement and progression of the atherosclerotic process following long-term 
exposure to PM and traffic pollution[127, 128, 131]. Similarly, epidemiological studies 
have  reported a relationship between long-term exposure to PM and markers of 
atherosclerosis[52, 146].   
Atmospheric pollutants are a complex mixture of particles and gases with road traffic as 
the main contributor. The individual health effects of particles and gases are difficult to 
separate because of high correlation between pollutants, due to their common sources.  
Gaseous pollutants CO, NO2 and NO are surrogates for other combustion-derived and 
unmeasured pollutants such as fine and ultrafine particles. A study in Manchester has 
shown a strong linear correlation between particles in the size range of 95-470 nm and 
NOx (r2 = 0.85) and between particles in the same size range and CO (r2 = 0.78)[198]. 
The finding of strong associations between concentrations of CO, NO and NO2 and 
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AMI in the current study indicates that traffic-related sources are related to ACS. Thus, 
it could be hypothesized that fine or ultrafine particles which are highly correlated with 
CO and NOx may be driving the effects found in this study.  
A major strength of this study is its use of a quantifiable outcome parameter (cTnT) 
which is relatively less prone to misclassification. In addition, the observed associations 
are not confounded by individual risk factors like hypertension, smoking, diabetes or 
other underlying comorbid conditions, as these factors have been accounted for by the 
inherent characteristics of the case-crossover design. Furthermore, this design reduces 
the bias which may result from long-term trends and seasonality, as the control periods 
are selected close to the case period.  
The study also has some potential limitations. The exposure data were obtained from 
fixed central site monitors and thus may not be adequate surrogate for personal 
exposure, so there is potential for exposure misclassification. However, exposure 
measurement error of this sort is generally non-differential to the measured clinical 
outcomes, thus leading to bias towards the null[26].  
The diagnosis of ACS was based on emergency department presentation for cardiac 
chest pain and subsequent measurement of cTnT. The study did not include other 
diagnostic biomarkers such as CK-MB or parameters such as ECG or evidence of 
myocardium imaging. Furthermore, no assessment was made for epidemic influenza 
and other acute respiratory infections which could contribute to wintertime respiratory 
and CV morbidity and mortality including acute cardiac events. This may have led to 
residual confounding. However, the time stratified case-crossover design used in the 
study effectively controls for seasonal variations and time trends in the design stage, by 
restricting the control intervals to the same day of the week and to the same calendar 
month and year for each case[31].  
The study did not evaluate the role of other causes of elevated cTnT. Although cTnT is 
highly cardiac muscle specific, it is not ACS specific, and in a minority of clinical 
presentations elevation of cTnT can be caused by conditions such as sepsis, atrial 
fibrillation, pulmonary embolism, myocarditis, myocardial contusion and renal failure. 
These conditions may have led to misclassification of ACS. 
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2.5 Conclusion 
 
The result of this study suggests that short-term changes in ambient PM10 and gaseous 
pollutants (NO2, NO, CO and SO2) are associated with myocardial damage as shown by 
elevated levels of cTnT in patients who were admitted via the emergency department. 
Whilst the risk for individuals is small, the high population exposure to ambient 
pollutants and the high prevalence of acute coronary syndrome mean that the public 
health impact is enormous.  
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3 Chapter Three:  Short-term Effects of Ambient Particulates and 
Gaseous Pollutants on the risk of Transient Ischaemic Attack 
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3.1 Background 
 
Stroke is a significant public health problem and the second main cause of death and 
long term disability in the world[199], [181].  In Europe, it is the second leading cause 
of disability-adjusted life years5, exceeded only by ischaemic heart disease[200]. A 
recent review of all available data from population-based stroke incidence studies and 
documents worldwide has shown considerable geographical variation in incidence of all 
strokes, with 100% increase in stroke incidence in low- to middle-income countries 
from 1970 to 2008[201]. The review further reveals that the overall stroke incidence 
rates in years 2000-2008 in low- to middle-income countries exceeded those in high-
income countries. 
Several studies have identified a number of modifiable and non-modifiable risk factors 
for stroke[202]. Among the well established conventional risk factors are hypertension, 
smoking, diabetes mellitus, asymptomatic carotid stenosis, hyperlipidaemia and atrial 
fibrillation[202]. Less well documented risk factors include obesity, physical inactivity, 
alcohol and drug abuse, hyperhomocysteinaemia, hypercoagulability, hormone 
replacement therapy, oral contraceptive use and inflammatory processes[202]. In spite 
of a through diagnostic evaluation, only about 50% of CV and stroke risk is explained 
by the traditional risk factors and 15-30% of all stroke cases have no known cause[68, 
203].  
Epidemiological studies have consistently shown associations between increased  
concentrations of ambient air pollution and various health outcomes including increased 
risk of mortality, morbidity and emergency department visits[9, 10]. A number of 
cardiovascular diseases such as AMI, hypertension, tachycardia, arrhythmia and 
repolarisation changes have been related to exposure to particles. There is increasing 
                                                 
5
 The Disability Adjusted Life Year or DALY is a measure of the gap in healthy years of life lived by a 
population as compared with a normative standard. More formally, DALYs are a time based measure 
which adds together years of life lost due to premature mortality with the equivalent number of years of 
life lived with disability or illness. http://www.who.int/healthinfo/global_burden_disease/en/index.html 
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recognition of the health effects of ambient pollutants on cerebrovascular disease 
following the results of a few studies that have shown the increased risk of hospital 
admission and death due to stroke following short-term exposure to ambient air 
pollution[71, 74, 204]. Several biological mechanisms are suggested (discussed in 
section 1.10) to link air pollution to stroke, but exact underlying pathways are not yet 
fully understood.   
Cerebrovascular risks, particularly of ischaemic stroke, may be related to the 
hypercoagulability of blood[97], destabilization of atheromatous plaques[154] or release 
of inflammatory mediators[95], factors which are well described in the epidemiological 
literature.  Epidemiological studies have demonstrated an increased incidence of stroke 
mortality[205] and morbidity[17, 69, 71, 73, 204] following short-term variations in 
ambient particulate and gaseous pollution. Air pollution studies have found that the 
effects of particle exposure occur mainly amongst certain susceptible subgroups, such as 
the elderly or people with diabetes mellitus and those suffering from respiratory and 
cardiovascular diseases[10, 49, 107].  
While several studies have investigated the effects of air pollution on CV and 
respiratory health, comparatively few have been conducted on stroke and even fewer on 
TIA. Besides, the results of the studies on stroke are inconclusive, with some conflicting 
results[17, 206, 207]. Some studies have found a positive association between ambient 
air pollutants and stroke morbidity and mortality[72, 74], while others have found no 
such association[62, 207, 208]. Furthermore, most of these studies were conducted in 
countries where the level of air pollution is greater than in the UK.  
As exposure to ambient air pollution is a modifiable risk factor, understanding the risks 
attributed to it would enable preventive health measures to be taken. A study in 
Sheffield has calculated that 11% of stroke-related deaths are attributable to the adverse 
effects of outdoor air pollution[204]. Based on the analysis of 2,979 deaths, 5,122 
admissions and a population of 199,682, the authors found increased stroke mortality 
and hospital admission in association with NOx, PM10 and CO. After adjusting for 
potential confounders, the risk of stroke mortality was 37%, 33% and 26% (all 
statistically significant) higher in the highest quintile categories relative to the lowest, 
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 for NOx, PM10 and CO respectively. Corresponding increases in risk of admission for 
stroke were 13% (95% CI, 1 to 27), 13% (95% CI, -1 to 29), and 11% (95% CI, -1 to 
25)[204]. 
 
The main purpose of the present investigation is to study the effects of ambient 
particulate matter and gases on risk of TIA and minor stroke. The working hypothesis is 
that short-term changes in ambient air pollution are related to onset of TIA or minor 
stroke. The primary objective of the study is to investigate the effects on the onset of 
TIA of short-term exposure to PM10 and the following gases: NO, NO2, CO, SO2 and 
ozone. To accomplish this objective, a secondary analysis of the NORTHSTAR dataset 
was performed.  
3.2 Methods 
3.2.1 Study Population 
 
The study population consisted of 709 subjects aged 27 to 93 years from 5 counties in 
North West England who were attending 5 TIA services at five centres (Salford, Central 
Manchester, Trafford, Walton and Aintree) for the period from May 2003 to January 
2006 as part of the NORTHSTAR study, a prospective multicentre study designed to 
investigate the prognostic role of peripheral and genetic inflammatory markers in 
patients with recent index TIA or minor stroke[209]. The primary outcome of the study, 
whose results have been published,[209] was onset of incident TIA, stroke, acute 
coronary syndrome or cardiovascular death at three months follow-up. Three TIA 
service centres in and around greater Manchester and two from Liverpool took part in 
the study. Patients were recruited from TIA clinics which received referred TIA patients 
from primary care, accident and emergency services and other hospital specialities. 
Furthermore, some patients were recruited directly from accident and emergency units 
or stroke units. Participant inclusion criteria were developed for the primary objective of 
the NORTHSTAR study and included diagnosis of TIA or minor stroke confirmed by a 
consultant stroke physician or neurologist, symptom onset within the preceding 6 
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weeks, age >18 years, modified Rankin Scale (mRS)6 ≤ 1, no known cognitive 
impairment sufficient to interfere with independent daily living, no significant 
comorbidity limiting participation in the study and intention to remain resident within 
the area for the duration of the study, with access to a telephone.   
The study included all confirmed index cases of TIA, which the NORTHSTAR study 
defined as a clinical syndrome of acute loss of focal cerebral or monocular function, of 
vascular origin, with symptoms resolving within 24 h. Minor stroke was defined as a 
clinical syndrome of rapidly developing symptoms and signs of focal loss of cerebral 
function, of vascular origin, lasting more than 24 hour with mRS ≤ 1[209]. 
3.2.2 Study Design 
 
A time stratified case-crossover design was employed to estimate the effect of ambient 
particle/gaseous pollutants and the onset of TIA (discussed in section 1.3.1.2).   For 
each index TIA event, three to four controls were chosen. The exposure levels and other 
covariates of each case of TIA were compared with exposure on non-event referent 
periods corresponding to the same weekday of the month in the same year in which no 
events occurred. In time stratified design the control periods could be before or after the 
cases. 
3.2.3 Environmental data 
 
Historical environmental air quality data were obtained from the UK National Air 
Quality Archive available at http://www.airquality.co.uk/data_and_statistics_home.php. 
Data were extracted from 8 background monitoring stations located in Greater 
Manchester (6) and Liverpool (2). Urban background monitors are typically placed 
distant from emission sources and are generally representative of city-wide background 
concentrations. Hourly data on the following pollutants were acquired: PM10, NO, NO2, 
CO, SO2 and ozone. Some of the monitors provide data for all pollutants and others for 
a limited number of them, depending on the monitoring needs of the specific site. The 
distribution of TIA cases and ambient air monitoring stations in Greater Manchester and 
Merseyside are shown in Figure 3.1.  
                                                 
6
 The scale runs from 0-6: 0 for no symptoms at all to 6 for death. 
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Figure 3.1 Distribution of TIA cases and Air Quality Monitoring stations in 
Greater Manchester and Merseyside 
 
Data on meteorological confounders (temperature and relative humidity) were obtained 
from the UK Meteorological Office[185]. Data for Greater Manchester were obtained 
from the Ringway station, situated 17 km south of Manchester city centre. For 
Liverpool, data were obtained from the Crosby station, 13 km north of Liverpool town 
centre. Time varying weather covariates including temperature and relative humidity are 
known confounders of the association between air pollutants and short-term health 
effects. In addition, data on weekly influenza epidemics in the region were provided by 
the Health Protection Agency North West. 
From the hourly data obtained from the monitoring networks, a 24-hour average 
exposure parameter (midnight to midnight) was created, except for ozone, for which a 
daytime 8-hour average was used. Four exposure lags were evaluated for the 
118 
environmental data, comprising data for the same day as the TIA (lag 0) and the three 
immediately preceding days (lag 3 to lag 1). Similarly, meteorological variables 
temperature and relative humidity were averaged over each 24-h period up to three 
days.  
Missing data for some days were imputed by a multiple imputation method using data 
from other monitors and incorporating daily mean temperature and relative humidity. 
The proportion of missing values ranged from 2.3% to 49%. Where more than 25% 
were missing for a particular pollutant from a particular monitor, this was excluded 
from the imputation.    
3.2.4 Statistical Analysis  
 
Baseline participant characteristics and environmental variables were examined by 
descriptive statics. Time series plots were created for each air pollutant to examine 
variations in time. To explore the relationship between each ambient air pollutant and 
TIA, conditional logistic regression analysis was performed. Adjusted odds ratios and 
95% confidence intervals were estimated, each scaled to the IQR increase of each 
pollutant. All pollutant measures and meteorological variables were entered into the 
model as linear terms. The statistical analysis was carried out using Stata version 11.0 
(Stata Corp, College Station, Texas). 
In a time stratified case-crossover design, each subject serves as his or her own control, 
so fixed individual level covariates like age and gender cannot be estimated, but 
potential effect modification can be determined for these variables. Earlier studies have 
shown that the effect of air pollutants is modified by age, gender and season. Thus, 
effect modification by age (cut-off at 65 years), gender and season (October to March 
vs. April to September) were assessed.  
Published findings regarding the relationship between weather and stroke incidence are 
inconsistent, with some studies finding positive associations with warm or cold 
temperature and others finding no association[210]. The present study adjusted for 
observed confounders like temperature, relative humidity, weekly influenza count and 
holiday. Mean temperature and relative humidity were entered into the model as linear 
terms and UK public holidays were coded as binary variables and entered as such into 
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the model. The final model was adjusted for meteorological variables (temperature and 
relative humidity), holiday and influenza epidemics.  
In a further analysis, the effect of two pollutants was explored to address the potential 
confounding effect of co-pollutants and to identify which of the pollutants remained 
stable in explaining the relationship with the outcome. This was achieved by first 
analyzing the independent effect of each pollutant and then modelling the effects of two 
pollutants together.  
The patients participating in this study were from five different centres clustered into 
two main groups: Manchester and Liverpool. As these two locations are far apart, 
separate exposure estimates were made for each centre.  
Effect estimates were provided with 95% CI, statistical significance of p < 0.05 was 
used. Ethical approval for the project was obtained from the Central Manchester 
Research Ethics Committee and Salford Royal NHS Foundation Trust. 
3.3 Results  
3.3.1 Characteristics of the Study Population and Exposure 
 
The analysis was based on 709 TIA patients originally recruited to the NORTHSTAR 
study, 374 (52.8%) from Liverpool and 335 from Manchester. Baseline participant 
characteristics are shown in Table 3.1. The participants were mainly elderly patients 
with an age range of 27-93 years and a mean of 66.8 ± 11.  62% of the participants were 
above the age of 65. Their mean body mass index (BMI) ranged from 14.8-55 kg/m3. 
The majority of the participants (99%) were white and they were predominantly male 
(58.7%). About a third were current smokers. The majority were prescribed medications 
such as antihypertensive medication (79%), aspirin (74%), statins (55%) and treatment 
for diabetes (11%).  
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Table 3.2 shows the distribution of measured pollutants for each study centre.  Mean 
concentrations of CO, PM10, NO and NO2 were high in Manchester, whereas those of 
SO2 and ozone were higher in Liverpool. The daily mean concentration of NO in 
Manchester was roughly twice that of Liverpool and mean concentration of NO2 was 
10 µg/m3 more than that measured in Liverpool. On the other hand, the concentration of 
SO2 was more than twice as high in Liverpool as in Manchester. The concentration of 
all pollutants in both centres was well below the current UK Air Quality Objectives for 
the protection of human health. The table also shows large daily variations in the 
distribution of all measured pollutants and temperature during the study period for both 
centres. The measured daily temperature varied between -1.5 and 23.8 °C for 
Manchester and between -2.7 and 24.2 °C in Liverpool.  
The pairwise correlation coefficients for average daily pollutants and meteorological 
variables are shown in Table 3.3 and Table 3.4 for Manchester and Liverpool 
respectively. In both centres a strong correlation is evident between NO and CO 
(r = 0.89 and 0.91 for Manchester and Liverpool respectively). Similarly, there was a 
high correlation between CO and NO2 in both centres with r = 0.75 for Manchester and 
r = 0.72 for Liverpool. In both centres ozone was negatively correlated with all other 
pollutants. The largest negative correlation of ozone was with NO2 (r = -0.69 in 
Manchester and -0.67 in Liverpool). Ambient temperature was negatively correlated 
with all pollutants except ozone.   
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Table 3.1 Baseline patient characteristics 
(N=709) 
Age in y, (mean, range) 66.8 (27-93) 
Age  ≥ 65, in % 62.2 
Gender, male % 58.7 
Smoking status, % 
 
Never smoker, % 26.4 
Ex-smoker, % 41.3 
Current smoker 32.3 
BMI, mean (median) 27.7(27.1) 
Index event, in % 
 
Cerebral TIA 43.7 
Minor stroke 42.3 
Ocular TIA 8.9 
Ocular stroke 5.1 
Co- morbidity, % 
 
Previous stroke/TIA 40.1 
CAD* 25.7 
Hypertension 70.2 
Diabetes mellitus 16.6 
Atrial fibrillation 10.2 
History of dyslipidaemia 72.1 
History of peripheral vascular disease 11.4 
Medication use, % 
 
Aspirin 73.8 
Other anti platelets 21.3 
Statins 54.6 
ACE*-inhibitors 28.9 
Angiotensin II receptor blocker 10.3 
Other anti hypertensive medication 50.1 
Anti-anginal therapy 17.9 
Anti coagulation 5.2 
Treatment for diabetes, % 11 
 
* CAD =coronary artery disease; ACE = angiotensin converting enzyme  inhibitor 
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Table 3.2 Descriptive statistics for environmental variables 
(May 2003 – Jan 2006) 
 
  Manchester Liverpool 
Variable Mean SD* Min.* Max.* Mean SD* Min. Max. 
CO†(mg/m3) 0.4 0.2 0.2 1.6 0.2 0.1 0.1 1.1 
PM10†( µg /m3) 22.3 8.7 7.7 60.0 19.8 7.8 5.0 58.5 
NO†( µg /m3) 16.2 20.6 2.2 200.4 8.2 11.2 1.0 105.5 
NO2†( µg /m3) 32.3 12.2 11.8 83.0 21.4 10.8 4.5 62.0 
SO2†( µg /m3) 2.8 2.9 0.0 22.0 5.8 3.4 0.0 22.0 
Ozone( µg /m3) 38.6 17.7 1.7 85.7 47.0 16.4 1.0 90.0 
Temperature(°C) 10.7 4.9 -1.5 23.8 11.2 4.7 -2.7 24.2 
Relative humidity, % 79.3 8.2 56.3 96.0 82.8 7.8 56.0 99.1 
     
* SD, standard deviation; Min, minimum; Max, maximum 
† PM10, mass concentration of particles less than 10 µm in aerodynamic diameter; 
CO, carbon monoxide, NO, nitric oxide; NO2, nitrogen dioxide; SO2, sulphur 
dioxide 
 
Table 3.3 Correlations of mean daily concentrations of pollutants, Manchester 
 (May 2003 – Jan 2006) 
 
 
CO PM10 NO NO2 SO2 Ozone Temperature RH* 
CO 1 
       
PM10 0.53 1       
NO 0.89 0.49 1 
     
NO2 0.75 0.54 0.77 1     
SO2 0.50 0.61 0.49 0.55 1    
Ozone -0.54 -0.23 -0.59 -0.68 -0.38 1 
  
Temperature -0.39 -0.04 -0.42 -0.48 -0.20 0.20 1 
 
RH* 0.31 -0.09 0.32 0.30 -0.06 -0.50 -0.25 1 
         
* RH, relative humidity 
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Table 3.4 Correlations of mean daily concentrations of pollutants, Liverpool  
(May 2003 – Jan 2006) 
 
 
CO PM10 NO NO2 SO2 Ozone Temperature RH* 
CO 1 
       
PM10 0.44 1       
NO 0.91 0.42 1 
     
NO2 0.72 0.49 0.72 1     
SO2 0.14 0.25 0.17 0.29 1    
Ozone -0.55 -0.20 -0.55 -0.67 -0.09 1 
  
Temperature -0.40 -0.05 -0.37 -0.48 0.01 0.19 1 
 
RH* 0.23 -0.08 0.23 0.24 -0.11 -0.42 -0.19 1 
    
* RH, relative humidity 
Figure 3.2 to Figure 3.8 show time series of observed background pollutants and 
temperature for Manchester. These figures show some evidence of seasonal trends in 
the distribution of pollutants, with wintertime peaks and falls in summer for all 
pollutants except ozone, which has a reverse trend. A similar trend was observed for the 
Liverpool data (data not shown). 
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Figure 3.2 Time-series of daily concentrations of CO  
(May 2003 - January 2006) 
0
50
10
0
15
0
20
0
N
O
 
(µg
 
/m
3)
01/07/03 01/01/04 01/07/04 01/01/05 01/07/05 01/01/06
 
Figure 3.3 Time-series of daily concentrations of background NO  
(May 2003-January 2006) 
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Figure 3.4 Time-series of daily concentrations of background NO2  
(May 2003 - January 2006) 
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Figure 3.5 Time-series of daily concentrations of background PM10  
(May 2003 - January 2006) 
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Figure 3.6 Time-series of daily concentrations of background ozone 
(May 2003 - January 2006) 
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Figure 3.7 Time-series of daily concentrations of background SO2 
(May 2003 - January 2006) 
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Figure 3.8 Time-series of daily temperature  
(May 2003 - January 2006) 
 
3.3.2 Associations with TIA 
 
The associations between ambient pollutants and the occurrence of TIA are shown in 
Table 3.5.  Figure 3.9 and 3.10 present the effect estimates for the associations between 
TIA and ambient air pollutants for Manchester and Liverpool respectively. In a single 
pollutant model, no statistically significant positive association was found in Liverpool 
for any pollutant, apart from a negative effect of PM10 at lag 1 and NO for lag 3.  
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Figure 3.9 Associations of TIA with ambient air pollutants (Manchester) 
 
The triangles, squares and circles indicate odds ratio, vertical lines 95 % CI calculated for an 
IQR of the respective pollutant under consideration. 
L0, average pollutant concentration 0-23 hours before the occurrence of TIA 
L1, average pollutant concentration 24-47 hours before the occurrence of TIA  
L2, average pollutant concentration 48-71 hours before the occurrence of TIA 
L3, average pollutant concentration 72-95 hours before the occurrence of TIA 
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Figure 3.10 Associations of TIA with ambient air pollutants (Liverpool) 
The triangles, squares and circles indicate odds ratio, vertical lines 95 % CI calculated for 
an IQR of the respective pollutant under consideration. 
           L0, average pollutant concentration 0-23 hours before the occurrence of TIA 
L1, average pollutant concentration 24-47 hours before the occurrence of TIA  
L2, average pollutant concentration 48-71 hours before the occurrence of TIA 
L3, average pollutant concentration 72-95 hours before the occurrence of TIA 
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Table 3.5 Associations between ambient particulates and gases and TIA for all 
study subjects  
Adjusted odds ratio and 95% CI for an IQR change in air pollutant 
 
  Manchester Liverpool 
Lag Pollutant* OR† 95% CI† P† OR† 95% CI† P† 
0 CO 0.95 0.84 , 1.07 0.39 1.06 0.99 , 1.12 0.09 
0 PM10 0.93 0.81 , 1.07 0.30 0.87 0.76 , 0.98 0.03¶ 
0 NO 0.96 0.90 , 1.02 0.20 1.04 0.99 , 1.09 0.16 
0 NO2 0.94 0.77 , 1.14 0.52 1.10 0.91 , 1.33 0.34 
0 SO2 0.93 0.79 , 1.08 0.32 0.93 0.79 , 1.09 0.36 
0 O3 1.15 0.94 , 1.40 0.18 0.83 0.68 , 1.01 0.07 
        
1 CO 0.96 0.85 , 1.08 0.49 1.02 0.96 , 1.09 0.48 
1 PM10 0.93 0.81 , 1.06 0.25 1.07 0.95 , 1.20 0.28 
1 NO 0.97 0.92 , 1.04 0.40 1.01 0.96 , 1.06 0.76 
1 NO2 1.01 0.84 , 1.21 0.95 1.06 0.87 , 1.28 0.57 
1 SO2 0.95 0.82 , 1.09 0.47 1.14 0.98 , 1.32 0.10 
1 O3 0.90 0.74 , 1.10 0.30 1.06 0.87 , 1.30 0.56 
        
2 CO 0.98 0.87 , 1.09 0.69 1.01 0.95 , 1.08 0.71 
2 PM10 0.95 0.84 , 1.09 0.48 0.94 0.82 , 1.06 0.31 
2 NO 0.97 0.92 , 1.03 0.36 1.03 0.98 , 1.09 0.19 
2 NO2 0.89 0.74 , 1.08 0.24 0.95 0.79 , 1.15 0.61 
2 SO2 0.98 0.85 , 1.13 0.77 1.03 0.88 , 1.21 0.70 
2 O3 1.06 0.87 , 1.30 0.55 1.09 0.89 , 1.33 0.43 
        
3 CO 1.08 0.97 , 1.19 0.15 0.95 0.88 , 1.02 0.13 
3 PM10 1.12 0.99 , 1.27 0.08 0.95 0.83 , 1.08 0.42 
3 NO 1.06 1.01 , 1.11 0.03¶ 0.93 0.86 , 1.00 0.04¶ 
3 NO2 1.12 0.93 , 1.35 0.23 0.91 0.75 , 1.11 0.36 
3 SO2 1.03 0.89 , 1.19 0.70 0.98 0.83 , 1.17 0.85 
3 O3 0.87 0.71 , 1.07 0.18 1.17 0.95 , 1.44 0.14 
 
*
 CO, carbon monoxide;PM10, particles with a aerodynamic diameter less than 10 
µm; NO, nitric oxide;NO2, nitrogen dioxide;SO2, sulphur dioxide;O3, ozone  
† OR, odds ratio; 95% CI, 95% confidence interval; P, p value 
¶ P<0.05 
All models are adjusted for temperature, humidity, holiday and influenza epidemics. 
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For Manchester data, in all dataset analysis a statistically significant positive association 
was observed between NO and TIA/minor stroke for lag 3 with estimated OR of 1.06 
(95% CI: 1.01-1.11%). Effects of similar or larger magnitude which were not significant 
were observed for all other pollutants except ozone, for lag 3 in Manchester. For 
example, an IQR increase in CO was associated with an OR of 1.08 (95% CI0.97-1.19), 
whereas an IQR in PM10 was associated with an OR of 1.12 (95% CI 0.99-1.27).  
Conversely, all effect estimates at lag 3 for Liverpool data were below unity, except for 
ozone. A large but non-significant effect of ozone was observed in both centres, with a 
risk of 15% (95% CI: -0.06–4%) for Manchester at lag 0 and 17% (95% CI: -0.05%–
44%) for Liverpool at lag 3.  
3.3.3 Effect Modification 
 
Evidence of effect modification by age, gender and season was observed in the analyses 
shown in Table 3.6 to Table 3.11. In participants above the age of 65 from Manchester, 
the risks of TIA/minor stroke for an IQR increase of CO and NO at lag 3 were 19% 
(95% CI: 1.03-1.38%) and 11% (95% CI: 1.03-1.19%) respectively when compared to 
those below 65. All effect estimates for those below 65 years were close to unity and 
were non-significant except that of PM10, which was 1.12 (95% CI: 0.93-1.35). For 
Liverpool, no significant effect modification by age was observed. 
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Figure 3.11 Associations of TIA with ambient air pollutants, Manchester age ≥ 65 
 
 
Figure 3.12 Associations of TIA with ambient air pollutants, Manchester age < 65 
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Regarding gender, there was an increased risk of TIA for males at lag 3 in association 
with NO, with an OR of 1.09 (95% CI: 1.01-1.17). Large but non-significant effects of 
CO, PM10 and NO2 for lag 3 were observed for Manchester data. The OR values for 
these associations with TIA were 1.13 (95% CI: 0.99-1.3), 1.12 (95% CI: 0.95-1.32) 
and 1.23 (95% CI: 0.99-1.3) for the respective pollutants. The Liverpool dataset showed 
an increased risk of TIA in males at lag 2. For each IQR increase in NO there was an 
8% increase in risk of TIA (95% CI: 1-16%).   
In females, no statistically significant association was found between TIA any of the 
pollutants for Manchester data. However, a borderline increase in risk at lag 3 with SO2 
(OR = 1.24, 95% CI: 0.99-1.54) was found. For Liverpool a significant increased risk of 
TIA was found in association with CO and NO on the same day and with SO2 at lag 1. 
An IQR increase in NO was associated with a 12% increase in TIA (95% CI: 1.01-
1.24). Similarly, CO was associated with a 9% increase in TIA (95% CI: 1.0-1.17). For 
lag 1, there was a 26% increase in risk of TIA with SO2 (95% CI: 1.01-1.58%). 
 
Figure 3.13 Associations of TIA with ambient air pollutants (Manchester, male) 
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Figure 3.14 Associations of TIA with ambient air pollutants (Manchester, female) 
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Table 3.6 Associations between ambient particulates and gases and TIA in females 
Adjusted odds ratio and 95% CI for an IQR change in air pollutant 
  
Manchester Liverpool 
Lag Pollutant* OR† 95% CI† P† OR† 95% CI† OR† 
0 CO 0.96 0.80 , 1.16 0.69 1.12 1.01 , 1.24 0.04¶ 
0 PM10 0.91 0.74 , 1.12 0.37 0.87 0.71 , 1.07 0.18 
0 NO 0.98 0.89 , 1.07 0.58 1.09 1.00 , 1.19 0.05¶ 
0 NO2 0.98 0.73 , 1.31 0.90 1.20 0.89 , 1.61 0.24 
0 SO2 0.99 0.79 , 1.24 0.93 1.00 0.80 , 1.26 0.98 
0 Ozone 1.04 0.76 , 1.43 0.79 0.85 0.61 , 1.17 0.32 
         
1 CO 0.91 0.75 , 1.10 0.33 1.03 0.93 , 1.15 0.55 
1 PM10 0.93 0.76 , 1.13 0.45 1.05 0.86 , 1.28 0.63 
1 NO 0.95 0.86 , 1.04 0.28 1.03 0.94 , 1.13 0.51 
1 NO2 0.94 0.71 , 1.24 0.67 1.09 0.80 , 1.47 0.59 
1 SO2 0.78 0.61 , 1.01 0.06 1.26 1.01 , 1.58 0.04¶ 
1 Ozone 1.07 0.79 , 1.43 0.67 1.00 0.72 , 1.39 0.99 
        
2 CO 1.06 0.90 , 1.25 0.50 0.95 0.85 , 1.06 0.36 
2 PM10 0.99 0.81 , 1.21 0.95 0.96 0.78 , 1.18 0.68 
2 NO 1.01 0.93 , 1.11 0.78 0.96 0.87 , 1.06 0.42 
2 NO2 0.98 0.74 , 1.30 0.90 0.82 0.60 , 1.11 0.19 
2 SO2 1.01 0.81 , 1.26 0.94 0.83 0.64 , 1.07 0.15 
2 Ozone 1.03 0.77 , 1.39 0.83 1.07 0.77 , 1.50 0.67 
        
3 CO 1.01 0.86 , 1.19 0.91 0.96 0.86 , 1.07 0.45 
3 PM10 1.12 0.92 , 1.36 0.25 0.95 0.78 , 1.17 0.64 
3 NO 1.03 0.95 , 1.11 0.50 0.94 0.85 , 1.04 0.22 
3 NO2 1.01 0.76 , 1.33 0.96 1.07 0.78 , 1.46 0.68 
3 SO2 1.24 0.99 , 1.54 0.06 1.19 0.93 , 1.52 0.18 
3 Ozone 0.91 0.67 , 1.23 0.53 1.21 0.85 , 1.71 0.29 
 
*
 CO, carbon monoxide; PM10, mass of particles with aerodynamic diameter < 10 
µm; NO, nitric oxide; NO2, nitrogen dioxide; SO2, sulphur dioxide  
† OR, odds ratio; 95% CI, 95% confidence interval; P, =p value 
¶ P < 0.05 
All models are adjusted for temperature, humidity, holiday and influenza epidemics. 
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Table 3.7  Associations between ambient particulates and gases and TIA in males 
Adjusted odds ratio and 95% CI for an IQR change in air pollutant 
  Manchester Liverpool 
Lag Pollutant* OR† 95% CI† P† OR† 95% CI† P† 
0 CO 0.93 0.79 , 1.10 0.42 1.02 0.94 , 1.11 0.62 
0 PM10 0.94 0.79 , 1.12 0.49 0.86 0.73 , 1.02 0.08 
0 NO 0.94 0.85 , 1.03 0.20 1.01 0.94 , 1.08 0.83 
0 NO2 0.90 0.69 , 1.16 0.41 1.04 0.81 , 1.32 0.78 
0 SO2 0.87 0.70 , 1.07 0.18 0.87 0.70 , 1.09 0.22 
0 Ozone 1.23 0.95 , 1.61 0.12 0.81 0.62 , 1.05 0.12 
        
1 CO 1.00 0.85 , 1.16 0.96 1.02 0.94 , 1.10 0.68 
1 PM10 0.92 0.77 , 1.10 0.38 1.08 0.93 , 1.26 0.32 
1 NO 1.00 0.92 , 1.08 0.94 1.00 0.93 , 1.07 0.92 
1 NO2 1.07 0.83 , 1.38 0.59 1.04 0.82 , 1.33 0.75 
1 SO2 1.06 0.89 , 1.27 0.50 1.04 0.85 , 1.28 0.70 
1 Ozone 0.77 0.58 , 1.01 0.06 1.10 0.85 , 1.42 0.45 
        
2 CO 0.92 0.79 , 1.07 0.29 1.05 0.97 , 1.14 0.23 
2 PM10 0.92 0.77 , 1.10 0.35 0.92 0.79 , 1.09 0.34 
2 NO 0.94 0.86 , 1.02 0.14 1.08 1.01 , 1.16 0.02¶ 
2 NO2 0.81 0.62 , 1.05 0.11 1.04 0.82 , 1.31 0.75 
2 SO2 0.95 0.78 , 1.15 0.58 1.21 0.99 , 1.49 0.07 
2 Ozone 1.09 0.83 , 1.42 0.55 1.09 0.85 , 1.41 0.50 
        
3 CO 1.13 0.99 , 1.30 0.08 0.94 0.85 , 1.03 0.20 
3 PM10 1.12 0.95 , 1.32 0.18 0.95 0.81 , 1.12 0.55 
3 NO 1.09 1.01 , 1.17 0.02¶ 0.91 0.82 , 1.01 0.09 
3 NO2 1.23 0.95 , 1.58 0.12 0.84 0.66 , 1.08 0.17 
3 SO2 0.89 0.73 , 1.09 0.26 0.86 0.69 , 1.09 0.21 
3 Ozone 0.84 0.63 , 1.11 0.21 1.14 0.88 , 1.48 0.31 
 
*
  CO, carbon monoxide;PM10, mass of particles with aerodynamic diameter less 
than 10 µm; NO, nitric oxide;NO2, nitrogen dioxide;SO2, sulphur dioxide  
† OR, odds ratio; CI, confidence interval; P, p value 
¶ P<0.05 
All models are adjusted for temperature, humidity, holiday and influenza epidemics. 
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Table 3.8 Associations between ambient PM and gases and TIA for age ≥ 65 
Adjusted odds ratio and 95% CI for an IQR change in air pollutant 
  Manchester Liverpool 
Lag Pollutant* OR† 95% CI† P† OR† 95% CI† P† 
0 CO 0.90 0.76 , 1.07 0.24 1.08 0.99 , 1.17 0.081 
0 PM10 0.89 0.74 , 1.06 0.19 0.95 0.82 , 1.11 0.54 
0 NO 0.95 0.88 , 1.04 0.26 1.07 0.99 , 1.14 0.07 
0 NO2 0.87 0.68 , 1.13 0.30 1.10 0.86 , 1.40 0.44 
0 SO2 0.83 0.67 , 1.03 0.09 0.97 0.80 , 1.17 0.74 
0 Ozone 1.29 0.99 , 1.69 0.06 0.85 0.66 , 1.10 0.22 
        
1 CO 1.01 0.86 , 1.18 0.93 1.01 0.92 , 1.10 0.84 
1 PM10 0.93 0.78 , 1.10 0.41 1.04 0.89 , 1.21 0.61 
1 NO 1.00 0.93 , 1.08 0.96 0.99 0.92 , 1.07 0.85 
1 NO2 1.08 0.85 , 1.37 0.51 0.94 0.74 , 1.19 0.62 
1 SO2 1.02 0.85 , 1.22 0.81 1.09 0.90 , 1.31 0.39 
1 Ozone 0.84 0.65 , 1.10 0.21 1.13 0.88 , 1.45 0.32 
        
2 CO 0.90 0.77 , 1.07 0.23 1.00 0.91 , 1.09 0.92 
2 PM10 0.91 0.76 , 1.09 0.29 0.85 0.72 , 1.00 0.05 
2 NO 0.93 0.84 , 1.01 0.09 1.03 0.95 , 1.12 0.47 
2 NO2 0.81 0.63 , 1.04 0.09 0.91 0.72 , 1.15 0.42 
2 SO2 0.98 0.81 , 1.18 0.80 0.99 0.82 , 1.21 0.94 
2 Ozone 1.06 0.82 , 1.38 0.65 1.12 0.87 , 1.44 0.37 
        
3 CO 1.19 1.03 , 1.38 0.02¶ 0.96 0.87 , 1.06 0.45 
3 PM10 1.13 0.95 , 1.34 0.17 1.00 0.85 , 1.16 0.96 
3 NO 1.11 1.03 , 1.19 0.00¶ 0.94 0.85 , 1.03 0.19 
3 NO2 1.22 0.96 , 1.57 0.11 0.98 0.77 , 1.24 0.85 
3 SO2 1.05 0.88 , 1.27 0.58 0.99 0.80 , 1.22 0.91 
3 Ozone 0.83 0.64 , 1.09 0.18 1.14 0.88 , 1.47 0.32 
 
*
  CO, carbon monoxide;PM10, mass of particles with aerodynamic diameter less 
than 10 µm; NO, nitric oxide;NO2, nitrogen dioxide;SO2, sulphur dioxide;   
† OR, odds ratio; CI, confidence interval; P, p value 
¶ P<0.05 
All models are adjusted for temperature, humidity, holiday and influenza epidemics. 
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Table 3.9 Associations between ambient PM and gases and TIA for age < 65 
Adjusted odds ratio and 95% CI for an IQR change in air pollutant 
  Manchester  Liverpool   
Lag Pollutant* OR† 95% CI† P† OR† 95% CI† P† 
0 CO 1.00 0.84 , 1.2 0.98 1.02 0.92 , 1.12 0.75 
0 PM10 1.01 0.82 , 1.24 0.94 0.67 0.52 , 0.86 0.00¶ 
0 NO 0.97 0.87 , 1.07 0.52 0.99 0.91 , 1.08 0.89 
0 NO2 1.04 0.76 , 1.41 0.83 1.05 0.76 , 1.44 0.77 
0 SO2 1.04 0.83 , 1.29 0.73 0.83 0.62 , 1.11 0.20 
0 O3 1.01 0.74 , 1.37 0.96 0.81 0.57 , 1.15 0.24 
        
1 CO 0.90 0.74 , 1.10 0.30 1.04 0.95 , 1.15 0.37 
1 PM10 0.92 0.75 , 1.12 0.40 1.13 0.92 , 1.37 0.25 
1 NO 0.94 0.84 , 1.04 0.24 1.03 0.95 , 1.11 0.49 
1 NO2 0.91 0.67 , 1.22 0.52 1.31 0.96 , 1.80 0.09 
1 SO2 0.84 0.66 , 1.07 0.16 1.25 0.96 , 1.62 0.10 
1 Ozone 0.97 0.72 , 1.32 0.87 0.93 0.66 , 1.31 0.68 
        
2 CO 1.05 0.90 , 1.22 0.55 1.03 0.94 , 1.13 0.51 
2 PM10 1.01 0.83 , 1.23 0.91 1.11 0.90 , 1.37 0.31 
2 NO 1.02 0.94 , 1.11 0.65 1.04 0.97 , 1.11 0.25 
2 NO2 1.01 0.75 , 1.35 0.96 1.05 0.76 , 1.44 0.77 
2 SO2 0.99 0.79 , 1.24 0.91 1.11 0.84 , 1.46 0.47 
2 Ozone 1.07 0.78 , 1.46 0.68 1.01 0.71 , 1.43 0.97 
        
3 CO 0.95 0.80 , 1.13 0.57 0.93 0.83 , 1.04 0.20 
3 PM10 1.12 0.93 , 1.35 0.24 0.86 0.68 , 1.09 0.21 
3 NO 0.99 0.91 , 1.08 0.88 0.91 0.80 , 1.03 0.12 
3 NO2 1.00 0.75 , 1.34 0.99 0.81 0.58 , 1.12 0.20 
3 SO2 0.99 0.79 , 1.25 0.95 0.98 0.75 , 1.3 0.91 
3 Ozone 0.92 0.67 , 1.26 0.60 1.23 0.86 , 1.78 0.26 
 
*
  CO, carbon monoxide;PM10, mass of particles with aerodynamic diameter less 
than 10 µm; NO, nitric oxide;NO2, nitrogen dioxide;SO2, sulphur dioxide;   
† OR, odds ratio; CI, confidence interval; P, p value 
¶ P<0.05 
All models are adjusted for temperature, humidity, holiday and influenza epidemics. 
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In addition, variations in risk of TIA by season classified as cold (October to March) 
and warm (April to September) was observed. For warmer months the risk of TIA was 
increased in association with NO2 in the Liverpool data. An IQR increase of NO2 at lag 
1 was associated with a 42% increase in TIA (95% CI: 1.02-1.97). Non-significant large 
effects of ozone and CO were observed in the warm season in Manchester as well. 
Ozone on the same day was associated with an OR of 1.32 (95%CI: 0.96-1.82) and an 
effect of similar size at lag 2 was found with CO. 
 
 
 
Figure 3.15 Associations of TIA with ambient air pollutants (Manchester, warm 
season) 
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Figure 3.16 Associations of TIA with ambient air pollutants (Manchester, cold 
season) 
 
 
In contrast, an increased risk of TIA in association with the cold season was observed 
for both Manchester and Liverpool data. Significant same day effects of CO, NO and 
NO2 were found in the Liverpool data. An IQR increase in levels of these pollutants was 
followed respectively by increases in TIA of 9% (95% CI: 1.02-1.18), 6% (95% CI: 1.0-
1.13) and 41% (95% CI: 1.07-1.86). Likewise, an increased risk of 6% (95% CI: 1.0-
1.12) was found for lag 3 in association with NO in the Manchester data. A non-
significant effect of NO2 with an OR of 1.25 (95% CI: 0.97-1.62) was observed in 
association with an IQR increase of NO2 at lag 3 in Manchester in the cold season.  
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Table 3.10  Associations between ambient particulates and gases and TIA in cold 
season 
Adjusted odds ratio and 95% CI for an IQR change in air pollutant 
  Manchester Liverpool 
Lag Pollutant* OR† 95% CI† P† OR 95% CI P 
0 CO 0.96 0.83 , 1.11 0.55 1.09 1.02 , 1.18 0.02¶ 
0 PM10 0.90 0.75 , 1.09 0.30 0.85 0.71 , 1.03 0.09 
0 NO 0.96 0.90 , 1.03 0.30 1.06 1.00 , 1.13 0.04¶ 
0 NO2 0.95 0.72 , 1.24 0.69 1.41 1.07 , 1.86 0.02¶ 
0 SO2 0.99 0.81 , 1.20 0.90 0.96 0.76 , 1.22 0.74 
0 Ozone 1.00 0.77 , 1.31 0.98 0.70 0.53 , 0.92 0.01¶ 
        
1 CO 0.96 0.83 , 1.11 0.60 0.98 0.91 , 1.06 0.68 
1 PM10 0.95 0.79 , 1.15 0.61 0.96 0.80 , 1.15 0.66 
1 NO 0.98 0.92 , 1.05 0.60 0.99 0.93 , 1.05 0.78 
1 NO2 1.00 0.77 , 1.30 1.00 0.78 0.58 , 1.04 0.09 
1 SO2 0.98 0.82 , 1.18 0.84 1.07 0.86 , 1.35 0.54 
1 Ozone 0.85 0.65 , 1.11 0.23 1.11 0.84 , 1.46 0.46 
        
2 CO 1.00 0.87 , 1.15 0.99 1.01 0.94 , 1.09 0.72 
2 PM10 1.08 0.90 , 1.30 0.43 0.96 0.80 , 1.15 0.65 
2 NO 1.00 0.94 , 1.08 0.93 1.05 0.99 , 1.11 0.10 
2 NO2 0.95 0.73 , 1.24 0.73 1.03 0.79 , 1.34 0.83 
2 SO2 1.01 0.84 , 1.22 0.93 0.98 0.77 , 1.24 0.84 
2 Ozone 1.11 0.85 , 1.44 0.43 1.02 0.78 , 1.34 0.86 
        
3 CO 1.10 0.98 , 1.25 0.11 0.94 0.86 , 1.02 0.14 
3 PM10 1.12 0.93 , 1.35 0.24 0.92 0.77 , 1.11 0.41 
3 NO 1.06 1.00 , 1.12 0.05¶ 0.91 0.84 , 1.00 0.04 
3 NO2 1.25 0.97 , 1.62 0.09 0.84 0.63 , 1.11 0.21 
3 SO2 0.99 0.81 , 1.20 0.89 1.00 0.78 , 1.28 1.00 
3 Ozone 0.82 0.63 , 1.08 0.16 1.29 0.97 , 1.71 0.08 
 
*
  CO, carbon monoxide;PM10, mass of particles with aerodynamic diameter less 
than 10 µm; NO, nitric oxide;NO2, nitrogen dioxide;SO2, sulphur dioxide;   
† OR, odds ratio; CI, confidence interval; P, p value 
¶ P<0.05 
All models are adjusted for temperature, humidity, holiday and influenza epidemics 
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Table 3.11  Associations between ambient particulates and gases and TIA in warm 
season 
Adjusted odds ratio and 95% CI for an IQR change in air pollutant 
  Manchester Liverpool 
lag Pollutant* OR† 95% CI† P† OR† 95% CI† P† 
0 CO 0.92 0.63 , 1.35 0.67 1.04 0.82 , 1.32 0.76 
0 PM10 0.98 0.78 , 1.23 0.89 0.89 0.73 , 1.08 0.23 
0 NO 0.90 0.62 , 1.31 0.59 1.02 0.79 , 1.32 0.87 
0 NO2 1.01 0.67 , 1.51 0.97 0.93 0.66 , 1.30 0.67 
0 SO2 0.85 0.65 , 1.13 0.26 0.92 0.73 , 1.16 0.50 
0 Ozone 1.32 0.96 , 1.82 0.09 0.93 0.65 , 1.32 0.67 
        
1 CO 1.00 0.70 , 1.41 0.99 1.18 0.95 , 1.47 0.13 
1 PM10 0.89 0.71 , 1.10 0.28 1.15 0.97 , 1.36 0.11 
1 NO 0.93 0.69 , 1.24 0.61 1.04 0.83 , 1.31 0.73 
1 NO2 1.07 0.75 , 1.52 0.72 1.42 1.02 , 1.97 0.04¶ 
1 SO2 0.89 0.69 , 1.15 0.39 1.16 0.93 , 1.44 0.18 
1 Ozone 0.99 0.72 , 1.37 0.97 1.14 0.81 , 1.60 0.46 
        
2 CO 1.32 0.94 , 1.84 0.11 1.03 0.84 , 1.27 0.75 
2 PM10 0.93 0.75 , 1.16 0.53 0.93 0.77 , 1.12 0.43 
2 NO 1.01 0.79 , 1.28 0.96 0.94 0.74 , 1.20 0.64 
2 NO2 1.08 0.76 , 1.55 0.66 0.87 0.62 , 1.22 0.42 
2 SO2 1.07 0.84 , 1.38 0.58 1.11 0.89 , 1.38 0.36 
2 Ozone 0.88 0.63 , 1.22 0.44 1.16 0.82 , 1.66 0.40 
        
3 CO 0.81 0.57 , 1.15 0.24 1.06 0.86 , 1.32 0.58 
3 PM10 1.09 0.89 , 1.34 0.39 1.01 0.84 , 1.22 0.92 
3 NO 0.98 0.75 , 1.28 0.89 1.06 0.84 , 1.35 0.61 
3 NO2 0.81 0.57 , 1.17 0.26 1.18 0.83 , 1.68 0.35 
3 SO2 1.04 0.82 , 1.32 0.76 1.02 0.80 , 1.30 0.86 
3 Ozone 0.99 0.72 , 1.36 0.96 0.93 0.65 , 1.33 0.67 
 
*
  CO, carbon monoxide;PM10, mass of particles with aerodynamic diameter less 
than 10 µm; NO, nitric oxide;NO2, nitrogen dioxide;SO2, sulphur dioxide;   
† OR, odds ratio; CI, confidence interval; P, p value 
¶ P<0.05 
All models are adjusted for temperature, humidity, holiday and influenza epidemics. 
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3.3.4 Two Pollutant Model 
 
After modelling each pollutant individually, a two-pollutant model was fitted to 
estimate the independent effect of each pollutant at lag 3 where significant association 
was observed with NO. The two-pollutant models provide estimates of the independent 
effects of each pollutant on TIA controlling for the other pollutant in the model. The 
result of this analysis is shown in Table 3.12 and Figure 3.17. As the table and the 
figure reveal, the effect of NO remained stronger when analyzed in combination with 
CO and SO2. An IQR change of NO was associated with a 14% increase in TIA (95% 
CI: 1.0-1.3%) and 7% (95% CI: 1.02-1.1.14%) respectively. The effect of NO was 
borderline significant with NO2 and ozone, and non-significant with PM10; however, the 
estimates were above unity and slightly larger than that of PM10. 
 
 
Figure 3.17 Associations between ambient pollutants and TIA, two pollutant model  
The figure shows the result of a two pollutant model analysis on lag 3.  The black circles and 
the squares are odds ratios, vertical lines 95 % CI calculated for an IQR of pollutants in 
consideration. The squares indicate the estimates for NO, whereas the black circles show the 
estimate for other pollutant specified on the x-axis with which a comparison is being made. 
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Table 3.12 Association between TIA and ambient pollutants in a two pollutant 
model for lag 3 
Adjusted odds ratio and 95% CI for an IQR change in air pollutant 
 
 
Effect of other pollutant Effect of NO 
 
OR* 95% CI* P* OR* 95% CI* P* 
CO 0.84 0.65 , 1.09 0.18 1.15 1.01 , 1.31 0.04† 
PM10 1.04 0.88 , 1.23 0.64 1.05 0.98 , 1.12 0.15 
NO2 0.95 0.74 , 1.23 0.71 1.07 1.00 , 1.15  0.06 
SO2 0.93 0.78 , 1.11 0.43 1.07 1.01 , 1.14 0.02† 
Ozone 0.95 0.76 , 1.19 0.65 1.05 1.00 , 1.11 0.07 
 
*   OR, odds ratio; CI, =confidence interval; P, p value 
† P < 0.05 
All model are adjusted for temperature, humidity, holiday and influenza epidemics 
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3.4 Discussion 
 
This study has examined the short-term effects of ambient air pollutants on the risk of 
TIA in a large prospective cohort of patients attending TIA services in five UK centres. 
To date, this is the first study to have investigated the effect of ambient air pollutants 
specifically on the occurrence of TIA. Its main finding is that traffic-related pollutants 
such as NO and CO may be weakly associated with the occurrence of TIA. A 
statistically significant association between the occurrence of TIA and exposure to NO 
with a 3-day lag was observed for the Manchester dataset. An IQR increase in NO was 
associated with an OR of 1.06 (95% CI: 1.01- 1.11). Similar large effects, albeit non-
significant, were observed for CO and PM10 in the Manchester data. In Liverpool, there 
was no positive association between TIA and any of the pollutants, except for an 
isolated negative relationship between PM10 and TIA at lag 0. However, large effect 
estimates which did not achieve statistical significance were observed with various 
other pollutants. The study also found effect modification by age, gender and season. 
Measured pollutants seem to have had more pronounced effects on participants above 
65 years old than on those below that age. Gender and season were also found to modify 
the association between ambient air pollutants and TIA.  
In a two-pollutant model, the effect of NO remained stronger and significant when 
modelled with CO and SO2, and borderline significant with NO2 and ozone. The effect 
was, however, attenuated when NO was paired with PM10.   
Earlier studies from Europe, Asia and North America have investigated associations 
between different subgroups of stroke mortality and morbidity, and measured 
concentrations of different indices of ambient PM and gases, or indirect measures like 
proximity to sources of pollution, using routine data. Their findings are inconsistent, 
with some studies reporting positive associations of short-term changes in ambient air 
pollutants with stroke mortality[43, 74-77, 80, 211], hospitalization[61, 69, 71, 72, 78, 
212] and emergency department visits[70, 73], while others found no association[62, 
207]. A few studies have also used data from population-based surveillance sources or 
stroke registers to capture all incident cases or all cases of stroke in a specified 
community[17, 79]. Most of these studies were conducted in countries with different 
levels of ambient air pollutants. 
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A recent US study using population-based stroke surveillance data found an association 
between same-day and previous day exposure to fine particles and ozone and ischaemic 
stroke, as well as TIA[79]. An earlier study of Medicare recipients above the age of 65 
investigating the relationship between hospital admissions for stroke and ambient air 
pollutants in nine US cities[71] reported small positive associations of CO, NO2, SO2 
and PM10 with ischaemic stroke, but not hemorrhagic stroke[71]. Similarly, another 
study that combined existing US databases on airborne allergens, air pollutants, season, 
upper respiratory infections, asthma incidence and stroke data found statistically 
significant associations between stroke incidence and air pollutants (SO2, PM10) as well 
as with grass pollen, warmer and drier air, and upper respiratory infections[212]. A 
Canadian study found a positive association between same-day exposures to PM10, SO2, 
NO2 and CO and an increased risk of emergency department visits for ischaemic stroke 
in the warm season (April to September)[73]. A UK study has reported that stroke 
mortality was 5% higher in those participants living within 200 metres of a main road 
than in those living far from a main road[75]. The same authors report a recent 
ecological small-area spatial variation study in Sheffield, UK, where they found a 
positive correlation between stroke mortality and residing in highly polluted areas[204].  
All of the studies listed above were conducted in areas where the levels of ambient 
concentrations of most pollutants were relatively low. In contrast, some studies have 
found associations between ambient air pollutants and certain stroke subtypes in towns 
where the concentrations of air pollutants were relatively high. A study by Tsai and 
others investigated the risk of short-term fluctuations in ambient air pollutants and 
stroke admissions in Kaohsiung, Taiwan[72]. They found statistically significant 
associations of PM10, NO2, SO2, CO and ozone with ischaemic and haemorrhagic stroke 
when the ambient temperature was above 20 °C[72], while the effect of CO was also 
observed in cooler months. In contrast to most other studies, which found stronger 
evidence for the association of ambient air pollutants with ischaemic stroke, a few have 
reported positive associations of haemorrhagic stroke with ambient PM and gases[72] or 
total suspended particles (TSP)[74]. The finding of more association with ischaemic 
rather than haemorrhagic stroke is plausible and in line with the inflammatory 
hypothesis, which suggests that pollutant-related alveolar inflammation could lead to 
increased blood coagulability and adverse CV events[97]. Exposure to air pollutants is 
related to acute inflammatory response with release of inflammatory cytokines[112, 
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113],  WBC[99, 110],  various mediators like CRP[35, 112], fibrinogen[101, 121] and 
adhesion molecules[34]. The combined effect of the inflammatory cells and mediators 
as well as the accompanying endothelial disturbance may lead to platelet activation and 
thrombus formation, which could eventually lead to ischaemic stroke. 
Previous research has found associations between stroke and various air pollutants 
including different metrics of PM and gaseous pollutants such as CO, NOx, SO2 and 
ozone. The current study has found statistically significant associations mainly with 
NO.  A study from Finland has also found a strong positive association between NO and 
emergency admission for ischaemic CV and cerebrovascular diseases[78]. Its authors 
report statistically significant associations between emergency admissions and TSP and 
NO2[78].   
Nitrogen oxide emissions occur largely in the form of NO, which is a major primary 
pollutant and precursor of NO2. It typically comprises about 95% of NOx from a 
combustion source[16]. Because of the high correlations among measured pollutants in 
the current study, it is difficult to separate their individual effects; however, NO is 
probably associated with TIA more than the other pollutants, for several reasons. 
Firstly, the association was consistently observed in the whole dataset analysis and in a 
subgroup analysis of the Manchester dataset. Secondly, the effect persisted in a two-
pollutant model with all other pollutants except PM10. Furthermore, the association was 
observed for data from Manchester, where the concentration of NO was twice that of 
Liverpool. All these factors argue for an association between NO and the occurrence of 
TIA. 
However, the biological mechanism by which NO causes CV diseases has not been 
widely elucidated so far and there is little information from published literature that 
would substantiate this finding. Various studies have linked NO2 to increased 
morbidity[46, 62], yet related substances like NO are rarely investigated in most 
epidemiological studies. Those few studies that have included NO as an exposure 
parameter to link to an outcome of interest have highlighted its positive associations 
with the respective outcomes as well as a higher correlation with UFP than observed 
with NO2[213], which suggests that NO is an important pollutant to be considered in 
epidemiological studies.  
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On the other hand, in the current study the observed association between NO and TIA 
could be attributed to chance, due to multiple testing undertaken in the study. In the 
main analysis, a total of 48 conditional logistic regressions were performed and with a 
conventional 5% significance level, one would expect 2 to 3 effect estimates that would 
have occurred by chance. Thus, chance is an alternative explanation for the observed 
effect of NO on the occurrence of TIA and needs to be confirmed by further research.  
It is also possible that NO is acting as a marker for other pollutants such as UFP. In 
support of this view, a study in  Manchester has shown a strong correlation between 
UFP and NOx (r = 0.85) and CO (r = 0.78)[198]. A Finnish study investigated the effect 
of UFP, PM10 and gaseous pollutants on respiratory health and reported a significant 
association between UFP and reduced peak expiratory flow rate (PEFR), a measure of 
lung function[213]. In that study, UFP was highly correlated with NO (r = 0.81) and the 
effect of UFP on PEFR diminished in a two-pollutant model when paired with traffic-
related gaseous pollutants CO, NO and NO2, suggesting strong co-variation between 
UFP and NO[213].  
From this finding it could be hypothesized that ultrafine particles, which are highly 
correlated with CO and NO, are the underlying cause of the observed effects of this 
study and that NO is acting as a surrogate for such unmeasured pollutants. In addition, 
NO, through a previously unrecognized mechanism, may be responsible for the 
observed association. NO is endogenously generated and involved in various regulatory 
and inflammatory functions of the vascular endothelium. It is possible that ambient NO 
influences the function of endogenous NO by inhibition of its production. Inhibition of 
NO and the concomitant changes are known to contribute to essential hypertension, 
myocardial ischaemia, atherogenesis, thrombosis, insulin resistance and heart 
failure[175].  Recent experimental human and animal studies have shown that exposure 
to diesel exhaust, which contains significant amounts of NO and UFP, is related to 
impairment of vascular function and vasoconstriction, possibly through inhibition of 
endogenous NO synthesis[214, 215].  
This study has adjusted for meteorological variables of temperature and relative 
humidity, which are known confounders for the association of stroke and air pollution.  
However, the documented associations between season / temperature and stroke are 
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controversial, with some studies finding evidence of seasonal variation and others 
none[212, 216, 217].    
Most earlier studies have aggregated all cerebrovascular disease and strokes, although 
they have different pathophysiological mechanisms and underlying causes[66]. Those 
air pollution studies that have differentiated stroke subtypes have shown stronger effects 
of air pollutants on ischaemic stroke[17, 71, 74], suggesting that  different stroke 
subtypes are unequally affected by air pollution. The main cause of ischaemic stroke is 
atherosclerosis[66] and current evidence supports the hypothesis that ischaemic stroke 
is related to ambient air pollutants. 
Reported regression results of the study are based on statistically significant 
associations, but a statistically non-significant association does not mean that a 
relationship does not exist. This study has found several large but non-significant 
associations between various pollutants and TIA, where the lack of significance may be 
attributed to the small study size in the two centres. 
The main strength of this study is the fact that all TIA cases were confirmed by a 
consultant stroke physician or neurologist. Thus, the possibility of outcome 
misclassification is negligible or absent. Most previous studies have used hospital 
admission or discharge data to confirm the diagnosis of stroke morbidity and mortality.  
Major drawbacks of using such routinely available administrative data and medical 
records of admission, discharge and death for CVD and stroke research are the 
incompleteness of records and the occurrence of coding errors and inaccuracy, which 
could result in outcome misclassification[59, 66]. If such errors are differential and 
systematic, they may lead to misclassification and could bias the results.  
This study has several limitations that could affect interpretation and generalization of 
its findings. First, the participants were not randomly selected and are likely to represent 
mild cases of TIA, as they took part in the study only a few days after the first incident.  
Severe cases of TIA which might have subsequently led to stroke or death were not 
represented in this study. It is not known whether air pollution is related to the mild 
forms or severe forms of the disease and this would affect interpretation of the study 
results. Second, the exposure data were obtained from fixed central site monitors which 
do not necessarily reflect personal exposure and this may have led to exposure 
misclassification. As most individuals spend most of their time indoors, use of exposure 
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data from central monitors will introduce exposure measurement error. However, such 
error is non-differential and expected to underestimate the observed effects[26]. The 
size of exposure misclassification depends on the type of pollutants. It has been shown 
that PM10 is spatially homogeneous in metropolitan areas, so that fixed site central 
monitors are good proxies for personal exposure[189]. Conversely, gaseous pollutants 
like NOx or CO are not homogeneous, arising as they do from disparate local sources 
like traffic. One would expect that measurement error would attenuate the effects of 
these more spatially heterogeneous pollutants.  
Another limitation is the relatively small number of study subjects, who were further 
divided into two centres. This may be one reason why several positive associations were 
not statistically significant. Another limitation is that the study did not correct for 
multiple comparison, which means that it may have yielded results which appeared 
more significant than was truly the case. 
 
In conclusion, this study has shown a positive association between ambient NO and the 
occurrence of TIA, which was modified by age, gender and season. Given the number 
of multiple comparisons performed, the finding may have occurred by chance and 
additional epidemiological research with a larger sample size in a different study 
population and advanced exposure measurement is required to confirm this finding.
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4 Chapter Four: The Effects of Personal and Ambient Air 
Pollution on Blood Markers of Inflammation, Thrombosis and 
Endothelial Function in Diabetic Patients  
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4.1 Background 
 
Diabetes mellitus is a highly prevalent chronic metabolic condition characterized by 
diverse vascular and non-vascular complications. Diabetes is a strong risk factor for 
CVD and is associated with all-cause and CV mortality[87]. Patients with diabetes, with 
or without CVD, are more sensitive to the effects of air pollution[218, 219].   
Epidemiological studies have suggested that individuals with diabetes mellitus 
constitute a subgroup susceptible to the harmful effects of air pollutants[49, 50, 107, 
218] and diabetics with CVD are particularly sensitive to this effect[219, 220]. 
Diabetics are more likely to die following exposure to particle pollutants than non-
diabetics[48] and they have a twofold risk of PM10-related cardiovascular hospital 
admission when compared to non-diabetics[220]. In a recent study, presence of diabetes 
was associated with a twofold risk of respiratory or stroke mortality following exposure 
to PM10[221].  Furthermore, exposure to NO2, a marker of traffic-related air pollution, is 
positively associated with the prevalence of diabetes among women[222]. Animal 
studies have shown that exposure to PM can increase blood glucose level, visceral 
adiposity and insulin resistance[223].    
Both diabetes and exposure to PM are independently associated with an increased risk 
of atherosclerosis[10, 87], which is widely recognized as a consequence of chronic 
inflammatory process[136]. Human epidemiological[52, 146] and animal experimental 
studies[127, 128] have shown development and acceleration of atherosclerotic processes 
following long-term exposure to PM. Both conditions are also associated with increased 
inflammatory response, with elevated circulating inflammatory biomarkers like CRP, 
fibrinogen and IL-6, and with endothelial dysfunction. Thus, it is plausible that air 
pollution initiates or exacerbates CV outcomes through chronic inflammation and 
through coagulation disturbances and/or activation of endothelial cells; and diabetes 
may play a synergistic role in this process. Understanding the mechanism that underlies 
the susceptibility of diabetic subjects to the effects of air pollutants is a public health 
priority, as air pollution is a modifiable risk and diabetes is a highly prevalent disease.   
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The main aim of the present study was to investigate associations between exposure to 
particulates as well as gases and changes in markers of inflammation, coagulation and 
endothelial activation among type 2 diabetic patients. Diabetics are particularly 
susceptible to the effects of air pollutants, based on earlier studies which have shown 
increased morbidity, mortality or inflammatory response among diabetics[111, 219, 
220].   
Earlier epidemiological studies have relied on fixed central site monitors to estimate 
individual-level exposure and this could lead to exposure misclassification and 
underestimation of associated risks. In a vulnerable population like diabetics, accurate 
estimation of personal exposure is essential to assess the risks associated with air 
pollutants. This study estimates personal exposure by means of ambient site background 
monitors as well as by personal air sampling.  
The study investigated several markers of systemic inflammation (IL-6, IL-8, CRP and 
fibrinogen), coagulation (D-dimer and fibrinogen) and endothelial function (E-selectin, 
ICAM-1, ICAM-2 and vWF). These are recognized markers which are associated with 
atherosclerosis and worsening of the diabetic condition and which are also related to 
exposure to air pollution. Markers of inflammation, coagulation and endothelial 
function are also risk predictors for CVD[137, 138, 142]. 
4.2 Materials and Methods  
4.2.1 Study Setting 
 
The study was conducted in Salford, an urban district in Greater Manchester, North 
West England, with a population of 216,103 (106,191 males and 109,912 females) 
according to the 2001 census. Salford has established a population-based district 
diabetic information system to improve the process and outcome of diabetic care in all 
primary care and hospital diabetes services in the district, providing an integrated 
diabetic service[224].  
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4.2.2 Study Design 
 
This was a short-term prospective panel study whose panel consisted of 35 Caucasian 
subjects with type 2 diabetes mellitus and residing in the Salford district. Subjects were 
monitored fortnightly between March 2008 and February 2009 for exposure to PM2.5, 
measured by personal monitor, and to ambient particulates and gases. The main aim of 
the study was to evaluate the short-term effect of personal and ambient particulates and 
gases on inflammatory, coagulation and endothelial markers in a type 2 diabetic 
population. The study protocol was approved by the national and local ethics 
committees. Patients who expressed interest to participate were given an information 
leaflet, detailing the purpose of the study, potential risks and benefits of taking part and 
what the participation would involve. From each patient a written informed consent was 
obtained on the first visit (Appendices 1 and 2).  
4.2.3 Study Population 
 
Subjects were recruited by attending physicians at the diabetes centre of Salford Royal 
Hospital, which has excellent and comprehensive documentation of diabetes follow-up 
in the Salford district. Eligibility criteria for the study were physician-diagnosed type 2 
diabetes mellitus and age of 40 to 80 years.   
The following exclusion criteria were used: 1) recent infection which needed long-term 
antibiotic therapy; 2) long-term use of steroids and anticoagulants; 3) any chronic 
inflammatory condition such as inflammatory bowel disease; 4) recent myocardial 
infarction, congestive heart failure and stroke; 5) acute infectious disease; 6) current 
smoker or smoking history in the last six weeks. In addition, patients who were unable 
to co-operate or who were acutely sick were not included in the study. Of 35 recruited 
subjects, 32 completed the study. Three patients who had a single visit were not 
included in the analysis; nor was the smoker who was not recruited (Appendix 3). 
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Figure 4.1 Map showing monitoring stations and subjects’ residences 
The shaded area is the district of Salford and stars represent residences of subjects. The triangles 
represent fixed-site monitoring stations in Greater Manchester. Ambient air pollution data for 
this study were obtained from one background monitor, located at Salford Eccles. 
 
According to the study protocol, each subject was scheduled for 4 clinical visits, to take 
place every two weeks. On each occasion a personal air sampler was mounted and 
patients were sent home to record an activity diary for a day, then to return after 24 
hours for blood sampling and clinical examination by means of a questionnaire 
(Appendix 4). Each patient attended hospital on the same day and at the same time for 
the entire study period to control for circadian rhythm, with which an association is 
exhibited by some of the outcome measures. The blood was assayed for markers of 
inflammation including cytokines, thrombosis and endothelial function. On the first 
visit, a detailed questionnaire was administered to collect information on lifestyle, 
health status, indoor exposure and dwelling characteristics, medication use and smoking 
history (Appendix 4). On each subsequent visit, a short questionnaire was administered 
to collect information on general health status, intercurrent illness, medication use and 
exposure to ETS, followed by collection of blood (Appendix 5). The sequence of 
actions and follow-up of the study population is shown in a flow chart in Figure 4.2.
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Figure 4.2 Flow chart for follow-up visit of the study population 
4.2.4 Exposure Measurement 
4.2.4.1 Personal Exposure Monitoring 
 
Personal exposure to fine particles was measured using the SidePak AM510, a compact 
portable personal aerosol monitor (TSI Inc, Shoreview, MN, USA) (Figure 4.3). This is 
a lightweight (540 g) nephelometer that uses an inbuilt sampling pump to draw in air 
and measure ultrafine, fine and coarse particle concentrations (0.1-10 µm) based on the 
intensity of scattered light. This device was chosen for personal monitoring because of 
its small size, making it easy to carry around comfortably without interfering with the 
behaviour of the subject.  
Before each measurement session, all devices were cleaned, charged and zero calibrated 
according to the instructions of the manufacturer. Depending on the preference of each 
participant, the device was set to be carried in a bag or worn on the belt. The inlet of the 
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SidePak, which was attached to a Tygon tube, was fitted with a 2.5 µm impactor to 
measure concentration of PM2.5 and the air flow was adjusted to a rate of 1.7 L/min.  
The battery operated device, which provides continuous real-time display of measured 
pollutants, was set to log data to the memory every minute. Study participants were 
given a SidePak monitor one day before blood collection, which they wore the entire 
time and returned 24 hours later, usually between 11 am and noon, for blood sampling. 
Data from the SidePak were downloaded to a PC by TSI TrakPro software V4.2.2.8 and 
exported to a suitable format for analysis.   
The time-weighted average (TWA) of each PM2.5 measurement for each patient and 
each visit was calculated from the total time of measurement averaged over one minute.  
Portable real time monitors like SidePak provide effective exposure estimates as they 
can measure temporal and spatial variations in particle concentration better than 
gravimetric methods.  Studies have also shown nephelometers have good precision 
compared to the gravimetric methods. Liu et al. found a high coefficient of 
determination (R2) ranging from 0.77 - 0.93 between nephelometers and gravimetric 
methods[225]. The main drawbacks of SidePak and other personal nephelometers 
compared with gravimetric methods is that the response of light scattering is affected by 
the size, density and optical properties and composition of aerosols[226]. There is also a 
potential loss of particles within non-conductive Tygon tubing. Furthermore, the 
accuracy and performance of such devices can be significantly affected by relative 
humidity affects, particularly at higher values above 80%[227]. Under such conditions, 
nephelometers overestimate the mass concentration of particles due to moisture-induced 
particle growth.  
Overall the study period five TSI SidePak aerosol monitors were used to measure 
personal PM2.5 concentration. Side-by-side measurement of PM was conducted in an 
office setting to evaluate the performance of the monitors and make a comparison. Due 
to lack of a gravimetric instrument to measure the concentration of PM2.5, no 
comparison was made between the SidePak monitors and other reference methods. 
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Figure 4.3 TSI SidePak AM510 aerosol monitor 
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4.2.4.2 Ambient air pollutants 
 
Data on ambient PM10 and gaseous pollutants (CO, NO, NO2, ozone and SO2) were 
obtained from a fixed central site monitor in Salford Eccles, representing the 
background concentrations of PM10 and gaseous pollutants (Figure 4.1). This 
monitoring station was housed within a self-contained, air-conditioned housing unit 
situated close to local amenities and approximately 100 metres from Eccles town centre. 
Hourly measurements of each pollutant were obtained and a 24-hour average was 
calculated for each pollutant, except for ozone, for which an eight-hour daytime average 
was calculated, to represent an exposure parameter for each individual. Meteorological 
temperature and relative humidity data were obtained from the British Atmospheric 
Data Centre, which has a station at Hulme Library, Manchester, located 6 km south-east 
of the air pollution monitoring station.  
For each subject and visit, a 24-hour lagged average exposure parameter was created for 
0 to 3 days (lag 0 to lag 2), as well as a five-day average. Similarly, mean temperature 
and relative humidity were averaged over each 24-h period corresponding to ambient air 
pollutants. The air pollutant data were averaged from noon to noon.  
4.2.5 Outcome Parameters 
 
According to the study protocol, each participant had to undertake four clinical visits, 
which should take place on the same weekday and at the same time. On each visit, 
venous blood samples were collected from each subject according to the SOP of the 
vascular research unit of the University of Manchester. Samples were immediately 
placed on ice and centrifuged within 2 hours after collection. The aliquots were stored at 
-80 °C for batched analysis. In addition, height and weight measurement for calculation 
of BMI and blood pressure measurements were made. 
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4.2.6 Method of Assay Measurement  
 
High sensitivity CRP (hs-CRP) was measured in serum samples using a solid-phase, 
enzyme labeled, chemiluminescent immunometric assay on an Immulite auto-analyser 
(Siemens Medical, UK). The assay had an analytical sensitivity of 0.1 mg/L, an inter-
assay coefficients of variation (COV) of < 10% and an intra-assay COV of < 6%.  
IL-6 and IL-8 were measured in serum samples using a solid-phase, enzyme-labeled, 
chemiluminescent immunometric assay on an Immulite auto-analyser (Siemens 
Medical, UK). The assay for IL-6 had an analytical sensitivity of 2 pg/ml, an inter-assay 
variation of < 8% and an intra-assay variation of < 7%, while the assay for IL-8 had an 
analytical sensitivity of 2 pg/ml, an inter-assay COV of < 8% and an intra-assay COV 
of < 4%. 
Human E-selectin was measured using a commercial enzyme-linked immunosorbant 
assay (ELISA) (Bender MedSystems). The assay had an analytical sensitivity of 
0.3 ng/ml with intra-assay COV of < 6% and inter-assay COV of < 7%. 
Human ICAM-1 and ICAM-2 were measured using a commercial ELISA (Bender 
MedSystems). The ICAM-1 assay had an analytical sensitivity of 2.2 ng/ml with intra-
assay COV of < 5% and inter-assay COV of < 8%. The ICAM-2 assay had an analytical 
sensitivity of 0.3 U/ml with intra-assay COV of < 7% and inter-assay COV of < 8%. 
D-dimer and vWF were analysed by the turbidimetric method and fibrinogen by the 
Clauss clotting method using an STA Fibrinogen 5 kit. The intra-assay COV were less 
than 3%, 2% and 4% for D-dimer, vWF and fibrinogen respectively.   
4.2.7 Statistical analysis 
 
The data were analyzed using the Stata statistical package (version11, StataCorp LP, 
College Station, Texas 77845, USA). All inflammatory, coagulation and endothelial 
markers were skewed in distribution, so they were all log transformed to normalize their 
distribution and stabilize the variance before the analyses. Effect estimates are presented 
in a natural scale, subtracting 1 and multiplying by 100 to present the percentage change 
of each marker per IQR change of each pollutant.  
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A mixed model with random intercepts for each subject (Stata xtmixed procedure) was 
employed to determine the relationship between each pollutant and measures of 
inflammation (hs-CRP, fibrinogen, IL-6 and IL-8), thrombosis (D-dimer) and 
endothelial markers (E-selectin, ICAM-1, ICAM-2 and vWF). A random intercept for 
each individual was used to account for autocorrelation of measurement and 
heterogeneity among the study subjects.  
The linear mixed effect model was modelled as: 
Y=X +Zβ+ , β ~N(0,G),  
var(e) =R, 
Var(y) =V=ZGZ´+ R 
where 
Y is the vector of observations (for subject i at observation j) 
X is design matrix for fixed effects 
 is the fixed effects regression parameter 
Z is the design matrix for random effects 
β are random effects regression parameters 
 is the vector of residual errors 
R is the residual variance matrix 
G is the matrix of covariance parameters. 
The response variable Y can be expressed as the sum of the fixed effect matrix Xß, the 
random effects matrix Zu and the vector of random errors. The random effects are 
hypothesized to follow a normal distribution with mean 0 and variance σ2 random 
effect.  
The models were adjusted for known associations with outcome variables such as age, 
gender, smoking history and meteorological variables (temperature and relative 
humidity). In addition, effect modification by age (above and below 65), gender, 
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obesity, statin use and a surrogate of glycaemic control as measured by HbA1c (above 
and below 6.5%) was explored. Smoking status was either never-smoker or ex-smoker 
and obesity was defined as BMI ≥ 30 kg/m2. 
Ambient air pollutant data for lags 0, 1, 2 and 5 days were evaluated in the study 
corresponding to  0-24 h (lag 0), 24-48 h (lag 1) and 48-72 h (lag 2) before blood 
collection. In addition, a 5-day average exposure metric was evaluated. PM2.5 
concentration measured by SidePak was evaluated for lag 0, since the measurement of 
PM2.5 was undertaken for less than 24 hours. 
As all outcome parameters were skewed, effect estimates of regression analysis are 
presented as percentage increase per IQR increase in the respective pollutant. 
Statistically significant association is based on a p-value ≤ 0.05.   
4.3 Results 
4.3.1 Study Population  
 
In total 28 patients (87.5%) completed all four visits and all 32 patients completed at 
least three visits. Overall, a total of 124 plasma measures of inflammation and 
thrombosis were performed in 32 individuals. Table 4.1 presents the baseline 
demographic and dwelling characteristics of study participants. The study population 
consisted of 32 elderly patients (22 male and 10 female) with an age range from 48 to 
78 years. All participants were current non-smokers. Most participants were taking 
various medications, the main ones being statins (88%), low dose acetylsalicylic acid 
(66%) and various anti-hypertensive medications (59%). The mean HbA1c was 7 (range 
5.4 to 9.8), which indicates a poor control of the diabetic state. The BMI of the 
participants ranged from 23 to 47 kg/m2 with 30 patients (84%) fulfilling the WHO 
definition of obesity, i.e. BMI ≥ 30 kg/m2. Seven of the participants (22%) lived with a 
smoking spouse and only two participants had a history of CAD.  
Most of the study participants had central heating, 75% used gas cookers and 86% had 
double glazed windows. About half of the patients described traffic around their 
domicile as light, while 32% resided in areas of heavy traffic.  
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4.3.2 Outcome Parameters 
 
Table 4.2 provides the overall summary statistics and distribution of biomarkers. The 
biomarkers are generally higher than comparable studies. The mean concentrations of 
CRP, fibrinogen, ICAM-1, IL-6, E-selectin and vWF were higher than the levels 
measured in comparable panel studies in Germany[34] and the USA[112]. In addition, 
the mean concentration of some of the biomarkers, including CRP, was above the cut 
point of high risk (> 3 mg/L) for CVD[144].  Table 4.3 shows the Spearman’s 
correlation coefficients between outcome parameters. IL-6 was correlated with CRP (r = 
.32), which was correlated with ICAM-1 (r = .49). Similarly, ICAM-1 and ICAM-2 
were correlated (r = .44). IL-8 was negatively correlated with all other markers except 
with fibrinogen (r = .17) and D-dimer (r = .13).  Baseline blood parameters are shown in 
Table 4.4.  
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Table 4.1 Dwelling and demographic characteristics of participants  
(March 2008 and Feb 2009) 
Age (mean, range) 66.8 48-78 
Gender(% male) 22 69 
BMI ( kg/m2 ) * 
  
Mean(range) 33.7 23- 47 
>=30 27 84 
Co-morbidity 
  
History of CAD [n (%)]* 2 6 
Hypertension [n (%)] 17 54.8 
HbA1c [mean(range)] * 7 5.4-9.8 
Past history of stroke [n (%)] 1 0.03 
History of blood clots 3 0.09 
History of bronchial asthma 2 6.3 
Medication use [n (%)] 
  
Statin  28 87.5 
Aspirin  21 65.6 
Anti hypertensive medications 59 
ACE inhibitors* 11 34.4 
Ca+ channel blockers 8 25 
Beta blockers 9 28 
Central heating (%) 
 
85 
Cooker type (%) 
  
Gas 
 
75 
Electric 
 
25 
Glazing type (%) 
  
 
Double 86 
 
Single 14 
Environmental tobacco smoke (n, %) 7 22 
Ever smoked (%) 
 
46 
Kitchen extraction system (%) 69 
Intensity of traffic   around house (%) 
 
 
Light 51 
 
Intermittent 17 
 
Heavy 32 
Median number of people in  household (range) 2 1-5 
Median of distance to the nearest main road in meters 
(range) 
149 3-800 
Distance of residence from central site ambient monitoring 
station in km (mean, range)  
4.4 1.3-25.2 
%  Working 17 
 
Travelled by car/bus/taxi on the date of data collection (%) 83 
* BMI, body mass index; CAD, coronary artery disease; HbA1c, glycated haemoglobin 
(haemoglobin A1c); ACE, angiotensin-converting enzyme inhibitors;  
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Table 4.2 Description of inflammatory, coagulation and endothelial markers 
Biomarker N Mean S.D. Min 25th quartile Median 75th quartile Max 
IL-6 123 11.66 12.44 2.4 5.7 8.1 12.1 95.8 
IL-8 124 11.99 7.51 1 1 13.35 17.45 24.4 
hs-CRP 123 4.42 6.64 0.3 0.91 2.2 4.7 46.4 
ICAM-1 123 362.1 148.71 152.7 251.6 336.1 435.9 848.7 
ICAM-2 123 351.75 69.06 209.5 308.4 345.4 386.4 563.3 
E-selectin 123 111.79 50.88 36.5 71.1 103 141.7 259.4 
vWF 124 144.19 45.73 54 111 137 158.5 273 
Fibrinogen 124 3.68 0.66 2.31 3.26 3.58 4.04 7.1 
D-dimer 124 213.2 112.74 3.44 134 186 261 627 
 
* IL-6 and IL-8 (pg/ml); hs-CRP (mg/L); E-selectin, ICAM-1 and ICAM-2 (ng/ml);   
 vWF u/dl and fibrinogen g/ml; D-dimer ng/l 
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Table 4.3 Spearman’s correlation coefficients between biomarkers 
 
 
IL-6 IL-8 CRP ICAM-1 ICAM-2 E-selectin vWF Fibrinogen D-dimer 
IL-6 1         
IL-8 
-0.11 1        
CRP 0.32 -0.16 1       
ICAM-1 0.37 -0.20 0.49 1      
ICAM-2 0.08 -0.04 0.18 0.44 1     
E-selectin 0.26 -0.08 0.33 0.49 0.29 1    
vWF 0.25 -0.32 0.35 0.24 -0.15 0.04 1   
Fibrinogen 0.17 0.18 0.17 0.03 -0.19 -0.05 0.09 1  
D-dimer 0.13 0.13 -0.02 -0.12 -0.20 -0.02 0.11 0.09 1 
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Table 4.4 Summary of baseline blood parameters  
 
Variable Mean SD Min. Max. Normal values 
Haemoglobin(g/dL) 13.2 1.3 10.8 15.3 11.5-17.7* 
MCV (fL) † 87.7 4.9 77.4 101.5 80-96 
WBC [total(109/ L)] † 7.1 2.0 4.4 13.9 4-11 
Neutrophils(109/ L) 4.2 1.3 2 8.5 2-7.5 
Lymphocytes (109/ L) 2.0 0.6 1.2 3.8 1.5-4 
Monocytes (109/ L) 0.6 0.2 0.4 1.3 0.2-0.8 
Platelets (109/ L) 242.7 63.1 137 381 150-400 
Total cholesterol (mmol/L) 3.8 1.0 2.4 7.5 3.5-6.5 
HDL cholesterol (mmol/L) 1.2 0.4 0.54 2.79 0.8-2.3‡ 
Triglycerides (mmol/L) § 1.8 1.0 0.68 4.4 0.5-2.1 
LDL(mmol/L) † 1.7 0.7 0.7 3.1 < 4 
 
*  Haemoglobin: - men: 13.5-17.7 g/dL; women: 11.5-16.5 g/dL;  
†    MCV, mean cell volume; WBC, white blood cells; LDL, low-density lipoprotein  
‡ HDL, high-density lipoprotein: - men: 0.8-1.8 mmol/L, women: 1-2.3 8 mmol/L;   
§  Triglycerides: - men: 0.7-2.1 mmol/L, women: 0.5-1.7 mmol/L;   
 
4.3.3 Exposure and Meteorological Parameters 
 
Table 4.5 gives descriptive statistics for personal and ambient air pollutants as well as 
meteorological variables. The 24-hr mean concentrations of ambient pollutants were 
generally below the WHO air quality guideline levels. Besides, the mean concentrations 
of most of the measured pollutants were below the annual average guideline of the 
WHO except NO2, which exceeded the annual mean concentration guideline of 40 
µg/m3 for NO2.  On the other hand, the measured mean concentration of personal PM2.5 
(103 µg/m3) in this study considerably exceeded the 99th percentile of 24-h average of 
25 µg/m3 and the annual average of 10 µg/m3 stipulated in the guideline of the WHO 
(Table 1.1).  
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Table 4.5 The distribution of personal and ambient pollutants 
(March 2008 - Feb 2009) 
 
Pollutant Mean SD Min 25th Median 0.75 Max 
PM25 (µg/m3) 103.03 154.6 1.61 14.08 30.54 133.11 796.26 
CO (mg/m3) 0.15 0.08 0.1 0.1 0.12 0.15 0.61 
PM10  (µg/m3) 18.87 6.11 9.38 14.38 17.71 23.04 40 
NO2 (µg/m3) 41.12 14.87 20.21 29.35 38.79 47.95 87.13 
NOx (µg/m3) 73.15 50.49 24.75 41.21 56.88 89.77 261.58 
O3 (µg/m3) 15.05 8.76 0.83 8.46 14.63 19.42 40.17 
SO2 (µg/m3) 2.46 2.34 0 0.64 1.71 3.13 10.21 
Temperature (°C) 9.57 5.14 -3.33 6.29 9.71 14.00 19.54 
RH*, % 81.27 8.57 60.93 74.38 82.83 88.75 94.50 
 
* RH, relative humidity 
 
Table 4.6 shows correlation coefficients between pollutants. Personal PM2.5 was 
moderately correlated with CO (r = 0.52), but poorly correlated with ambient PM10 (r = 
0.20). NOx was highly correlated with NO2 and CO, with r = 0.88 and 0.89 respectively. 
Ozone was negatively correlated with all other pollutants, with r values ranging from -
0.61 for NOx to -0.07 for PM10. All measured pollutants except ozone were negatively 
correlated with ambient air temperature, with NO2 showing the largest negative 
correlation(r = -0.55).  
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Table 4.6 Pairwise correlation coefficients between air pollutants and 
meteorological variables 
 
 
PM25 CO PM10 NO2 NOX Ozone SO2 Temp* RH* 
PM25 1         
CO 0.49 1        
PM10 0.21 0.40 1       
NO2 0.37 0.72 0.38 1      
NOX 0.40 0.89 0.41 0.88 1     
Ozone -0.24 -0.52 -0.07 -0.58 -0.61 1    
SO2 0.17 0.39 0.32 0.44 0.41 0.10 1   
Temp* -0.29 -0.55 -0.10 -0.57 -0.55 0.45 -0.08 1  
RH * 0.22 0.33 -0.07 0.37 0.38 -0.64 -0.18 -0.24 1 
 
* Temp, temperature; RH, relative humidity 
 
Table 4.7 presents the intra and inter individual variations in exposure during the study 
period.  In comparison to other pollutants, personal PM2.5 exhibits substantial variation 
between and within individuals.   
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Table 4.7 The within and between variances of measured pollutants 
 
Variable  Mean SD Min Max 
PM2.5 overall 103.0 154.6 1.6 796.3 
 
between  127.0 9.7 513.5 
 
within  86.1 -230.5 392.4 
CO overall 0.1 0.1 0.1 0.6 
 
between  0.0 0.1 0.3 
 
within  0.1 -0.1 0.4 
PM10 overall 18.9 6.1 9.4 40.0 
 
between  3.2 14.6 29.5 
 
within  5.3 8.6 38.4 
NO2 overall 41.1 14.9 20.2 87.1 
 
between  9.9 28.0 66.4 
 
within  11.1 14.3 74.5 
NOx overall 73.1 50.5 24.8 261.6 
 
between  30.1 37.3 173.4 
 
within  40.4 -34.1 210.2 
O3 overall 15.0 8.8 0.8 40.2 
 
between  6.9 6.7 32.2 
 
within  5.6 3.7 27.7 
SO2 overall 2.5 2.3 0.0 10.2 
 
between  1.6 0.6 6.3 
 
within  1.7 -3.4 8.9 
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The duration of personal sampling ranged from 03:44 to 15:19 hours. The mean TWA 
of PM2.5 of all PM2.5 measurements was 103 µg/m3 with a range of 1.6-796 µg/m3. The 
mean PM2.5 for each participant over a visit ranged from 9.7 to 513 µg/m3.  A sample 
graph for smoker and non-smoker household is shown in Figure 4.4. As the figure 
shows, the peak concentrations of PM2.5 for a subject living with a smoking partner was 
close to 1500 µg/m3, whereas the peak for a non-smoking household is approximately 
100 µg/m3.   
 
The mean straight-line distance between the residence of the study participants and 
central site ambient monitoring station was 4.4 km (range 1.3-25.2 km). All participants 
except one resided within 10 km of the monitoring station.  
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Figure 4.4 Sample plot of PM2.5 against time for participants living with and 
without a smoker 
 
The dotted- dash line shows PM2.5 recording for a participant living with a smoking partner, 
while  the solid line depicts a  recording  from a participant living with a non-smoking partner.  
PM2.5, mass concentration of particles < 2.5 µm in aerodynamic diameter; ETS , environmental 
tobacco smoke 
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Figure 4.5 to Figure 4.7 present the time series for measured ambient PM10, NO2, and 
ozone
 
during the study period respectively. The figures exhibit expected seasonal 
variation.  
The UK national Air Quality monitoring site started monitoring PM2.5 at the end of 
2008 or early in 2009. In order to validate the PM2.5 data sampled by SidePak, PM2.5 
was simultaneously measured at the fixed site over several weeks and compared to 
PM2.5 data measured by central monitors. There was strong correlation between PM2.5 
measured by SidePak and the central monitor (r = 82). In addition, a 5 minute averaged 
indoor PM2.5 concentrations determined by three SidePak monitors has shown excellent 
agreement with each other, with r values ranging from 0.95-0.97.  
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Figure 4.5 Time series of background PM10 concentrations during the study period 
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Figure 4.6 Time series of background NO2 concentrations during the study 
period 
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Figure 4.7 Time series of background ozone concentrations during the study 
period 
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4.3.4 Regression analysis 
 
The results of the regression analysis of biomarkers are shown in Table 4.8 to 4.10 and 
Figure 4.10 to Figure 4.18. All nine biomarkers were regressed against one personal 
PM2.5 and six ambient pollutants using lags of 0, 1, 2 and 5 days, thus resulting in 9 
models for personal PM2.5 and 216 models for ambient pollutants. The regression 
estimates are based on log transformed data which were retransformed into natural scale 
and presented as percentage change of the outcome for an IQR increase of each 
respective pollutant with 95% CI.     
4.3.4.1 Personal PM2.5 and biomarkers 
A significant positive association was observed between PM2.5 and IL-6, and a negative 
association with D-dimer and ICAM-2 (Figure 4.8). Positive but non-significant 
increases were observed with CRP (15.7%, 95% CI -2.2-36.9) and IL-8 (3.8%, 95% CI 
-3.1-11.2). Modest non-significant increases in fibrinogen (1.6%, 95% CI -0.65-3.9) and 
vWF (1.9%, 95% CI -2-6) were observed in association with personal PM2.5. On the 
other hand, an IQR increase in PM2.5 was related to a reduction of 14.3% (95 % CI 3.2-
4.2) in D-dimer and 2.6% (95% CI 0.7- 4.4) in ICAM-2. Five of the largest positive 
effect estimates observed at lag 0 were in association with personal PM2.5 (Figure 4.9).     
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Figure 4.8 Associations between biomarkers and personal PM2.5 
 
The black triangles indicate percent increase, vertical lines 95 % CI calculated for an 
IQR of PM2.5. The percent change was obtained from antilog of effect estimate of 
regression output minus 1 multiplied by 100.  
CRP, C-reactive protein; ICAM-1, intracellular adhesion molecule 1; ICAM-2, 
intracellular adhesion molecule 2; IL-6, interleukin 6; IL-8, interleukin 8; vWF, von 
Willebrand factor antigen; 
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Figure 4.9 Associations between pollutants and selected biomarkers on lag 0 
Per cent changes and 95% CI for an IQR change in air pollutant 
 
4.3.4.2 Ambient Air Pollutants and Biomarkers 
4.3.4.2.1 Markers of Inflammation (CRP, IL-6, IL-8 and Fibrinogen) 
 
Few positive associations between inflammatory markers and central monitor PM10 and 
gaseous pollutants were observed (Table 4.8 to Table 4.10). The observed positive 
associations were between IL-8 and PM10 as well as with SO2. An IQR increase in PM10 
was associated with a 22.8% increase in IL-8 (95% CI 4.9 to 43.6) at lag 2 (Figure 
4.17). The associations with IL-6, fibrinogen and CRP were generally negative. 
Consistent and statistically significant decreases in CRP were observed with CO, NO2, 
NOx and PM10 at lag 2(Figure 4.10). Similar non-significant reductions of CRP were 
seen in association with PM10 and SO2 at lag 5. For IL-6, a consistent reduction was 
seen in association with CO, NO2 and NOx at lags 2 and 5 (Figure 4.16). Similarly, 
there was a reduction in IL-6 in association with PM10 and SO2 at lag 5.   
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Figure 4.10 Associations between CRP and ambient air pollutants 
 
Per cent changes and 95% CI for an IQR change in air pollutant 
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Table 4.8 Association between particulate and gaseous air pollutants and CRP, D-dimer and E-selectin 
Per cent changes and 95% CI for an IQR change in air pollutant   
 
  CRP*   D-dimer   E-selectin   
Pollutant† lag‡  %  ↑ § 95% CI§ P§ %  ↑ § 95% CI§ P§ %  ↑ § 95% CI§ P§ 
PM2.5 0 15.7 -2.2 , 36.9 0.09 -14.3 -24.2 , -3.2 0.01¶ -0.7 -5 , 3.7 0.74 
           
CO 0 -7.9 -19.9 , 5.9 0.25 -9.8 -19.5 , 1 0.07 -1.7 -5 , 1.7 0.32 
 1 -12.5 -23.6 , 0.4 0.06 -3.6 -13.4 , 7.5 0.51 1.1 -2.2 , 4.6 0.51 
 2 -8.4 -14.8 , -1.5 0.02¶ 1.6 -4.5 , 8 0.62 -0.5 -2.2 , 1.3 0.58 
 5 -17 -33.2 , 3.2 0.09 -15.5 -28.9 , 0.5 0.06 -1.8 -6.8 , 3.5 0.51 
           
NO2 0 -16.2 -39.3 , 15.8 0.28 -16.4 -36 , 9.2 0.19 -1.6 -8.9 , 6.4 0.69 
 1 -17.3 -38.6 , 11.5 0.21 -10.4 -29.7 , 14.3 0.38 3.1 -4 , 10.8 0.4 
 2 -28.5 -43.1 , -10 0.00¶ -3.2 -20.3 , 17.7 0.75 -1 -6.4 , 4.7 0.74 
 5 -32.8 -54.9 , 0.2  0.05 -18.3 -40.9 , 13 0.22 -0.3 -9.5 , 9.9 0.95 
           
NOx 0 -12.3 -25.9 , 3.9 0.13 -7.7 -19.9 , 6.2 0.26 -1.6 -5.5 , 2.5 0.44 
 1 -11 -22.8 , 2.7 0.11 -3.7 -14.2 , 8 0.52 1.1 -2.3 , 4.7 0.53 
 2 -15.2 -24 , -5.4 0.00¶ 1.6 -7.5 , 11.7 0.74 -0.7 -3.3 , 2 0.59 
 5 -21.9 -38.1 , -1.3 0.04¶ -10.6 -26 , 8.1 0.25 -1.2 -6.7 , 4.5 0.67 
           
Ozone 0 -6.2 -41.1 , 49.5 0.79 39.7 -3.8 , 102.9 0.08 1.5 -9.4 , 13.7 0.8 
 1 -23 -45.1 , 7.9 0.13 8 -18.5 , 43.1 0.59 -1.4 -9.1 , 6.9 0.72 
 2 -8.7 -37.4 , 33.3 0.64 17.8 -12.3 , 58.2 0.28 1.6 -7.4 , 11.5 0.73 
 5 -31.3 -61.9 , 23.8 0.21 37.8 -14.9 , 123.3 0.19 0.5 -12.7 , 15.7 0.94 
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PM10 0 1.1 -21 , 29.5 0.93 -16.2 -31.4 , 2.3 0.08 -3.4 -9.1 , 2.7 0.27 
 1 -7.1 -26.7 , 17.8 0.54 -23.6 -36.8 , -7.7 0.01¶ 1.9 -3.7 , 7.8 0.52 
 2 -18.6 -32.7 , -1.7 0.03¶ 1.9 -13.1 , 19.5 0.82 0.6 -3.9 , 5.3 0.79 
 5 -28.5 -53.5 , 10.1 0.13 -34.9 -54 , -7.9 0.02¶ -2.8 -11.7 , 7 0.56 
           
SO2 0 -12.8 -31.7 , 11.2 0.27 -8.7 -24.8 , 10.8 0.36 -0.4 -6.2 , 5.8 0.91 
 1 -3.8 -27.3 , 27.4 0.79 -2.6 -22.8 , 22.8 0.82 5 -1.8 , 12.2 0.15 
 2 -14.6 -35.2 , 12.7 0.26 -2.9 -22.4 , 21.6 0.8 -0.9 -7.3 , 5.9 0.79 
 5 -17.3 -46.5 , 27.9 0.39 -25.9 -46.8 , 3.3 0.08 -1 -11.3 , 10.5 0.86 
 
* CRP, C-reactive protein 
† PM2.5, mass of particles with aerodynamic diameter less than 2.5 µm; CO, carbon monoxide; NO2, nitrogen dioxide; NOx, 
oxides of nitrogen; PM10, ,particles with a diameter less than 10 µm;SO2  ,sulphur dioxide 
‡  Lag 0, average pollutant concentration 0-23 hours before blood collection; 
Lag 1, average pollutant concentration 24-47 hours before blood collection; 
Lag 2, average pollutant concentration 48-71 hours before blood collection; 
5 day average, average of 0-119 hours before blood collection; 
§ % ↑, anti log of effect estimate from the regression output minus 1* 100; CI, confidence Interval; P, P value 
¶ P < 0.05 
All models are adjusted for temperature, relative humidity, age, gender, BMI, statin use, environmental tobacco smoke and HbA1c 
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Table 4.9 Association between particulate and gaseous air pollutants and fibrinogen, ICAM-1 and ICAM-2 
Per cent changes and 95% CI for an IQR change in air pollutant   
 
  Fibrinogen  ICAM-1*   ICAM-2*   
Pollutant† lag‡   %  ↑ § 95% CI§ P§ %  ↑ § 95% CI§ P§ %  ↑ § 95% CI§ P§ 
PM2.5 0 1.6 -0.6 , 3.9 0.16 1 -1.3 , 3.4 0.38 -2.6 -4.4 , -0.7 0.01¶ 
           
CO 0 -0.9 -2.6 , 0.9 0.33 -0.5 -2.2 , 1.2 0.56 -0.6 -2.2 , 1.1 0.51 
 1 0.2 -1.6 , 2 0.86 -0.4 -2.2 , 1.4 0.66 1.9 0.2 , 3.6 0.03¶ 
 2 -0.3 -1.3 , 0.6 0.49 -0.2 -1.1 , 0.7 0.7 0.3 -0.5 , 1.2 0.46 
 5 -0.4 -3 , 2.3 0.77 0.4 -2.3 , 3.1 0.78 0.9 -1.7 , 3.6 0.49 
           
NO2 0 -0.9 -4.9 , 3.2 0.66 0.4 -3.6 , 4.5 0.86 -1.6 -5.4 , 2.3 0.41 
 1 0.9 -3 , 4.9 0.65 0.9 -2.8 , 4.9 0.63 3.2 -0.4 , 7 0.09 
 2 -0.4 -3.4 , 2.6 0.77 -0.1 -3 , 2.9 0.97 1 -1.8 , 3.9 0.47 
 5 0.2 -4.7 , 5.3 0.93 1.2 -3.7 , 6.3 0.65 1.2 -3.6 , 6.2 0.63 
           
NOx 0 -1.3 -3.4 , 0.9 0.24 -0.6 -2.6 , 1.5 0.6 -0.7 -2.7 , 1.4 0.5 
 1 0.1 -1.7 , 2 0.89 -1.1 -2.9 , 0.8 0.25 1.7 -0.1 , 3.5 0.06 
 2 -0.7 -2.1 , 0.8 0.36 -0.3 -1.7 , 1.1 0.69 0.7 -0.6 , 2.1 0.28 
 5 -0.7 -3.5 , 2.3 0.65 -0.2 -3 , 2.8 0.92 1.5 -1.3 , 4.4 0.3 
           
Ozone 0 -0.8 -6.5 , 5.4 0.8 -3.6 -9.1 , 2.2 0.22 0.6 -5 , 6.4 0.84 
 1 -0.2 -4.5 , 4.3 0.93 -2.5 -6.6 , 1.7 0.23 -2.5 -6.4 , 1.6 0.23 
 2 -4.4 -8.9 , 0.4 0.07 -3.8 -8.4 , 1 0.12 -1.8 -6.3 , 2.9 0.45 
 5 -3.8 -10.5 , 3.4 0.29 -7.6 -13.9 , -0.9 0.03¶ -3.1 -9.6 , 4 0.38 
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PM10 0 -2.5 -5.5 , 0.6 0.11 0 -3.1 , 3.3 0.99 0 -3 , 3.1 1 
 1 1.2 -1.9 , 4.3 0.45 2.7 -0.2 , 5.7 0.07 1.7 -1.1 , 4.6 0.24 
 2 -0.1 -2.5 , 2.4 0.92 0.7 -1.7 , 3.2 0.55 1.5 -0.8 , 3.8 0.21 
 5 -2.3 -7.6 , 3.2 0.4 2.2 -3.3 , 8 0.43 0.6 -4.7 , 6 0.84 
           
SO2 0 -0.4 -3.5 , 2.8 0.79 0.8 -2.3 , 4 0.62 -0.8 -3.8 , 2.2 0.59 
 1 3.6 -0.1 , 7.4 0.05 1.1 -2.5 , 4.7 0.56 0.9 -2.4 , 4.4 0.59 
 2 0 -3.4 , 3.6 0.98 0.6 -2.8 , 4.2 0.73 0.1 -3.2 , 3.5 0.96 
 5 1.6 -3.8 , 7.3 0.56 3.3 -2.3 , 9.3 0.26 0.2 -5 , 5.8 0.93 
 
* ICAM, 1- Intracellular adhesion molecule-1; I CAM, 2- Intracellular adhesion molecule-2 
† PM2.5, particles with a diameter less than 2.5 µm; CO, carbon monoxide; NO2, nitrogen dioxide; NOx, oxides of nitrogen; PM10, 
,particles with a diameter less than 10 µm;SO2  ,sulphur dioxide 
‡  Lag 0, average pollutant concentration 0-23 hours before blood collection; 
Lag 1, average pollutant concentration 24-47 hours before blood collection; 
Lag 2, average pollutant concentration 48-71 hours before blood collection; 
5 day average, average of 0-119 hours before blood collection; 
§ % ↑, anti log of effect estimate from the regression output minus 1* 100; CI, confidence Interval; P, P value 
¶ P < 0.05 
All models are adjusted for temperature, relative humidity, age, gender, BMI, statin use, environmental tobacco smoke and HbA1c 
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Table 4.10 Association between particulate and gaseous air pollutants and IL-6, IL-8 and vWF 
Per cent changes and 95% CI for an IQR change in air pollutant   
 
  IL-6*   IL-8*   vWF*   
Pollutant† Lag‡ %  ↑§ 95% CI§ P§ %  ↑§ 95% CI§ P§ %  ↑§ 95% CI§ P§ 
PM2.5 0 12.7 1.3 , 25.3 0.03¶ 3.8 -3.1 , 11.2 0.28 1.9 -2 , 6 0.35 
           
CO 0 -4.6 -13.2 , 5 0.34 1.7 -3.8 , 7.6 0.55 0 -3.1 , 3.2 0.99 
 1 -8.1 -15.9 , 0.4 0.06 -3.3 -8.4 , 2.2 0.23 -2 -5.1 , 1.2 0.23 
 2 -6.7 -11 , -2.2 0.00¶ 1.3 -1.5 , 4.1 0.37 0.7 -1 , 2.4 0.43 
 5 -21 -31.4 , -9.1 0.00¶ 1.7 -6.1 , 10.1 0.68 1.3 -3.3 , 6.2 0.57 
           
NO2 0 -11.5 -29.1 , 10.4 0.28 2 -10.2 , 16 0.76 2.9 -4.3 , 10.5 0.44 
 1 -7.8 -24.4 , 12.4 0.42 -3.5 -14.2 , 8.5 0.55 -2.2 -8.7 , 4.7 0.52 
 2 -17.2 -28.9 , -3.6 0.01¶ 2.9 -5.9 , 12.5 0.53 0.2 -5 , 5.8 0.93 
 5 -23.2 -41 , -0.1 0.05¶ 3 -11.3 , 19.7 0.7 1.6 -6.8 , 10.8 0.72 
           
NOx 0 -8 -18.1 , 3.3 0.16 3.7 -3.1 , 10.9 0.3 0.4 -3.3 , 4.3 0.83 
 1 -3.7 -12.4 , 5.9 0.44 -1.1 -6.6 , 4.7 0.7 -2.2 -5.4 , 1.1 0.2 
 2 -11 -17.2 , -4.4 0.00¶ 1.7 -2.5 , 6.2 0.43 0.4 -2.2 , 3 0.77 
 5 -18.3 -29.9 , -4.9 0.01¶ 3.4 -5.3 , 12.8 0.46 0.6 -4.3 , 5.8 0.8 
           
Ozone 0 -3.8 -30 , 32.2 0.81 1.6 -15.6 , 22.3 0.87 -8.2 -17.3 , 1.8 0.11 
 1 -13 -30.7 , 9.3 0.23 0.2 -12.3 , 14.5 0.98 -0.7 -8.2 , 7.3 0.85 
 2 -5.5 -26.1 , 20.6 0.65 -0.1 -13.7 , 15.7 0.99 -4.5 -12.6 , 4.3 0.31 
 5 -5.2 -36.2 , 40.9 0.79 -7.4 -25.5 , 15.1 0.49 -10.2 -20.6 , 1.7 0.09 
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PM10 0 -0.1 -15.6 , 18.2 0.99 3.4 -6.4 , 14.1 0.51 -0.4 -5.9 , 5.3 0.88 
 1 -5.8 -19.5 , 10.3 0.46 -1.6 -10.1 , 7.8 0.73 1.2 -4.1 , 6.9 0.66 
 2 -8.4 -19.3 , 4.1 0.18 3 -4.3 , 10.8 0.43 0.1 -4.2 , 4.6 0.95 
 5 -34.7 -50.4 , -14.1 0.00¶ 22.8 4.9 , 43.6 0.01¶ -2.6 -11.3 , 7 0.59 
           
SO2 0 -13.1 -26.2 , 2.3 0.09 -1.1 -10.3 , 9.1 0.83 -1.4 -6.7 , 4.2 0.61 
 1 -4.8 -21.2 , 14.9 0.61 -10.9 -20 , -0.9 0.03¶ -1.8 -8 , 4.7 0.58 
 2 -14.7 -28.9 , 2.3 0.09 9.8 0.6 , 19.8 0.04¶ 2.6 -3.7 , 9.3 0.43 
 5 -30.6 -47.5 , -8.4 0.01¶ 13.8 -0.9 , 30.8 0.07 1.3 -8 , 11.6 0.79 
 
* IL-6, Interleukin- 6; IL-8, Interleukin- 8; vWF, von Willebrand factor antigen 
† PM2.5, particles with a diameter less than 2.5 µm; CO, carbon monoxide; NO2, nitrogen dioxide;  
NOx, oxides of nitrogen; PM10,   particles with a diameter less than 10 µm; SO2, sulphur dioxide 
‡  Lag 0, average pollutant concentration 0-23 hours before blood collection; 
Lag 1, average pollutant concentration 24-47 hours before blood collection; 
Lag 2, average pollutant concentration 48-71 hours before blood collection; 
5 day average, average of 0-119 hours before blood collection; 
§ % ↑, anti log of effect estimate from the regression output minus 1* 100; CI, confidence Interval; P, p value 
¶ P < 0.05 
All models are adjusted for temperature, relative humidity, age, gender, BMI, statin use, environmental tobacco smoke and HbA1c 
  
184 
 
4.3.4.2.2 Endothelial markers  
 
Inconsistent effects of ambient air pollutants on adhesion molecules ICAM-1 and 
ICAM-2 were seen with different pollutants (Figure 4.14 and Figure 4.15). An IQR 
increase in CO was associated with a 1.9% increase in ICAM-2 (95% CI 0.2 to3.6%). 
On the other hand, an IQR increase in ozone was associated with a 7.6% reduction in 
ICAM-1 (95% CI, -13.9 to -0.9). No consistent association was seen between 
concentration of E-selectin and any pollutant.  
4.3.4.2.3 Coagulation parameters 
 
Ambient PM10 and gases were associated with D-dimer at various lags, with some of the 
pollutants having significant associations (Table 4.7). An IQR increase in PM10 was 
associated with a 23.6% reduction (95% CI -36.8 -7.7) at lag 1 and a 34.9% reduction 
(95% CI -54 to -7.9) for a lag of 5 days. A similar non-significant reduction was 
observed in SO2 at lag 5. 
 
Figure 4.11 Associations between D-dimer and ambient air pollutants 
Per cent changes and 95% CI for an IQR change in air pollutant 
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Figure 4.12 Associations between E-selectin and ambient air pollutants 
Per cent changes and 95% CI for an IQR change in air pollutant 
 
 
 
Figure 4.13 Associations between fibrinogen and ambient air pollutants 
Per cent changes and 95% CI for an IQR change in air pollutant 
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Figure 4.14 Associations between ICAM-1 and ambient air pollutants 
Per cent changes and 95% CI for an IQR change in air pollutant 
 
 
 
Figure 4.15 Associations between ICAM-2 and ambient air pollutants 
Per cent changes and 95% CI for an IQR change in air pollutant 
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Figure 4.16 Associations between IL-6 and ambient air pollutants 
Per cent changes and 95% CI for an IQR change in air pollutant 
 
 
 
Figure 4.17 Associations between IL-8 and ambient air pollutants 
Per cent changes and 95% CI for an IQR change in air pollutant 
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Figure 4.18 Associations between vWF and ambient air pollutants 
Per cent changes and 95% CI for an IQR change in air pollutant 
 
4.3.4.3 Effect modification by personal covariates  
 
To investigate potential effect modification by various individual characteristics by age, 
gender, environmental tobacco smoke, smoking status, statin use, BMI and HbA1c, 
subgroup analyses were conducted. Table 4.11 and Table 4.12 show the distribution of 
outcome and exposure variables among various subgroups and Figure 4.19 to Figure 
4.25 show effect estimates of personal PM2.5 on various biomarkers by subgroups.   
Generally, male participants had higher mean PM2.5, CO and NOx than female 
participants. Regarding the blood markers, men had higher levels of D-dimer, ICAM-1 
and vWF, whereas women had higher levels of CRP and ICAM-2.  
The mean concentration of personal PM2.5 was higher in males, those above the age of 
65, statin users, those who had smoking spouses, ex-smokers, individuals with 
HbA1c < 6.5 and BMI ≥ 30 compared with females, those below 65, non-statin users, 
those with non-smoking spouses, never-smokers, participants with HbA1c ≥ 6.5 and 
BMI < 30 respectively.  
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Similarly, the concentrations of NO, NO2 and NOx were moderately higher in those 
participants living with smoking spouses and in ex-smokers compared with those living 
with non-smoking spouses and never-smokers respectively. PM10 was evenly 
distributed across these groups.  
 
Table 4.11 Distribution of exposure and outcome parameters by subgroups 
 
 Gender Age HbA1c* Statin 
Parameter 
 
Female Male  < 65  >= 65 < 6.5 >= 6.5 No  Yes 
PM2.5† 80.7 113.4 96.8 105.9 119.1 91.9 57.6 109.5 
CO 0.1 0.2 0.2 0.2 0.2 0.1 0.1 0.2 
PM10 18.7 19.0 19.7 18.5 19.8 18.2 19.2 18.8 
NO2 40.9 41.2 41.9 40.8 42.0 40.6 34.7 42.0 
NOx 66.5 76.1 76.3 71.7 75.7 71.5 58.3 75.3 
Ozone 13.7 15.6 13.6 15.7 16.5 14.1 23.0 13.9 
SO2 2.2 2.6 1.7 2.8 3.0 2.1 3.3 2.3 
CRP‡ 4.9 4.2 4.9 4.2 4.5 4.4 7.0 4.1 
D-dimer 198.9 219.8 234.6 203.0 238.7 196.0 192.3 216.1 
E-selectin 115.5 110.1 101.2 116.7 104.0 117.2 121.5 110.5 
Fibrinogen 3.8 3.6 3.8 3.7 3.8 3.6 3.7 3.7 
IL-6 12.0 11.5 14.8 10.2 11.0 12.1 8.2 12.1 
IL-8 12.7 11.6 13.9 11.1 13.6 10.9 9.0 12.4 
ICAM-1 355.2 365.3 331.1 376.5 371.4 355.7 341.0 365.0 
ICAM-2 368.8 343.8 344.9 355.0 354.4 349.9 332.8 354.4 
vWF 134.9 148.5 149.3 141.8 141.6 145.9 141.7 144.5 
 
* 
 HbA1c,   haemoglobin A1c  
† PM2.5, particles with a diameter less than 2.5 µm;CO ,carbon monoxide;NO2 ,nitrogen 
dioxide; NOx  ,oxides of nitrogen;PM10 ,particles with a diameter less than 10 µm;SO2 
,sulphur dioxide;  PM2.5, PM10, O3, SO2 and NOx are all in (µg/m3). CO mg/m3 
‡ CRP, C-reactive protein; IL-6, interleukin  6; IL-8, interleukin- 8; ICAM, 1- 
Intracellular adhesion molecule-1; ICAM, 2- Intracellular adhesion molecule-2; vWF, 
von Willebrand Factor antigen 
IL-6 and IL-8 (pg/ml), CRP (mg/L), E-Selectin, ICAM-1 and ICAM-2 (ng/ml), vWF 
u/dl, Fibrinogen g/ml, D-dimer ng/L 
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4.3.4.3.1 Age 
 
Older study participants (≥ 65) had an increased response to the effects of PM2.5 
exposure. Elevated biomarkers were observed in association with ambient pollutants at 
various lags. An IQR increase in PM2.5 was associated with a 31.9% increase in CRP 
(95% CI 9.6-58.8) and the same amount of exposure was related to a 2.7% increase in 
D-dimer (95% CI 0.9-38.7) in participants below the age of 65 (Figure 4.19).  Likewise, 
in this age group, CO, NO2, NOx, PM10 and SO2 were related to an increase in IL-8(data 
not shown). 
 
 
Figure 4.19 Associations between biomarkers and personal PM2.5 stratified by age 
Per cent changes and 95% CI for an IQR change in air pollutant 
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Table 4.12 Differences in exposure and outcome parameters by subgroups 
 
 ETS* Smoking status BMI* 
Exposure & 
outcome 
parameters 
 
NO  Yes Never 
smoker 
Ex-
smoker 
<30 >= 30 
PM2.5† 63.9 244.5 54.0 172.7 87.3 108.8 
CO 0.1 0.2 0.1 0.2 0.2 0.1 
PM10 18.4 20.4 18.0 20.1 18.4 19.0 
NO2 40.0 45.0 38.2 45.0 43.7 40.2 
NOx 68.1 91.4 62.1 87.9 85.7 68.8 
O3 15.4 13.9 15.9 14.1 14.8 15.1 
SO2 2.3 3.1 2.4 2.7 3.3 2.2 
CRP† 3.9 6.4 4.6 4.5 6.7 3.6 
D-dimer 218.5 194.3 213.6 217.3 207.2 215.3 
E-selectin 103.4 141.8 121.6 103.6 109.9 112.5 
Fibrinogen 3.6 3.9 3.6 3.8 3.7 3.7 
IL-6 11.7 11.5 9.6 14.6 10.3 12.1 
IL-8 11.9 12.5 12.1 11.7 11.7 12.1 
ICAM-1 343.8 427.1 358.3 377.5 419.1 342.0 
ICAM-2 347.2 367.8 357.6 350.1 366.2 346.7 
vWF 146.0 137.6 135.3 156.9 141.3 145.2 
 
* 
 HbA1c,   environmental tobacco smoke; BMI, body mass index;  
† PM2.5, mass concentration of particles < 2.5 µm in aerodynamic            
diameter; CO, carbon monoxide;NO2, nitrogen dioxide; NOx, oxides of 
nitrogen;PM10, mass concentration of particles < 10 µm in aerodynamic            
              diameter; SO2- sulphur dioxide;   
PM2.5, PM10, O3, SO2 and NOx are all in (µg/m3). CO mg/m3 
‡ CRP, C-reactive protein; IL-6, interleukin  6; IL-8, interleukin- 8; ICAM, 1- 
Intracellular adhesion molecule-1; ICAM, 2- Intracellular adhesion molecule-2; 
vWF, von Willebrand Factor antigen 
IL-6 and IL-8 (pg/ml), CRP (mg/L), E-Selectin, ICAM-1 and ICAM-2 (ng/ml), 
vWF u/dl, Fibrinogen g/ml, D-dimer ng/L 
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4.3.4.3.2 Gender 
 
There was no significant differential effect of PM2.5 by gender (Figure 4.20). On the 
other hand, gender was found to be a modifier of risk for ambient PM and gaseous 
pollutants for some of the markers. In females, PM10 was related to increased D-dimer, 
E-selectin and vWF, whereas in males increases in ICAM-2 and IL-8 were observed 
with increased CO, NOx and PM10.   
 
 
Figure 4.20 Associations between biomarkers and personal PM2.5 stratified by 
gender 
Per cent changes and 95% CI for an IQR change in air pollutant 
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4.3.4.3.3 Smoking 
 
Generally, participants who had never smoked had lower mean concentrations of most 
pollutants except ozone, which had a comparable concentration in both groups. Ex-
smokers had threefold concentrations of PM2.5 as compared to non-smokers. The 
outcome variables had comparable concentrations in both groups. The response of ex-
smokers to the effect of PM2.5 was stronger than that of non-smokers (Figure 4.21).  
 
 
Figure 4.21 Associations between biomarkers and personal PM2.5 stratified by 
smoking status 
Per cent changes and 95% CI for an IQR change in air pollutant 
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4.3.4.3.4 Environmental tobacco smoke 
 
Participants with smoking partners showed a significant increase in CRP and IL-6 and a 
decrease in D-dimer and ICAM-2 compared with those with non-smoking partners. The 
response of other biomarkers was comparable in both groups (Figure 4.22). 
 
 
Figure 4.22 Associations between biomarkers and personal PM2.5 stratified by ETS 
Per cent changes and 95% CI for an IQR change in air pollutant 
 
4.3.4.3.5 BMI 
 
Individuals with BMI < 30 have shown significant reduction in D-dimer and ICAM-2 in 
association with PM2.5. Similarly, they have shown a more pronounced non-significant 
increase in CRP compared with those with BMI ≥ 30 (Figure 4.23).    
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Figure 4.23 Associations between biomarkers and personal PM2.5 stratified by BMI 
Per cent changes and 95% CI for an IQR change in air pollutant 
 
4.3.4.3.6 Glycaemic control 
 
Individuals whose glycaemic control was not optimal as measured by HbA1c appear to 
have had an increased response to personal PM2.5 and ambient pollutants. In particular, 
personal PM2.5 appears to have had an increased effect on some of the markers (Figure 
4.24). An IQR increase of PM2.5 was related to an increase of 34% in CRP (95% CI 
5-71), 4.2% in fibrinogen (95% CI 1.3-7.1) and 3.1% in ICAM-1 (95% CI 0.1-6.2). 
Conversely, an IQR increase in PM2.5 was related to a significant reduction in D-dimer. 
The response of IL-6 was similar in both categories of HbA1c. Regarding ambient air 
pollutants, CO and ozone were related to increased ICAM-2 and D-dimer respectively 
in those with poor glycaemic control. 
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Figure 4.24 Associations between biomarkers and personal PM2.5 stratified by 
HbA1c 
Per cent changes and 95% CI for an IQR change in air pollutant 
 
4.3.4.3.7 Statin use 
 
Most study participants were receiving statin treatment (87.5%). Those who were not 
showed a significant increase in IL-8 and D-dimer dimer in association with personal 
PM2.5. They also had strong but non-significant associations with IL-6, ICAM-2 and 
vWF. Participants on statin treatment showed significant increases in CRP and IL-6 
(Figure 4.25). 
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Figure 4.25 Associations between biomarkers and personal PM2.5 stratified by 
statin use 
Per cent changes and 95% CI for an IQR change in air pollutant 
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4.4 Discussion 
 
This study aimed to investigate the potential pathways linking CV outcomes to air 
pollution in a diabetes mellitus type 2 population, which is known from earlier studies 
to be susceptible to the effects of air pollution. Several blood makers of inflammation 
were analyzed, including acute phase proteins (hs-CRP, fibrinogen), cytokines (IL-6 
and IL-8), adhesion molecules (E-selectin, ICAM-1 and ICAM-2), D-dimer and vWF, 
to assess their potential to predict CV events. In general, the study has shown a few 
inconsistent associations between exposure data from central background monitors and 
measured inflammatory biomarkers. These observed associations could possibly have 
arisen by chance. On the other hand, more significant negative associations were 
observed with ambient exposure data. The response of CRP and D-dimer to measured 
ambient pollutants was mostly negative at various lags. Adhesion molecules, fibrinogen, 
vWF and E-selectin showed no clear and consistent association with any of the ambient 
pollutants.  
By contrast, when personal PM2.5 exposure was examined in association with 
biomarkers, more positive and significant associations were observed. For example, 
IL-6 was positively and significantly associated with PM2.5. Of nine measured 
biomarkers, the five largest effects on day 0 were observed in association with personal 
PM2.5, including the three sensitive biomarkers in widest use: hs-CRP, fibrinogen and 
IL-6. Furthermore, the study has shown differential effect of personal PM2.5 in a 
subgroup analysis by various personal factors. Older participants (65 years and older) 
showed an increased response of CRP compared with those under the age of 65. 
Similarly, ex-smokers had positive and significant responses of IL-6 and CRP compared 
with non-smokers. They also showed a statistically significant reduction in D-dimer. 
Similarly, participants with partners who smoke had an increased positive response of 
IL-6 compared with those living with non-smokers. Interestingly, participants who were 
receiving statin treatment showed significant positive associations of personal PM2.5 
with IL-6 and CRP. One of the well established effects of statin treatment is a reduction 
of the CRP level[228].   
Like several earlier studies with null findings, this study has found no positive 
association with some of the measured biomarkers[34, 114]. There are several possible 
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explanations for the lack of associations in this study with central site exposure data.  
Firstly, the use of ambient exposure data from a single central site monitor might have 
led to exposure measurement error and underestimation of risk, as each participant was 
assigned the same level of exposure data irrespective of his/her personal exposure level.   
Secondly, the low exposure contrast observed during the study period might have 
contributed to observed lack of association. In contrast to large time series studies 
which are able to observe thousands of small fluctuations or air pollution episodes that 
are accompanied by extreme air pollution levels, this study observed small fluctuations 
in ambient pollutant levels over the study period and may thus have failed to detect 
weak relationships.   
Thirdly, the low statistical power of the study might also preclude detection of weak 
associations. Finally, most of the study participants were on cardio-protective therapy 
like low dose aspirin, statins, ACE inhibitors and beta blockers. Some of these agents, 
particularly aspirin and statins, are potent anti-inflammatory substances with beneficial 
effects on vascular endothelium and reduction of CAD risk[228].     
 Statins which were traditionally introduced as potent inhibitors of cholesterol 
biosynthesis have become a standard medical therapy in the prevention of CVD as a 
result of their multiple beneficial effects on the vascular function.  Statins improve 
endothelial function, reduce pro-coagulant and thrombotic responses, inhibit 
inflammation and oxidative stress and enhance stability of atherosclerotic plaques[229].   
Statin therapy reduces a number of biomarkers such as CRP, cytokines of inflammatory 
cascade (IL-6, IL-8 and TNF-α), endothelial markers (ICAM-1, E-selectin and vWF) as 
well as various coagulation factors[229].   
Current epidemiological literature investigating the relationship between air pollutants 
and various inflammatory markers is not consistent, with some studies showing positive 
associations and others none. Some observational epidemiological studies have shown 
associations between ambient air pollutants and increased levels of CRP[34, 35, 106, 
112], while others have found no such association[113-116]. Similarly, some 
investigators have shown positive associations between various pollutants and 
fibrinogen[99, 101],  whereas others have found negative correlations[35, 116] or no 
association[34, 102, 115]. Other biomarkers which have shown positive associations 
with various air pollutants are IL-6[95, 112, 113], vWF[107] and various adhesion 
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molecules[107]. These same biomarkers have shown null association in other 
studies[115].   
The observed inconsistency is not limited to epidemiological studies; toxicological 
studies and controlled human exposure studies have also shown inconsistent 
results[230]. An experimental study involving young volunteers has shown an increase 
in blood fibrinogen in healthy volunteers following CAPs exposure[121], while another 
found no association with fibrinogen, D-dimer or CRP[22]. Other CAPs studies have 
shown no association between CRP and CAPs or diesel exhaust particles[230]. Earlier 
CAPs studies have recruited predominantly young and healthy individuals, while recent 
ones have involved susceptible individuals like the elderly or those with underlying co-
morbidity[22, 230]. As regards the inconsistency observed in CAPs studies, this might 
be explained by type and duration of exposure, variable timing of sampling, presence of 
other co-morbid conditions, differences in the study population, the type and mix of 
pollutants and differences in exposure-response relationships[22, 230].  
Regarding observational epidemiological studies, the possible explanation for the 
observed discrepancy are lack of comparable air pollution measurement, use of different 
time relationships between exposure and outcomes and adjustment for multiple 
confounders such as age, gender, BMI, exercise, hyperlipidaemia, alcohol consumption, 
cigarette smoke, glucose concentrations and medication use[115, 116]. Response to 
short-term exposure could also vary among individuals depending on age, gender or 
disease status.  
Various studies have used differing exposure assessment methods and exposure metrics 
to estimate individual exposure. Most commonly, exposure data were obtained from one 
or more ambient fixed site monitors, while few researchers have monitored personal 
exposure by personal samplers[93], estimated it from models[35] or used 
combinations[103].  Variations also exist in terms of exposure metric: most studies have 
used particle mass as measured by PM10 or PM2.5, while some have used larger 
TSP[106] or smaller UFP[34]. Other studies have used particle number 
concentration[108] and still others have additionally evaluated the effect of gases. The 
toxicity of particles depends on their size, number and chemical composition; and these 
factors and the methods used to estimate the exposure as well as differences in 
averaging time may account for the observed discrepancies between the studies.  
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Despite this inconsistency, the weight of evidence from both observational and 
epidemiological studies supports the idea that air pollutants are involved in systemic 
inflammatory responses with possible links to acute and chronic CV events.  
This study is the first to investigate the association between various inflammatory 
markers among individuals with type 2 diabetes mellitus, by using exposure data from 
fixed site background monitors and by measuring personal exposure to PM2.5. In this 
study, the analysis of personal PM2.5 has shown a statistically significant positive 
association with IL-6 and positive but non-significant associations with hs-CRP, 
fibrinogen and ICAM-1. These results are partly in agreement with earlier panel studies 
which have shown elevation of CRP and IL-6[111] or IL-6 alone[95] [113]. A study of 
the effect of the Asian haze of 1997 on the blood of young healthy subjects showed a 
statistically significant association between air pollutants and IL-6[95]. A  recent panel 
study of 44 elderly subjects found significant associations of PM2.5 with CRP, IL-6 and 
WBC among diabetic subjects [111]. Another multi-centre panel study of myocardial 
infarction survivors found significant positive associations between particle number 
concentration and IL-6 and fibrinogen at a lag of 12-17 hours[113].   
IL-6 is a main proinflammatory cytokine, produced by various cellular elements 
including lymphocytes, activated macrophages, monocytes, fibroblasts and endothelial 
cells, which plays a central role in the inflammatory response[231]. It has a broad range 
of humoral and cellular immune effects and is a central mediator of most acute phase 
responses[139]. Through its action in leukocyte recruitment, coagulation cascade and 
effects on endothelium and other components of the vasculature, IL-6 is directly linked 
to CVD[231]. It also plays a key role in atherosclerosis by inducing endothelial 
dysfunction, generation of reactive oxygen species and increased synthesis of major 
acute phase proteins.  
In a number of population-based studies it has been shown that CRP and IL-6 are 
independent predictors of future CV events in both healthy subjects and patients with an 
underlying coronary heart disease[139, 140, 142]. A large prospective study by Ridker 
and others involving about 15,000 healthy men has shown that baseline IL-6 levels were 
significantly elevated among 202 men who subsequently developed AMI[142]. The 
study revealed that during the six years of follow-up, men in the highest quartile of IL-6 
had a risk ratio (RR) of 2.3 when compared to those in the lowest quartile of IL-6. The 
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association was independent of traditional CV risk factors like BMI, diabetes and 
cholesterol levels[142]. The upper quartile of IL-6 reported by Ridker et al was 
> 2.28 pg/ml, while in the present study it was 12.1 pg/ml.  
Another study by the same author involving about 28,000 women has revealed that the 
RR of first CV event for the fifth quintile of CRP was 2.3 when compared with women 
in the lowest quintile[148]. The CRP range for the fifth quintile reported by the author 
was > 4.19 mg/ml. The CRP value for upper quartile in the current study was 4.7 mg/L. 
This would suggest that the absolute values of both IL-6 and CRP in the current study 
fall in the upper risk category reported by Ridker et al. in two separate studies[142, 
148]. Besides, the Centres for Disease Control & Prevention & American Heart 
Association scientific statement defines hs-CRP values above 3 mg /L as high CV 
risk[144]; the mean CRP of the current study was 4.22 mg/L and this level falls in the 
highest CV risk category.  
One of the strength of this study is the use of a prospective panel study design. This 
design enables each individual to act as his/her own control and separately estimates 
within and between-person effects exposure. The presence of subject-level covariates 
and outcome in the study also provides strong evidence of association at an individual 
level. Another strength of this study is the personal exposure measurement, which will 
reduce exposure misclassification.  
Studies on human activity pattern have shown that people spend up to 87% of their time 
in enclosed buildings and about 6% in vehicles where they are exposed to a wide variety 
of sources in these microenvironments[232]. Accordingly, estimate of personal 
exposure from ambient sources are associated with some degree of exposure 
measurement error which may lead to underestimation of exposure, whereas personal 
exposure measured by a personal exposure sampler captures total personal exposure 
from all types of microenvironments (e.g., indoors at home, indoors at office or school, 
in-car, other public places etc...) which the subject entered.  However, the study did 
evaluate effects observed only at lag 0, as personal PM2.5 was measured for less than 24 
hours.   
Earlier cross-sectional studies that used a single measurement of biological endpoints 
are likely to have residual confounding. It has been shown that most of the measured 
biomarkers exhibit significant diurnal and seasonal variability, which could not be 
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captured in cross-sectional design[233]. In addition, cross-sectional studies cannot 
establish temporal relationships between inflammatory markers and exposure 
parameters, one key requirement for establishing epidemiological causality.    
The present study also has several weaknesses, the main one being the small sample 
size, which did not allow precise effect estimates to be made. Additionally, the use of 
exposure data obtained from one central background monitor might have led to 
exposure measurement error. Such error is random and non-differential and the 
consequence is to underestimate observed effect estimates, as highlighted by other 
researchers[26].  
The implication of the findings of this study is that personal exposure to PM2.5 has a 
significant effect on proximal proinflammatory markers like IL-6 and to a lesser extent 
CRP, fibrinogen and ICAM-1. IL-6 is a major mediator of inflammatory cascade and 
through its action on various acute phase proteins may be involved in CVD. The 
absence of association with ambient air pollutants suggests possible exposure 
measurement error rather than true absence of effect.  
In conclusion, this repeated measure panel study suggests that personal exposure to fine 
particulates is associated with a significant increase in inflammatory markers such as 
IL-6 and hs-CRP, in support of previous research. The findings highlight the importance 
of personal exposure measurement in studying susceptible populations to quantify true 
personal and total exposure to pollutants.  
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5 Chapter Five:  Final discussion 
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5.1 Summary of the Main Results  
 
The fundamental aim this study was to investigate novel aspects of the risks associated 
with short-term exposure to PM and gaseous air pollutants on CV outcomes focussing 
on earlier outcomes and specific markers as well as the underlying mechanisms. The 
study had three specific objectives. The first was to assess the relationship between 
short-term change in ambient air pollutants and ACS, by studying a sensitive and 
specific cardiac troponin level in patients admitted with chest pain of myocardial origin. 
The second objective was to assess the effect of transient change in ambient air 
pollutants on the occurrence of TIA. The third and final objective was to investigate 
potential associations between CV outcomes and gaseous and particulate pollutants with 
emphasis on one of the proposed pathways, specifically the systemic inflammation 
pathway. 
5.1.1 Acute coronary syndrome & Short-Term Exposure to Ambient 
Air Pollution 
 
The study has shown that exposure to PM10 and gaseous pollutants is related to the risk 
of ACS demonstrated by the specific marker troponin. There was a significant increased 
risk of ACS as measured by troponin levels above 0.03 ng/ml associated with increased 
levels of CO, NO, NO2 and SO2, as well as moderate risk in association with PM10. Most 
of the associations were observed with lags 2 or 3 days, indicating a delayed effect of 
pollutants. Stratification of the troponin level above and below 1 ng/ml further revealed 
a consistent and robust association of the two troponin categories with air pollutants at 
lags 2 and 3. Moreover, the study found differential effect of pollutants on ACS by 
gender, age and season. The observed effect estimates were stronger in female patients 
compared with male study subjects. Similarly, slightly elevated risk was shown in those 
above the age of 65 years compared with those below 65. Regarding season, the effects 
of CO, NO, NO2, PM10 and SO2 were strong and positive in colder months. In contrast, 
increased ozone exposure was associated with a decreased risk in colder months. The 
result of this research shows that short-term change in ambient air pollutants is 
associated with an increased risk of ACS and this risk varies by gender, season and to a 
lesser extent by age.  
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Numerous studies have examined the relationships of CV hospital admissions and 
deaths with air pollutants and most have relied on routinely available hospital admission 
and discharge data to establish the diagnosis of outcome. The shortcomings of using 
administrative data for epidemiological studies are well recognized[59, 66]. Hospital-
based mortality statistics as well as admission data are susceptible to inaccuracy in 
diagnosis and coding. In addition, the diagnostic sensitivity of some of the tools 
employed in ACS diagnosis like electrocardiogram is low, potentially leading to 
incorrect diagnosis. A UK study found 6% missed myocardial damage of prognostic 
importance in patients who presented to emergency department with chest pain and sent 
home without troponin measurement and confirmed on subsequent review[234]. In the 
elderly population who have several co-morbid conditions, a number of non-cardiac 
deaths are attributed to CAD and admission data equally suffer from inaccuracy and 
coding error for ACS and stroke[59].    
A recent study of the relationship between ACS admission and daily PM10 
concentration in Verona, Italy[235] established the diagnosis of ACS by suggestive 
cardiac symptoms, ECG and troponin measurement, but had several methodological 
limitations. Firstly, the study failed to adjust for important confounders like humidity, 
temperature, seasonal variation, time trend, day of the week and gaseous pollutants. 
Secondly, the study used exposure data from central monitors for the same day without 
consideration of the lagged effect of exposure. Thus, this thesis is the first to report a 
study investigating the relationship between ambient air pollutants and ACS by 
measuring cardiac troponin to confirm the diagnosis of ACS.     
 
5.1.2 Effect of Ambient Particulates and Gaseous Pollutants on the 
risk of TIA  
 
The second study has also shown that air pollution is significantly related to the risk of 
TIA. For data from Manchester, the study has shown a significant relationship between 
NO and TIA at lag 3, while data from Liverpool has shown no consistent positive 
association. Exploratory subgroup analysis by age, gender and season has shown 
variations of risk of TIA by these factors, mainly for data from Manchester. Gaseous 
pollutants CO, NO and NO2 were associated with significantly increased risk of TIA in 
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those participants above the age of 65 compared with those below the age of 65.  
Similar effects were observed in male patients compared with females. Moreover, 
inconsistent effect of pollutants by season was observed in Manchester and Liverpool. 
Data from Liverpool showed a large effect of NO2 on TIA in warm months, whereas 
data from Manchester indicated an association mostly in colder months. The results of 
this study also show that exposure to ambient air pollutants is related to another CV 
outcome, i.e. TIA. It is possible that gaseous pollutants, particularly NO, act as 
surrogates for UFPs and the observed results could be due to unmeasured UFPs, which 
were strongly correlated to CO and NOx in a Manchester study[198]. 
5.1.3 Air pollution and blood markers of inflammation, thrombosis 
and endothelial function in diabetic patients 
 
The last study involved investigation of the major pathway of CV damage caused by 
pollutants (see section 1.10.1). Using exposure data from ambient central monitors, the 
study failed to show any consistent association with measured biomarkers. The absence 
of a consistent effect using central monitor data could be related to exposure 
misclassification due to use of a single central site monitor. However, personal exposure 
to fine PM was shown to be strongly associated with IL-6. Similarly, large non-
significant positive associations were observed between personal PM2.5 and hs-CRP and 
fibrinogen. Like the two preceding studies, this study has also shown effect 
modification of PM2.5 by several factors including age, gender, HbA1c, cigarette smoke 
and ETS. The results of this study, which employed personal exposure measurement, 
support the hypothesis of a link between exposure to air pollutants and inflammatory 
markers.  
5.2 Air pollution, CV health and the current study 
 
Exposure to PM and gaseous air pollutants contributes to increased CV morbidity and 
mortality, as discussed in section 1.5, and the underlying mechanisms have been 
covered  in section 1.10. Short-term and long-term exposure to air pollution has been 
associated with CVD.  Short-term exposure plays an important role in triggering AMI, 
which represents the largest cause of death due to CVD. Additionally, short-term 
changes in air pollution have been associated with stroke, triggering of various forms of 
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arrhythmias, changes in heart rate and HRV, CHF and hypertension[9, 10, 59]. 
Moreover, long-term exposure to air pollution may contribute to CVD through initiation 
and progression of atherosclerotic process[9, 10, 59].   
Atherosclerosis is the most important risk factor for CAD and is widely accepted as a 
chronic process that is preceded by decades of asymptomatic phase.  The process is 
characterized by intimal thickening, luminal narrowing, atheromatous plaque formation 
and rupture, leading to complications such as AMI, stroke and peripheral vascular 
disease. Inflammation is involved at every step of the atherosclerotic process, including 
the final thrombotic phase which ultimately leads to organ damage[136]. Among the 
well established traditional risk factors for CAD and atherosclerosis are diabetes 
mellitus, hypertension, hyperlipidaemia and cigarette smoking.  
Recent evidence indicates that other non-traditional risk factors including exposure to 
air pollution may be involved in atherosclerosis and studies have shown that air 
pollution is a risk factor for chronic atherosclerotic process as well as acute 
complications such as AMI and stroke[10, 52, 127]. Although in comparison to well 
established risk factors, including smoking and hyperlipidaemia, the risk associated 
with air pollution for individuals is small, it nevertheless has a significant public health 
impact because of the size of the population at risk.   
The work reported in this thesis has studied two highly prevalent CV outcomes, ACS 
and TIA, in relationship with ambient air pollutants. In addition, it has explored the 
relationship between air pollutants and systemic inflammation, one major proposed 
mechanism through which air pollutants cause CV damage. For this purpose, the study 
has measured an array of blood biomarkers in subjects with type 2 diabetes. The 
subjects studied for this outcome are crucial for two reasons. Firstly, like ACS and 
stroke, diabetes is a highly prevalent disease that is an independent major risk factor for 
CVD[87, 91]. In addition, diabetics constitute a subgroup susceptible to the effects of 
air pollutants[50, 107, 111, 218] which may be related to their increased inflammatory 
state[83],  oxidative stress [85], endothelial dysfunction[84] and disturbance of the 
coagulation system[86].  
In general, the three outcomes considered in this thesis and the subjects recruited are 
recognized priority research areas[10]. Air pollution is a ubiquitous phenomenon that 
may affect large groups or entire communities in metropolitan areas and it is a 
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potentially modifiable risk factor for CVD; furthermore, the three limbs of this study 
have addressed important public health issues related to air pollution. 
The results of this thesis suggest that short-term changes in air pollution may potentially 
lead to admission for ACS, occurrence of TIA and an increase in IL-6, a major pro-
inflammatory cytokine. The results of the three studies can be linked and explained in a 
mechanistic pathway. Evidence from diverse sources indicate that IL-6 is related to the 
development of CAD through various mechanisms including disturbance of glucose 
metabolism, dyslipedemia, hypertension, endothelial dysfunction and alteration in 
haemostatic factors[236].   In addition, IL-6 induces hepatic synthesis of major acute 
phase proteins like CRP and fibrinogen as well as up regulation of endothelial adhesion 
molecules which are all implicated in CVD[236]. Increased IL-6, CRP and fibrinogen 
levels are independent predictors of future CV events[138, 237]. Consequently, in 
susceptible individuals systemic inflammation as evidenced by elevated IL-6 in this 
study could stimulate the synthesis of various inflammatory biomarkers in the liver 
which could potentially trigger life-threatening acute events like ACS and TIA, the two 
acute outcomes investigated in this thesis. Figure 5.1 shows potential pathways by 
which exposure to PM2.5 and associated increase IL-6 observed in this thesis may lead 
to acute CV outcomes (ACS and TIA). 
As pointed out under section 4.4, the lack of association between ambient air pollutants 
and all other biomarkers may be explained by exposure misclassification which could 
lead to underestimation of the true risk. In addition, the widespread uses of cardio-
protective medications like statin and low dose aspirin by the study participants could 
potentially blunt the association[115, 229]. The lack of association between fine PM 
measured by personal sampler and other biomarkers could also be explained by 
extensive medication use, particularly for biomarkers CRP and endothelial markers. In 
addition, the biomarkers may not be equally sensitive to the effects of fine PM and the 
activation of vascular responses might not be captured by one day lag as measured by 
the personal sampler.   Earlier studies that investigated related biomarkers have shown 
larger effect estimates with longer exposure averaging times[108, 111] [107]and 
suggested use of longer lag periods and cumulative exposure over several days  to 
reduce exposure measurement error and account for the necessary induction time[107].  
IL-6 is a proximal inflammatory marker released within the first 4 hours and reaches 
peak level within  24 hours following environmental insult, whereas CRP and 
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fibrinogen usually reach their peak levels after 24 hours[238]. Thus, the personal 
exposure used in the current study might not capture the full extent of the rise of 
biomarkers.   
 
 
Figure 5.1  Potential pathways for particle related CV damage 
Modified from Libby P, Ridker PM. Novel inflammatory markers of coronary risk: 
theory versus practice. Circulation 1999 September 14;100(11):1148-50 
   
Earlier epidemiological studies as well as the one reported in this thesis have shown that 
the effects of air pollutants vary considerably among individuals. Previous research has 
shown that there is no safe threshold of PM exposure and that constant exposure may 
contribute to subclinical atherosclerotic process, reduced life expectancy and death from 
respiratory or CV diseases. Large cohort studies that have documented increased risk of 
CV mortality and animal studies that mimic long-term exposure confirm this type of 
association. In addition to the background exposure which is related to the long-term 
risk, individuals who are susceptible to the harmful effects of air pollution—the elderly, 
  
211 
 
diabetics, persons with underlying COPD, AMI or CHF—are susceptible to sudden day-
to-day changes in air pollution. These abrupt changes in pollution levels will alter their 
background risk and might trigger life-threatening acute events such as ACS, TIA, 
stroke or arrhythmia in these individuals. Thus, acute events are superimposed on a 
background of chronic exposure. The two limbs of the present study examining ACS 
and TIA outcomes addressed this pattern of acute events following transient changes in 
pollution levels against a background of chronic exposure.  
In susceptible individuals with chronic exposure and atherosclerotic process, abrupt 
changes in ambient air pollution or exposure to traffic may trigger acute inflammatory 
process, as shown by the third limb of this study. The elevated inflammatory markers 
IL-6, CRP and fibrinogen would explain the final events of this process in which an 
inflammatory cascade would lead to acute events such as ACS and TIA in susceptible 
individuals. Figure 5.2 illustrates this relationship between chronic and acute exposure.  
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Figure 5.2 Schematic diagram of the impact of traditional risk factors and air 
pollution on CV health 
Acute coronary events may occur against a background of chronic exposure, which could lead to 
subclinical atherosclerotic process. On top of that, any sudden change in air pollution levels, particularly 
in susceptible individuals particularly in those with pre-existing lung or CV disease, would lead to 
oxidative stress and systemic inflammation, with release of proinflammatory cytokines such as IL-6 and 
acute phase proteins such as CRP and fibrinogen, as reported in this thesis. The final result may be an 
aggravated prothrombotic state, endothelial dysfunction, fibrinolytic imbalance, plaque rupture and 
myocardial damage, TIA or stroke. 
  
213 
 
 
In addition to the main limitations discussed under each project, one important 
limitation that might affect the interpretation of the results of this thesis is the multiple 
comparison undertaken in each study. The study has found several associations, and at 
least some of the observed significant results may have occurred by chance.  
Due to the multiplicity of pollutants and studied outcomes over several lags, multiple 
testing is common in air pollution related health effects study and that could potentially 
increase the likelihood of type I error.    However, the distinct projects of this thesis 
were undertaken with clear rationale and plausible biological mechanism.  The acute 
CV outcomes and blood biomarkers investigated in this study were selected to represent 
specific biological responses and different biological pathways linking PM and gaseous 
pollutant exposure to CVDs.  The statistical tests were thus driven by plausible 
hypothesis and were not exploratory or confirmatory in nature. Consequently, in such 
conditions statistical adjustment for multiple testing is irrelevant and unnecessary and 
waste useful information and any attempt to adjust could potentially lead to type 2 error 
and thus should be avoided[239, 240]. Adjustment for multiple testing should be based 
on the underlying hypothesis and should be undertaken in certain situations, such as in 
all confirmatory studies[241].  
In this thesis two different study designs were employed to investigate the effect of 
short-term changes in air pollution on different outcomes -case-crossover and panel 
study designs. Both designs do not require additional controls as each case serves as 
his/her own control. The main strengths of the case-crossover design are the ability of 
the design to control for key time-invariant confounders by design, and the potential to 
study effect modification on key covariates. However, case-crossover design has some 
drawbacks such as the difficulty in choosing proper referent periods and introduction of 
selection bias, particularly in some types of case-crossover design. There are no 
limitations on the number of outcomes to be followed in case-crossover design.  
The panel study design is usually employed to study a small group of a sensitive 
population prospectively by measuring exposure and outcome data. It has the advantage 
of differentiating within and between-person effects of exposure on a specific health 
outcome, and the presence of individual level data. A common concern of panel studies 
is that they rely on a small sample size, often based on convenience sampling, which 
  
214 
 
could hinder detecting small health risks that characterize environmental exposure.  In 
addition, due to the demanding follow-up of the design, compliance is reduced, 
ultimately leading to drop-outs and further loss of statistical power.    
 
While this study has enrolled sufficient number of subjects in the three projects, the 
number of subjects available for analysis was small number in some cases. In the ACS 
study, although there were 6096 cases of ACS for both categories of ACS, only 16% 
were cases of AMI, considerably reducing the number of subjects in the severe 
category. However, the strongest effect of ambient pollutants on ACS was observed in 
the severe category of ACS, suggesting the sample size did not affect detecting 
associations. Likewise, although the TIA study included 709 subjects from the 
Manchester and Liverpool, the data were analyzed separately, further reducing the 
sample size. In the TIA project, the single significant association observed was for 
Manchester data, which had somewhat smaller number of study subjects than Liverpool, 
suggesting that the study has sufficient power to detect associations had they occurred. 
In the panel study, although the number of study subjects was small, significant effect 
of personal PM2.5 was observed in association with IL-6. The few panel studies that 
have investigated comparable effects of air pollution on different health outcomes have 
investigated a varied number of patients with variable number follow-ups, with some 
studying only nine subjects with a total of 36 data points[103].  
 The current study included highly selected selective subjects, especially in the panel 
study, thus generalization of the study results to the whole population is impossible.  
However, the findings of the study could be generalized to most diabetics, especially 
those with CVD, who are thought to be more susceptible to the effects of air pollution 
than healthy subjects.  
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5.3 Future work 
 
The projects covered in this thesis (air pollution, ACS, TIA and inflammation) are broad 
topics in which several issues remain to be addressed. The study investigated the effects 
of ambient air pollution on ACS and TIA using ecological case- crossover design. 
Additionally it examined the effect of personal and ambient air pollution on markers of 
systemic inflammation in diabetes mellitus type 2 subjects.  The following section 
briefly discusses recommendations for future work. 
  
• This study found associations between ambient air pollutants and ACS, by 
measuring the level of cTnT.  Previous studies have demonstrated association 
between air pollution and IHD, but none have specifically used troponin as an 
outcome. The result of the current study needs to be confirmed in different 
settings and larger study populations. 
• The study found association between exposure to ambient NO and TIA for the 
Manchester data. Nevertheless, the biological mechanism to explain this link is 
still missing and the result of this study needs to be confirmed by other, larger 
studies. In addition, the increased understanding is needed on the role ambient 
NO on various cardio-respiratory health outcomes. 
• In the TIA study, in contrast to Manchester data where association was 
demonstrated, no association was found for the Liverpool data.  This difference 
might be related to differences in the composition of PM and gaseous pollutants 
in both cities; this discrepancy deserves to be explored.  
• In this study effect modification by some population and environmental 
characteristics such as age, gender, season, tobacco smoke and environmental 
tobacco smoke was observed. It is important to further investigate these and 
other covariates in a larger study and in different populations. 
•  This study shows that personal exposure to PM2.5 is significantly associated 
with IL-6, a major proinflammatory marker. It also showed elevation of several 
biomarkers, albeit not significant, in association with personal PM2.5. There is a 
need to confirm this finding and explore the time frame of elevations of these 
markers in association with air pollution. In addition, the biological relevance 
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and roles of these biomarkers in predicting future CV events in association with 
air pollution require further exploration. 
• The association of proinflammatory biomarkers with air pollution was observed 
only with personal exposure assessment and no association was found with 
exposure data from central monitors. This discrepancy need to be investigated 
using better exposure assessment methods. In addition, the relationship between 
central site monitors and personal exposure requires further exploration. 
Besides, there is a need to study the differential toxicity of different PM metrics, 
especially UFP.  
• Recent epidemiological and experimental studies have shown associations 
between air pollution and stroke, cognitive function, neuroinflammation and 
neurodegeneration[242]. In view of these findings, it is necessary to investigate 
whether ambient air pollution is associated with Alzheimer’s disease, 
Parkinson’s disease and depression.  
• Earlier studies have shown that the performance of personal nephelometers is 
influenced by environmental factors like relative humidity, especially at levels 
above 80%.  This needs to be investigated in future work. In addition, the effect 
of relative humidity could be substantial in this study due to use of the 
monitoring devices indoors and outdoors. This merits further investigation and 
correction by simultaneous measurement of relative humidity.  
 
5.4 Conclusions 
 
This is the first epidemiological study that has investigated the effects of ambient air 
pollutants on ACS by measuring cardiac troponin, a highly specific and sensitive 
marker of myocardial damage. Furthermore, the study is the first to study the effect of 
ambient air pollutants on a well characterized group of persons with TIA.  In addition, it 
is the first panel study to have repeatedly measured personal exposure to fine 
particulates in a diabetic population, to investigate associations with various 
inflammatory mediators. 
The results show that exposure to ambient air pollution was associated with admission 
for ACS and provided some evidence that link exposure to NO to increased occurrence 
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of TIA, two major acute CV outcomes which could accompany transient changes in air 
pollution levels. The association between NO and TIA could be causal or NO might act 
as a surrogate for unmeasured pollutants like UFP.  
Additionally, the study has confirmed that exposure to fine particles measured by a 
personal sampler is associated with an increased IL-6, a major pro-inflammatory 
cytokine in type 2 diabetic population. There was no consistent association between all 
measured inflammatory biomarkers and ambient air pollutants measured from a single 
background monitor. As increased IL-6 is a known predictor of CVD, the result of this 
thesis is clinically relevant as diabetics are at great risk CVD.   
Generally, the results of this thesis support previous findings that associate exposure to 
particulate and gases with acute CV outcomes such as AMI, stroke and TIA. It also 
supports the hypothesis of a link between exposure to fine particles and systemic 
inflammation.  Further research is needed to confirm the findings of this thesis. A 
comprehensive community based study with prospective follow-up of incident ACS, 
TIA and stroke cases with more advanced exposure measurement is needed.  Regarding 
the inflammatory outcomes, a larger study with more sample size and number of visits 
coupled with both personal and ambient monitoring data could shed light on this issue.     
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Appendix One: Patient Information Sheet 
Version 3, 28/02/2008 
1. Study Title The relationship between environmental exposure to particulates, 
inflammation and cardiovascular damage 
2. Invitation 
You are being invited to take part in a research study. Before you decide it is important 
for you to understand why the research is being done and what it will involve. Please 
take time to read the following information carefully and discuss it with others if you 
wish. Ask us if there is anything that is not clear or if you would like more information. 
Take time to decide whether or not you wish to take part. 
3. What is the purpose of the study? 
Research evidence from a number of countries has shown a link between exposure to air 
pollutants and deaths and hospital admissions from various heart and lung diseases. We 
are carrying out a research project to understand more about the changes in the blood in 
persons exposed to air pollution. In particular we are trying to determine how inhaled 
fine particles may have an effect on the heart, lung and blood vessels.  In order to 
address this issue the Hope Hospital, in collaboration with the Centre for Occupational 
and Environmental Health, at the University of Manchester has designed an educational 
PhD research project. Part of the research project is to look at diabetic subjects and 
study whether they are at increased risk from airborne particles. 
4. Why have I been chosen? 
You are being asked to consider volunteering because you have diabetes mellitus.  
Studies have shown that individuals like you might be more susceptible to the effect of 
air pollution. 
5. Do I have to take part? 
You do not have to take part, and whether or not you take part, the treatment and 
general support you get for your diabetes at Hope Hospital will not be changed at all. If 
you decide to take part you will be asked to sign a consent form during the first 
assessment visit. 
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6. What do I have to do? 
If you wish to take part after reading this letter then you will be asked to sign a consent 
form. Even if you consent to participate, you would be free to withdraw at any time later 
if you wished to do so.  
7. What does the procedure involve? 
This will involve collecting 45ml (three tablespoons) of blood at the start of the study 
and four further occasions every two weeks, completing a daily diary, answering some 
questions about your health and wearing a small air pollution monitoring device which 
will be clipped to your waistband for eight hours.  The monitor weighs about 540 grams 
or 19 ounces. 
8. What are the side effects? 
During the process of blood taking, there may be a slight discomfort. But the blood 
sample will be taken by specially trained staff to reduce this risk. 
9. What are the possible benefits of taking part? 
You will receive no direct benefit from taking part in the study, but the work may be 
helpful to understand the mechanism and the effect of air pollution on diabetic persons. 
10. What happens when the research study stops? 
When the study is completed and Ethical Approval ends, the samples will be destroyed. 
11. Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will be 
kept strictly confidential. Any information about you will have your name and address 
removed so that you cannot be recognised from it. 
12. Who is organising and funding the research?  
The study is being organized by researchers at Hope Hospital, Salford (Professor Martin 
Gibson and Dr. John New) in collaboration with the University of Manchester 
(Professor Raymond Agius, Dr. Adrian Hirst and Dr. Getahun Bero Bedada).  
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13. Contact for Further Information 
If you have any queries about this study, please contact Professor Martin Gibson, 
Director of Research and Development, Salford Royal Hospital (0161 2064276) or Dr. 
John New, Consultant physician at Hope Hospital (0161 2064625).  
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Appendix Two: Consent Form 
 
REC reference number: 07/H1004/107  
Patient Identification Number for this study: _________________________ 
 
Title of Project: The relationship between environmental and occupational exposure to 
particulates, inflammation and cardiovascular damage. 
Name of Researcher: Dr. Getahun Bero Bedada 
 
Please initial box  
 
1. I confirm that I have read and understand the information sheet Version 3, dated 
28/02/2008 for the above study and have received a copy to keep. I have had the 
opportunity to consider the information, ask questions and have had these answered 
satisfactorily.                                                                           
 
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time without giving any reason, without my medical care or legal rights being affected.                                                                                                           
 
3. I understand that relevant sections of my medical notes and data collected during the 
study may be looked at by individuals from Hope Hospital, from the University of 
Manchester or from the NHS Trust, where it is relevant to my taking part in this 
research. I give permission for these individuals to have access to my records.                                                   
 
 
4. I agree to take part in the above study.                                                          
 
_______________   ________________   _________________  
Name of Patient    Date     Signature  
 
_________________  ________________  ___________________  
Name of Person     Date                 Signature 
taking consent 
 
 
When complete, one copy for the patient, one copy for the researcher file and another kept in  
 patient’s  medical notes.  
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Appendix Three: Short Screening Questionnaire 
1) Subject ID: _____________________ 
2) Date of birth: _____________________ 
 
3) Are you on any long-term medication?   Yes  No 
a) If yes give details_________________________________________________ 
4) Do you regularly take aspirin?   Yes  No 
5) Do you regularly take statins?   Yes  No 
6) Do you regularly take steroid preparations such as prednisone / cortisone? 
   Yes  No 
7) Do you regularly take antibiotics?   Yes  No 
8) Do you have any infection now?  Yes  No 
9) Do you have recurrent infection?  Yes  No 
10) How often have you taken antibiotics in the last six months? 
   No 
   1  - 2 
   3  - 4  
   > 4  
 
11) Do you smoke (cigar, cigarette or pipe)?   Yes  No 
If  Yes: how many cigar, cigarette or pipe do you smoke? 
a) Usually less than 1 cigar or pipe per day  Yes  No 
(Casual smoker) 
b) At least a cigar, cigarette or pipe per day  Yes  No 
(smoker) 
12) Has a doctor diagnosed the following in the last six months? 
a) Inflammatory bowel disease  Yes  No 
b) Heart attack / Myocardial infarction  Yes  No 
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c) Heart failure  Yes  No 
d) Stroke/mini stroke /TIA  Yes  No 
 
13) Do you regularly take anticoagulants?       Yes  No 
(e.g . Warfarin,Coumadin,Nicoumalone,Fragmin,Lovenox,Heparin)  
 
14) Have you ever had coronary artery bypass  operation (CABG)  
 
   Yes  No    
a) If yes when was that? _____________________ 
 
15) Have you ever had coronary angioplasty?  Yes  No 
If yes when was that? _____________________ 
16) Did you have any of the following conditions?  
Please ask for an explanation if you do not understand any of the items. 
 
a) Hypertension        Yes   No 
b) Arrhythmias        Yes   No 
c) Cor pulmonale       Yes   No 
d) Valvular heart disease       Yes   No 
e) Other heart problems       Yes   No 
f) Asthma        Yes   No 
g) Chronic bronchitis       Yes   No 
h) COPD         Yes   No 
i) Emphysema        Yes   No 
j) Chronic renal disease       Yes   No 
k) Chronic liver disease        Yes   No 
l) Other chronic diseases      Yes   No 
m) If ‘Yes’, please describe: 
   __________________________________________________________________  
   __________________________________________________________________  
   __________________________________________________________________  
17) Do you have weakness or fatigue due to a long standing illness?       Yes  No 
a) If yes, please explain 
_____________________________________________________  
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18) Are you breathless at rest ?   Yes  No 
 
19) Are you willing to take part in a research study and visiting Hope Hospital every 
two weeks, on the same weekday, and at the same time on four occasions? 
 Yes       No 
20) Do you agree that we take blood for the study on all follow up visits? 
  Yes       No 
 
21) Do you plan to travel for a longer time in the coming four months?  
  Yes       No 
 
22) Are you willing to keep a daily diary during the entire study period? 
  Yes       No 
For the interviewer: 
23) Does the patient fulfil the inclusion criteria? 
  Yes        No 
24) Height _________cm 
25) Weight _________kg 
26) BP   ____/________  
27) Pulse __________/minute  
 
Name of the interviewer _______________________________ 
 
Comments: __________________________________________ 
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Appendix Four:  Main Questionnaire 
 
1. Date and Time: ________________________  Subject ID: ____________ 
 
2. Gender         q Male q Female  
 
3. Date of birth  ___________________ 
 
4. Education (in years)  _____________ 
 
5. What is your ethnic group?   
 
q White    q Black  q Asian   q Any mixed      q Other 
6. Postcode  
________________________________________ 
________________________________________ 
________________________________________ 
________________________________________ 
________________________________________ 
7. Neighbourhood type      
q City centre  q City outskirts  q Rural 
SYMPTOMS 
 
8. Did you have chest pain in the last two weeks?   q Yes  q No 
 
9. Did you have chest pain yesterday?    q Yes  q No 
 
 
10. Have you had fever in the last week?      q Yes  q No 
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11. Did you have an airway infection in the past two weeks? q Yes  q No 
  
12. Do you have an airway infection today?    q Yes  q No 
  
VISIT OF A PHYSICIAN AND MEDICATIONS 
 
13. Did you visit a doctor for any acute illness during the last two weeks?  
 
 q Yes          q No 
If yes, for what reason? 
 
13.1. Angina Pectoris?      q 
 
13.2. Chest conditions?      q 
 
13.3. Other (Specify):  
______________________________________________________________________
______________________________________________________________________
___________________________________________________________________ 
 
14. Were you hospitalized for any acute illness during the past 2 months  
          q Yes  q No 
14.1. If yes, for how long?  From _____________until _______________ 
 
 
15. Do you take medications regularly?    q Yes  q No 
 
15.1. If yes, please list (Brand and Dose): 
______________________________________________________________________
______________________________________________________________________
___________________________________________________________________ 
  
245 
 
______________________________________________________________________
______________________________________________________________________ 
 
16. Had there been any change in your medication recently? q Yes  q No 
 
16.1. If yes, please specify the dose and brand name of the medication 
_____________________________________________________________________ 
_____________________________________________________________________ 
_____________________________________________________________________ 
 
17. Did you take your medication today as prescribed?   q Yes  q No 
 
17.1. If no, please specify: 
_____________________________________________________________________ 
_____________________________________________________________________ 
      
18. Do you have any allergies?      q Yes  q No  
 
18.1. If yes, please list 
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
__________________________________________________________________ 
 
19. Have you ever had, or were you ever told by a physician that you had a heart 
problem?         q Yes  q No 
 
19.1. If yes please specify  
_____________________________________________________________________ 
______________________________________________________________________
____________________________________________________________________ 
_____________________________________________________________________ 
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20. Have you ever had, or were you ever told by a physician that you had a stroke?
      q Yes  q No 
20.1. If yes, when was that? _________________________ 
 
 
21. Have you ever had blood clots in the legs?   q Yes  q No 
 
 
22. Have you ever had any chest trouble?   q Yes  q No 
 
22.1. If yes please specify?  
______________________________________________________________________
____________________________________________________________________ 
_____________________________________________________________________ 
_____________________________________________________________________ 
EXPOSURE RELATED QUESTIONS 
 
23. How many people live in your household? ____________ 
 
24. Type of house (cross one)  
 
q Bungalow    q Detached    qSemi detached    q Terraced   q Flat   qOther 
24.1. If other please state 
____________________________________________________ 
 
25. When was the house built? (Year)______________________ 
 
26. What type of glazing does the house have?          q Double       q single 
 
27. Does your home have central heating?   q Yes  q No 
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27.1. If yes what type? __________________________________________ 
 
28. What kind of cooker do you mostly use for cooking? TICK ONE BOX ONLY  
 
q Coal, coke or wood (solid fuel)  
q Gas (gas from the mains) 
q Electric/ paraffin (kerosene) 
q Microwave  
q Gas from bottles or other non-mains source 
q Other: _____________________________________________  
 Does your kitchen have an extraction system?    q Yes  q No 
 
28.1. If yes, what type (hood, ducted, not ducted, fan)? 
____________________________________ 
29. Do you cook regularly?      q Yes  q No 
 
29.1. If yes, on average how many hours in a day do you spend cooking?  
_____________________________________________________________________ 
 
30. Do you air your house?       q Yes  q No 
 
30.1. If yes, how (e.g. open door/window, fans etc) and when (e.g. when 
cleaning, cooking etc...)?  
_____________________________________________________________________ 
31. Do you smoke more than one cigarette, cigar or pipe daily? 
 
 q Yes  q No 
32. Have you ever smoked as much as one cigarette, cigar or pipe daily for as long as 
one year?  
q Yes   q No 
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32.1. If yes when did you stop smoking? _____________________ 
33. Are there smokers living in your home?     q Yes  q No 
33.1. If yes, who? __________________________________ 
 
33.2. Do they smoke at home?     q Yes  q No 
 
33.3. Do they smoke in communal rooms?   q Yes  q No 
 
34. Have you been in any other smoky atmosphere in the last 7 days?   
         q Yes  q No 
If yes, where? ________________________________________ 
35. Have you been in rooms where people smoked during the last 24 hours? 
 q Yes  q No 
If yes, how long did you stay there? (In hours and minutes) 
 _________________ 
36. Do you ever use any of the following types of transport? 
36.1. Petrol car /taxi      q Yes  q No 
36.2. Diesel car /taxi     q Yes  q No 
36.3. Motorbike or moped      q Yes  q No 
36.4. Bus       q Yes  q No 
36.5. Bicycle      q Yes  q No 
36.6. Train       q Yes  q No 
36.7. If yes, to any of the above answer the following 
 
Means of transport How many 
trips/week 
How many 
hours per trip 
Mainly used 
for 
36.7.1. Petrol car /taxi    
36.7.2. Diesel car /taxi    
36.7.3. Motorbike or 
moped 
   
36.7.4. Bus    
36.7.5. Bicycle    
36.7.6. Train    
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Is the traffic around your house light   / intermittent/   heavy? (circle one) 
 
37. Distance of roads to your house in meters______________ 
 
38. How much are you annoyed by traffic noise if you keep the windows open? 
 +1        __________________________      +10 
 Quiet   __________________________      very loud 
 
39. How much are you annoyed by outdoor air pollution (from traffic, industry etc…) if 
you keep the windows open? 
 
  +1 ____________________________________ +10 
 No annoyance ______________________________ Intolerable annoyance 
 
40. Did you travel by car today?     q Yes  q No 
 
40.1. If yes, how long were you in the car?
 ________________________________ 
41. How often do heavy vehicles (e.g. trucks/buses) pass your house? TICK ONE BOX 
ONLY  
Constantly           q 
Frequently  q 
Seldom   q 
Never   q 
 
42. How often do cars pass your house? TICK ONE BOX ONLY  
Constantly           q 
Frequently  q 
Seldom   q 
Never   q 
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43. Do you have a job?      q Yes  q No 
 
If yes, please answer the following. 
 
43.1. What is the title of your current or last job? 
_____________________________ 
 
43.2. What did the firm, company or organisation does or what services did it 
provide? __________________________________________________ 
 
43.3. What are your main work activities? ____________________________ 
 
43.4. How many hours a day do you work?  __________________________ 
 
43.5. Transport to /from work  
 
q Walk  q Bicycles  q car  q Bus   q train 
 
43.6. Approximately how much time do you spend travelling to work per day? 
____________ 
 
43.7. Employers name and address (confidential)  
________________________________________________ 
________________________________________________ 
________________________________________________ 
________________________________________________ 
________________________________________________ 
 
44. Do you have any regular hobbies or social activities?  q Yes  q No 
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44.1. If yes, please describe in detail e.g. inside or outside, how often 
__________________________ 
45. Do you take regular physical activity?       q Yes  q No 
 
45.1. If yes, what and how often? __________________________ 
 
46. In the last three months, have you been drinking alcoholic drinks at all (e.g. beer, 
wine, Alco-pops, cider, or hard liquor such as whiskey, rum, gin, vodka)? 
                    q Yes  q No 
46.1. If yes, answer the following. 
 
46.2. On average, how many days per week have you been drinking Alco-
pops, cider, beer or wine? 
q None   q 1-2     q 3-4    q 5-6     q Everyday  
 
46.3. On a day when you have had Alco-pops, cider, beer or wine to drink, 
how many glasses, bottles, or cans have you been drinking? 
 
q 1-2    q 3-4    q 5-8   q  9-14  q15 or more 
46.4. On average how many days per week have you been drinking liquor (gin, 
vodka, rum, brandy, whisky etc.)? 
q None  q 1-2   q 3-4   q 5-6   q  Everyday 
46.5. On a day when you have had liquor to drink, how many single shots have 
you been drinking? 
q 1-2   q 3-4   q 5-8   q 9-14  q 15 or more 
47. Did you drink coffee or tea during the last 12 hours?  q Yes  q No 
47.1. If yes, how many cups of coffee or tea did you drink? 
 
   Coffee cups     Tea cups 
 
Date _________________________________ 
Time _________________________________ 
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Appendix Five: Clinic Visit Log 
 SUBJECT ID: ____________ 
DATE: _____________________  
1. BP      ____/____mmHg 
2. RR  ________/minute 
3. Weight _________KG 
 
SYMPTOMS 
4. Have you experienced the following since yesterday? 
 
4.1. Chest pain/tightness    q Yes  q No 
4.2. Shortness of breath     q Yes  q No 
4.3. Fever      q Yes  q No 
   
5. Did you visit a doctor for any acute illness during the last two weeks?  
q Yes  q No 
 If yes, for what reason? 
5.1. Angina Pectoris/chest tightness  q 
 
5.2. Breathlessness    q 
 
5.3. Fever     q 
 
5.4. Other (Specify):         
 
6. Were you hospitalized for any acute illness during the past 2 weeks  
       q Yes  q No 
6.1. If yes, for how long? From ________________until 
________________ 
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7. Did you experience any of the following symptoms in the last 24 hours? Write down 
if you had these symptoms and to what degree: 0= no, 1=slight, 2=severe 
7.1. Chest pain at rest _________ 
7.2. Chest pain on exertion        
7.3. Shortness of breath_______________ 
7.4. Feeling tired or too weak_______________ 
7.5. Cough ______________  
7.6. Wheeze_________________ 
7.7. Fever______________ 
7.8. Common cold_________________ 
8. Has there been a change in medication since we last saw you?  
q Yes  q No 
8.1. If yes please list the change. 
_____________________________________________________________________ 
_____________________________________________________________________ 
9. Did you take your medication today as prescribed?  q Yes  q No 
If not, please specify: 
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
_____________________________________________________________________ 
 
10. Did you smoke cigarettes or cigars since your last visit? q Yes            q No 
 
10.1. If yes, how many cigarettes in total during the past 2 weeks?  
q 1- 5      q 6-10     q 20-40      q >40 
10.2. What time and day did you last smoke? _______________________ 
 
10.3. Did you smoke during the last hour?   q Yes  q No 
 
11. Have you been in rooms where people smoked during the last 24 hours?  
q Yes  q No 
11.1. If yes, how long did you stay there? __________________________minutes 
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12. How did you travel to the hospital today? 
 
q Walking   q  Cycling         q Car     q Bus     q Train 
13. Did you drink coffee or tea during the last 12 hours?  q Yes  q No 
 
13.1. If yes, how many cups did you drunk? 
   Coffee cups     Tea cups 
14. Did you drink coffee or tea during the last 4 hours?  q Yes  q No 
14.1. If yes, how many cups did you drunk? 
   Coffee cups     Tea cups 
15. Did you drink alcoholic beverages during the last 24 hours? 
q Yes  q No 
 
 
Date _________________________________ 
 
Time _________________________________ 
 
Initials of interviewer_________________________________ 
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Appendix Six:  Activity Diary 
Subject ID _______________  
Date_______________ 
1. Did you smoke cigarettes, cigars or pipes in the last 24 hours?  q Yes         q No 
 
2. Has someone smoked cigarettes or cigars inside your home in the last 24 hours?  
         q Yes         q No
  
2.1. If “Yes”, how many cigarettes/cigars were smoked?      
 
3. Have you been in rooms where people smoked during the last 24 hours? (e.g. work 
place, restaurants or pubs)  
         q Yes         q No 
3.1. If yes, where? ________________________________________ 
 
3.2. How long did you stay? ________________________ minutes 
 
4. Were any meals cooked using a cooker in your home in the last 24 hours?  
 
qYes         q No 
If “No” go to question 5, If “Yes”, answer the following: 
 
4.1. How many times was the cooker used in the last 24 hours?  
 
4.2. Was the window open in the kitchen during the cooking?   
 
qYes        q No 
4.3. Who cooked the food?  
       q I myself       q Someone else 
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5. Did you or someone else in your home use a cooker in the last 24 hours for any of 
the following activities?      qYes        q NO 
If “Yes”,   answer the following? 
   Start time Duration Exhaust extractor present   
        (Yes/No) 
5.1. Frying   __________________________________________________
                              
5.2. Grilling __________________________________________________
  
5.3. Sautéing __________________________________________________
  
6. Did you light any of the following?    If “Yes”, for how long? 
 
6.1. Candles  q Yes  q No  _____________minutes 
6.2. Incense  q Yes  q No _____________ minutes 
 
7. Have you been outside home today?     q Yes  q No   
7.1. If “Yes”, how long were you outside? _____________________minutes 
 
8. Have you been out of town?     q Yes  q No   
8.1. If yes, for how many hours? ___________________________________ 
 
9. Have you travelled by car/bus/taxi today?  q Yes  q No 
 
If “Yes”, please answer the following: 
 
9.1. How long were you in the vehicle?               ___________ minutes 
 
9.2. Was the travel during rush hour (7-9AM and 4-6 PM)? q Yes q No 
 
9.3. Where was the trip undertaken?   q Within the city q In a rural area 
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10. Did you or someone else clean the house today?   q Yes    q No 
  
10.1. If “Yes”, what was used whilst cleaning? 
 
   q Vacuuming 
 q Sweeping 
 qClean the cooker 
 q Clean the windows 
 q Wash the floor 
 q Other 
11. How many minutes did you spend doing housework today? _____________ 
 
12. Were there any pets inside your house in the last 24 hours? q Yes   q No  
12.1. If “Yes”, how many? _______ 
 
13. Did you experience any of the following symptoms in the last 24 hours? Write down 
if you had these symptoms and to what degree: 0= no, 1=slight, 2=severe 
 
13.1. Chest pain at rest _________ 
13.2. Chest pain on exertion____________ 
13.3. Shortness of breath_______________ 
13.4. Feeling tired or too weak_______________ 
13.5. Cough ______________  
13.6. Wheeze_________________ 
13.7. Fever______________ 
13.8. Common cold_________________ 
 
14. How do you rate your overall health today? (1=good, 2= quite good, 3=average, 
4=bad, 5= very bad)_______________________________ 
 
15. Did you do anything that made you more breathless than usual today?  
q Yes  q No 
15.1. If yes, how long were you doing the activity? ____________minutes 
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16. Did you drink alcohol during the last 24 hours?   q Yes  q No 
 
17. Did you drink tea during the last 24 hours?    q Yes  q No 
 
 
18. Did you drink coffee during the last 24 hours?    q Yes  q No 
 
19. Did you take any medication today (including pain killers, vitamin preparations)?  
 
        q Yes  q No   
19.1. If yes please write down brand and dose____________________________ 
___________________________________________________________________
___________________________________________________________________
___________________________________________________________________ 
 
 
 
